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General introduction: 
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Introduction
Alcohol dependence is a chronic relapsing neuropsych iatric disorder. This 
disorder is thought to be resu lt from  a com bination o f genetic, d rug  induced, 
psychological and environm ental factors. In Europe the m edian  estim ates for 
12-month prevalence rates for alcohol dependence (according to DSM-IV, Table 1) 
are 6.1% for m ales and 1.1% for fem ales. In the N etherlands the prevalence o f alcohol 
abuse (according to DSM-IV, Table 1) is estim ated  at approxim ately 10% '. The 
m ajority  o f problem  drinkers are m en betw een 16 and 24 years o f age. The 
prevalence o f alcohol dependence in The Netherlands is estim ated  at around 3.7% 
o f the adult population  '.
Excessive use o f alcohol and drugs is associated w ith m any som atic and 
psychiatric com plications. Chronic use o f alcohol has been found to increase the 
risk  for certain  cancers, is associated w ith gastro in testin al in flam m ation s, and 
liver d isease and is a risk  factor for card iopu lm on ary  disease. In 2003 1900 alcohol 
related and 17 cocaine related deaths were registered in  The N etherlands1.
Besides health  related problem s drug and alcohol abuse and dependence pose a 
great burden on society w ith respect to crim inality , tra ffic  offences, unem ploym ent 
and social d isturbances. A pproxim ately 2700 people got in jured or k illed  in  traffic  
accidents in  The Netherlands in 2003 due to the use o f alcohol '. And about one 
th ird  o f all prisoners in The N etherslands report alcohol abuse '.
It is estim ated that in The N etherlands approxim ately  3% o f problem  drinkers 
seek treatm ent. Treatm ent o f substance dependence varies from  m aintenance 
treatm ent with m ethadone for opiate dependent patients to detoxification  w ith  the 
a im  o f prolonged abstinence in  patients dependent on alcohol and m any other 
drugs. W ith prolonged treatm ent, craving for drugs or alcohol is a m ajor obstacle 
for abstinence. Therefore, treatm ent focuses on prevention o f relapse and the 
reduction  o f craving. M edications such as naltrexone, acam prosate and d isu lfiram  
are found to significantly reduce the risk o f relapse in alcohol dependent patients 2 3.
However, 40-70% o f patien ts still relapse to drin k in g  alcohol w ith in  one year after 
detoxification  2 3.
Since treatm ent success rates are m oderate, it is ch allenging to search for 
opportun ities to im prove treatm ent resu lts. The developm ent o f new pharm aco- 
therapeutic agents is a prom isin g field o f research. Knowledge o f the underlying 
pathology o f substance dependence in d ifferent subgroups o f patients m ay facilitate 
m ore ind iv idualized  treatm ent allocation. It could be hypothesized, th at patients 
w ith disturbances in d ifferent neurotran sm itter system s m ay benefit from  
d ifferent treatm ent regim ens. A better understan din g o f the pathogenesis o f the 
disorder m ay help to develop m ore effective treatm ents, and indiv idualize and 
optim ize treatm ent based on knowledge o f the pathophysiology o f the disorder in 11
ind iv idual patients in the context o f a personalized  m edicine approach 2-6.
N
eu
ro
bi
ol
og
y 
an
d 
th
e 
co
ur
se
 
of
 
ad
d
ic
ti
on
Table 1 DSM-IV Criteria for Alcohol Abuse and Alcohol Dependence
Alcohol Abuse:
one or more o f  the following, w ithin a 
12-month period
Alcohol Dependence:
three or more o f  the follow ing occurring at 
any tim e w ithin a  12-month period
Recurrent alcohol use resu lting  in failure 
to fu lfil m ajor role obligations at work, 
school, or home (e.g., repeated absences or 
poor work perform ance related to substance 
use; substance-related absences, suspensions 
or expulsions from  school; or neglect o f 
children or household).
Tolerance, as defined by either o f  the 
following:
- A need for m arkedly increased am ounts o f 
alcohol to achieve intoxication or desired 
effect.
- Markedly dim inished effect with 
continued use o f  the sam e am ount of 
alcohol.
Recurrent alcohol use in situations in which 
it is physically hazardous (e.g., driv in g or 
operating a machine).
W ithdrawal, as defined by either o f  the 
following:
- The characteristic w ithdraw al syndrome 
for alcohol
- Alcohol is taken to relieve or avoid 
w ithdraw al sym ptom s.
Recurrent alcohol-related legal problem s 
(e.g., arrests for alcohol-related disorderly 
conduct).
Alcohol is often taken in larger am ounts or 
over a  longer period than was intended.
Continued alcohol use despite persistent or 
recurrent social or interpersonal problem s 
caused or exacerbated by the effects o f 
the alcohol (e.g., argum ents with spouse, 
physical fights).
There is a  persistent desire or there are 
unsuccessfu l efforts to cut down or control 
alcohol use.
These sym ptom s m ust never have met the 
criteria for alcohol dependence.
A great deal o f tim e is spent in activities 
necessary to obtain alcohol, use alcohol or 
recover from  its effects.
Im portant social, occupational, or 
recreational activities are given up or 
reduced because o f  alcohol use.
Alcohol use is continued despite knowledge 
o f  having a  persistent or recurrent physical 
or psychological problem  that is likely to 
have been caused or exacerbated by the 
alcohol (e.g., continued d rin k in g despite 
recognition that an ulcer was m ade worse 
by alcohol consumption).
12
Focus on neurobiological aspects of alcohol dependence
There is overw helm ing evidence th at psychiatric c lassification  system s, such 
as DSM-IV, describe c lin ically  and aetiologically  heterogeneous d isorders. A lso in 
alcohol dependence the existence o f subgroups, w ith d istin ct neurobiological ch ar­
acteristics, has previously been suggested 2-8. This heterogeneity o f patients is likely 
to contribute to the som etim es poor treatm ent outcom es, because a treatm ent that 
is effective for one patient m ay not be effective for the other.
The use o f (neuro)biological m easures, also  called biom arkers, m ay help to 
identify  such subgroups o f patients. Biom arkers are m easurable biological 
com ponents associated w ith a disorder, and can  reflect either a vu lnerability  factor 
for the disease, an indicator o f d isease or prognosis, a residual m arker o f d isease or 
a pleiotropic fin d in g (related to other traits associated w ith the disorder, and not to 
the disorder per se) 9-13. Biom arkers can be neurophysiological, biochem ical, endo­
crinological, neuroanatom ical, cognitive or neuropsychological. Exam ples of 
biom arkers are startle  responsivity, blood levels o f for exam ple certain  horm ones, 
or m easurable brain  features like am ygdale volum e 14-19. Studying biom arkers may 
also  help to identify  groups o f patients that share certain  biological features, 
thereby furth erin g  classification  and diagnosis, im proving treatm ent m atching, 
and possibly helping to im prove understan din g o f genetic background o f neuropsy­
ch iatric disorders.
In th is fir st  chapter I w ill f ir st  focus on neurobiological predictors o f the course 
o f addiction in  general. I w ill provide an overview o f current knowledge from  
d ifferent fields o f neurobiological research, including an im al research and neuro- 
pharm acological studies in hum ans. After th is overview I w ill narrow  down to the 
aim s o f the current thesis and give an outline o f the com ing chapters.
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Neurobiological predictors of the course of addiction
An im proved ability to identify  patients at high risk for relapse could also 
im prove treatm ent outcom e. More intensive treatm ent m odules could be developed 
for h igh risk  patients. Moreover, knowledge on predictors o f the course o f addiction 
would help health  care workers to refer patients to adequate treatm ent program s.
Im provem ent on such outcom e pred ictin g param eters during treatm ent m ight 
m otivate patients and indicate the righ t m om ent to sta rt rehabilitation  program s.
In studies o f predictors o f the course o f addiction, attention  has long-time been 
focussed on psychosocial and environm ental factors. However, m ost studies failed 
to bring about strong predictors o f the course o f addiction  and relapse in  particu lar.
Most im portant predictors o f relapse identified for opiate addiction are: h igh level 13
o f pre-treatm ent drug use, a h istory  o f prior treatm ent for dependence, co-morbid
depression, h igh stress, em ploym ent problem s, short duration  o f treatm ent and 
treatm ent drop-out 20. For alcoholism , the m ost im portant predictors o f poor 
treatm ent outcom e are: a positive fam ily  history  in a first-degree relative for 
alcohol dependence, pre-treatm ent use o f additional substances, and h igh anxiety
21-23
In this review we w ill focus on neurobiological predictors o f the course of 
addiction.
We provide an overview o f current knowledge from  four d ifferent fields o f neuro­
biological research. These include an im al research, neuropharm acological studies 
in  hum ans, as well as neuro-im aging studies and genetic research.
Animal models
A nim al m odels o f addiction m ay provide u sefu l in form ation  on neurobiologi­
cal differences pred icting the course o f addiction. The resu lts o f an im al studies 
m ay benefit d iagnosis, prognosis and therapy of hum an substance dependent 
patients. Studying an im al m odels has several advantages over hum an research. 
One im portant advantage is the possib ility  to control environm ental factors. This 
m akes case control com parisons less open to confounders. It is also  easier to test 
neuropharm acological m an ipulations in  vivo. N eurobiological m echanism s 
involved in  the addiction  process are therefore m ore accessible for research. Finally 
it is also possible to develop and test novel pharm acotherapeutic agents, based on 
observations o f the pathoyphysiology. On the other hand, psychosocial 
environm ental factors involved in the developm ent and m aintenance o f addiction 
are not readily accessible in an an im al m odel. The use of an im al m odels to predict 
the course o f addiction in hum ans, is therefore lim ited.
An im portant elem ent in the chronic course o f addiction is the propensity to 
relapse. Several an im al m odels have been developed to investigate m echan ism s 
underlying relapse in  rats, in order to elucidate the neuronal circu itry  involved. 
This knowledge m ight offer m ore in sigh t into the prognostic value o f individual 
neurobiological differences am ong addicted patients. Here we describe an im al 
m odels currently, used to study these inter-individual differences.
Models of relapse
Self adm in istration  o f addictive drugs is n atu rally  observed in  an im als. This 
provides a good opportun ity  to study the n atu ral course o f drug abuse and 
addiction, u sing an im al m odels. For the scope o f th is state o f the art study, we 
focused p rim arily  on an im als m odels on the course o f addiction. Models on the
14 vulnerability  to develop substance dependence are not discussed  here.
A nim al m odels for the study of the course of addiction, have m ainly  studied
tran sition  to uncontrolled drug  tak in g  behaviour and rein statem en t o f drug self 
adm in istration . The latter provides a good an im al m odel for relapse in  hum ans, 
w hich is one o f the m ost im portant problem s in  the long term  course o f addiction.
The study o f re instatem ent o f drug seeking behaviour, has been used to identify 
factors involved in  relapse in  hum ans. The p ast decades, several an im al 
rein statem en t m odels have been developed. These include the drug  deprivation, 
the cue and drug  induced reinstatem ent, and the stress m odel (table 1) 24-26. The 
underlying neurobiological m echan ism s o f re instatem ent have been studied, using 
pharm acological m anipulations. N eurobiological correlates o f individual 
d ifferences in  the propensity  to relapse to drug tak in g  behaviour have hardly been 
reported.
Point of no return model
The point o f no return  m odel has been  investigated p rim arily  w ith alcohol in 
rats 27. In th is m odel an im als are given free access to alcohol for a long period of 
tim e. In itially  an im als show controlled drin k in g behaviour. Alcohol in take is 
largely  dependent on internal and extern al factors, such as social rank, short term  
isolation  and taste. However, after approxim ately  six m onths an im als start to 
increase alcohol intake. Three m onths later, in take is no longer under the in fluence 
o f social rank, isolation  or taste.
D opam inergic agents have been  evaluated in  this m odel. Lisuride, a D2 receptor 
agonist, was shown to increase alcohol in take in  both  controlled, and uncontrolled 
alcohol consum in g rats. On the other hand, flupenthixol, a D1, D2, D5 and 5HT2 
receptor antagonist, increased ethanol consum ption, but in  the uncontrolled 
consum in g rats only. These observations are in  agreem ent w ith hum an research 
where both com pounds have been found to increase the risk  o f relapse in  abstinent 
form er, alcohol dependent, patients 28. These fin d in gs w ith the poin t o f no return  
m odel suggest th at DA n eurotran sm ission  is involved. However, a clear cut 
conclusion about the underlying m echan ism s cannot be draw n yet.
Deprivation model
One o f the m ost widely used m odels is the deprivation model. In the deprivation 
m odel the voluntary intake of a drug is determ ined, after prolonged periods of 
forced abstinence, in  previously exposed an im als. The deprivation effect has been 
investigated m ost thoroughly  for alcohol.
This effect is not a consequence o f (alcohol)w ithdrawal. It has been observed in 
an im als exposed to doses o f alcohol below  the threshold for physical dependence.
Moreover, the alcohol deprivation effect (ADE) occurs, long after w ithdraw al 
sym ptom s have d isappeared 24.
Repeated deprivation cycles resu lt in  increased and prolonged alcohol 15
consum ption, after deprivation 24. W hether th is is reflected  by increasing
1
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biochem ical changes in  the brain , is yet to be determ ined. Since both acam prosate 
and naltrexone have been found to attenuate the ADE, glu tam atergic and opioid 
neurotransm ission are thought to play an im portant role. To what extent individual 
differences in g lu tam atergic and opioid system s reflect differences in  the 
propensity  to relapse, rem ains to be determ ined.
Not all an im als show an ADE. It has been shown th at alcohol-preferring 
(P)-rats w ith increased  novelty seeking and anxiety  ch aracteristics, show an 
increased ADE 29. In the alcohol naive state, P-rats exh ib it decreased serotonin  and 
dopam ine innervation , and decreased activity o f the m esolim bic reward pathw ay 
29. These differences m ight underlie a pre-morbid neurobiological susceptib ility  to 
the rein forcing effect o f alcohol. This m ay also  be associated w ith increased 
vu lnerability  for the developm ent o f addictive behaviors and, possibly, relapse.
Reinstatement models
The reinstatem ent m odel is used to study factors th at lead to resum ption  of 
drug  seeking behaviour in rats. Re-initiation o f pressing a lever, previously paired 
w ith delivery o f a drug, can be induced by a sm all dose o f a drug, cues previously 
associated w ith drug  delivery, or stress 26.
Drug induced reinstatement
D rug induced rein statem en t has been shown for heroin, cocaine, alcohol, 
caffeine and nicotine. The m agn itude o f the drug-induced reinstatem ent, is 
positively correlated w ith the prim in g dose. There is also evidence for cross­
reinstatem ent, ind icating th at a certain  drug  can  rein state drug seeking o f a drug 
o f a d ifferent pharm acological class. Increased responsiveness to cocaine induced 
reinstatem ent has been found for fem ale rats than  in m ale rats. The neurobiological 
m echanism s underlying th is gender related difference, is not clear.
The m esolim bic dopam ine system  plays a pivotal role in  drug induced 
rein statem en t o f cocaine and heroin  seeking. Activation o f D2 receptors, using 
D2-like agonists, reinstates drug seeking. D1-like agonists however, show the 
opposite effect, at least for cocaine seeking. Studies u sing in tracran ial drug 
in jections show involvem ent o f DA neurons in  the Ventral Tegm ental Area (VTA) 
and Nucleus A ccum bens (Nac). Moreover, after p rim in g  doses o f cocaine, increased 
ex tracellu lar DA levels have been observed in  the Nac and am ygdale (AMG). 
Increased Fos protein  expression  has been observed after cocaine p rim in g  in the 
VTA and several term in al DA projections, including the AMG, putam en  and 
anterior cingulate. To w hat extend these structures are involved in individual 
vu lnerability  for drug induced reinstatem ent, rem ains to be elucidated.
Cocaine induced rein statem en t is also  under g lu tam atergic in fluence (12).
16 Blockade o f AMPA receptors in the NAc attenuates cocaine-prim ing effects, whereas
blockade o f NMDA receptors, shows ju s t  the opposite. In addition, pharm acological
Table 2 A nim al m odels o f addiction
Animal model Article
Deprivation model Shaham  2002 
Li 2000
Reinstatem ent m odels D rug induced Shaham  2002 
Shalev 2002 
Epstein 2003
Cue induced See 2002
Shalev 2002 
Epstein 2003
Stress induced Shaham  2000 
Shaham  2002 
Shalev 2002 
Epstein 2003
Loss o f  control m odel Spanagel 2000
Substance Main findings
Alcohol
Alcohol
Longer deprivation effect after repeated cycles 
Decreased after naltrexone, acamprosate
Deprivation effect, without physical dependence, even after withdrawal has 
disappeared
Heroin
Alcohol
Heroin
Cocaine
Alcohol
Cocaine
Heroin
Attenuation by naltrexone, DA antagonist (both Dl/2)
Decreased after naltrexone, no effect of fluoxetine 
Attenuation by D2 antagonist and naltrexone
Attenuation by cannabinoid antagonist, CRF antagonist, D1 (ant)agonist, 
GABA agonist and buprenorphine
Attenuated by naltrexone, naltrindole (delta opiod antagonist)
Attenuated by GABA agonist, buprenorphine, DA antagonists, cannabinoid 
antagonist
DA antagonists, naltrexone
Cocaine
Heroin
Cocaine/
Heroin
Alco/Coc
Reduced self administration after lesion of nucleus accumbens and 
ventral tegmental area, no change of cue induce reinstatement. Reduced 
reinstatement after lesion in basolateral amygdala, D1 receptors in particular 
Reduced reinstatement after lesion in basolateral amygdala 
Attenuation by cannabinoid,D2 antagonist and fluoxetine 
Attenuated by naltrexone, naltrindole, DA antagonists 
DA antagonists, cannabinoid antagonist, NMDA antagonist
Cocaine
Heroin
Alcohol
Cocaine
Heroin
Alcohol
Cocaine
Heroin
Attenuation by CRF antagonist; alfa 2 adreneceptor agonist
Attenuation by CRF antagonist; alfa 2 adreneceptor agonist
Decrease after fluoxetine; CRF antagonists, no effect naltrexon
Attenuation by CRF antagonist, alfa 2 adrenoceptor agonist
Attenuation by CRF antagonist, alfa 2 aderenoceptor agonist
Attenuation by Fluoxetine, CRF antagonists
Attenuation by CRF antagonist, alfa 2 adrenoceptor agonists
Attenuation by CRF antagonists, DA antagonists, acamprosate, naltrexone, alfa
2 adrenoceptor agonists
Alcohol After prolonged alcohol intake (six months), intake is no longer under 
influence of taste, stress, or social ranking, resembling a loss of control model. 
Both DA agonist and antagonist treatment increased alcohol consumption
N eu rob io logy  an d  th e co u rse  o f  ad d ic tio n
studies show evidence for the involvem ent o f |j-opioid receptors. Naltrexone, a 
^-receptor antagonist, can block heroin  induced rein statem en t in  rats, and 
-receptor agon ists reduce the cocaine-prim ing effect 26, 30, 31. Recent studies suggest, 
th at also  GABAb and cannabinoid antagonists attenuate cocaine-induced 
reinstatem ent. N eurobiological characteristics pred icting treatm ent outcom e have 
not yet been found 26.
Cue induced reinstatement
Exposure to conditioned stim u li can  also  readily  reinstate drug seeking 
behaviour. These stim uli can either be paired to drug adm inistration, be predictive 
o f drug availability, or contextual cues. Activation o f D1 receptors in the basolateral 
AMG is crucial, since D1 receptor blockade in  th is area attenuates cue induced 
rein statem en t o f cocaine seeking, w hereas am phetam ine in jections augm ent it. 
In addition, DA release and Fos im m uno-reactivity in the baso lateral am ygdale 
(BLA) are increased after cue exposure 32, 33. Again, the Fos B induction is attenuated 
by D1 receptor blockade 33.
For other drugs o f abuse, the neuronal m echan ism s o f cue induced reinstatem ent 
have not been studied extensively 26, 34, 35. The role o f ind iv idual differences in the 
associative learn ing process m ediated by the AMG for the propensity  for cue 
induced relapse rem ains to be clarified . Recently, also  D2, NDMA, and cannabinoid 
receptor an tagonists have been shown to decrease cue induced reinstatem ent of 
cocaine seeking 26.
Stress induced reinstatement
Stress induced by footshocks, deprivation o f food, but also  pharm acologically  
induced states o f stress by in jection  o f corticotrophin  releasing factor (CRF), has 
also  been shown to rein state drug seeking, including heroine, cocaine, nicotine 
and alcohol. The environm ent, as well as the drug free period, are crucial 
m odulators o f these stress-effects. Stress induced outside the se lf adm in istration  
environm ent, and after prolonged abstinence is less effective in re in statin g  drug 
seeking behaviour26, 36-39.
Stress is reflected by a range o f physiologic reactions in the body, m ainly 
through  the hypothalam ic p itu itary  adrenal (HPA) axis (figure 1). Stressors 
stim ulate the release o f CRF from  the hypothalam us, which in  turn  stim ulates 
release o f ACTH from  the anterior p ituitary. C irculating ACTH stim ulates the 
adrenals to produce glucocorticoids (cortisol in hum ans, corticosterone in rats and 
mice). The secreted glucocoticoids feed back on the hypothalam us and p itu itary  to 
inh ib it furth er CRF/ACTH release. In addition  stress also  rapidly activates the 
sym pathetic branch o f the autonom ic nervous system , increasin g secretion of 
18 catecholamines such as adrenaline and noradrenaline, which in turn  inhibit HPA
axis activity.
Figure 1 H ypothalam ic-Pituitatry-A drenal axis
Stressor
Stress is  re fle c ted  by a ran ge  o f  physio logic reac tio n s in  the body. S tresso rs st im u la te  the re lease  of 
CRF from  th e  h y p o th a lam u s, w hich st im u la te s  the re lease  o f  ACTH fro m  the an terio r  p itu itary . 
ACTH st im u la te s  the ad re n a ls  to p ro du ce g lu co co rtico id s (cortiso l in  h u m an s, co rtico stero n e  in 
an im als). These g lu co co tico id s feed back  on the h y p o th a lam u s an d  p itu ita ry  to in h ib it  fu rth e r  CRF/ 
ACTH release . S tress a lso  ac tiv a te s the sy m p ath etic  b ran ch  o f the au ton om ic n ervo us sy stem , 
in c rea sin g  secre tio n  o f ca tech o lam in es such  as ad re n a lin e  an d  n o rad ren a lin e , w hich  in h ib its  
h y p o th a lam ic , p itu ita ry  an d  ad re n a l (HPA) activ ity .
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Despite the concom itant activation  o f the opioid and DA system s after stress, 
these system s seem  not to be crucial in  the reinstatem ent o f drug seeking.
Treatm ent w ith  opioid and DA antagonists has no or am biguous effects on 
reinstatem ent. Second, the DA activation  after stress is m uch lower than  after a 
p rim in g  drug dose, even though the re in statin g  effect is at least as big 26, 36-39.
A CRF pathw ay seem s m ore relevant, since in jections o f CRF rein state heroin and 
cocaine seeking, and CRF receptor (m ainly CRF R1) an tagonists attenuate footshock 
induced reinstatem ent.
The CRF receptors in  the bed nucleus o f the stria  term in alis seem  to be involved, 
since local in fusion  o f a CRF agonists/ an tagonists has been found to reinstate, cq 
block, stress induced rein statem en t o f drug  seeking. There is no evidence that 
corticosterone is involved in th is reinstatem ent 26, 36-39. In addition it has been  19
observed th at CRF1 antagonists attenuate cocaine se lf adm in istration , in  actively
consum in g an im als 40, 41, 41. This would im ply that CRF is involved in both 
m aintenance and rein itiation  o f drug  seeking.
N oradrenergic m echan ism s have also  been shown to be involved in  the stress 
induced reinstatem ent o f drug seeking. Alfa-2 receptor agon ists, known to inhibit 
NA cell fir in g  and tran sm itter release, have been shown to attenuate footshock 
induced reinstatem ent. Beta-adrenoceptors in the bed nucleus nof the stria 
term in alis (BNST) and central AMG also  attenuate footshock induced reinstatem ent, 
su ggestin g these areas to be o f specific in terest 42-44.
The 5HT reuptake inhibitor fluoxetine attenuates footshock induced 
rein statem en t o f alcohol seeking. The poten tial role o f serotonin  (5HT) needs 
furth er study 26, 36-38.
Individual differences in  stress reactiv ity  have been  shown to be related to drug 
induced neurochem ical adaptations. Stress sensitive rats, as m easured by their 
stress-induced groom ing response, show enhanced m otivation to self-adm inister 
cocaine {{Hom berg, 2003 1363 /id;Homberg, 2004 1317 /id;Shalev, 2002 1312 /id}. 
This is associated w ith reduced reactiv ity  o f DA neurons in the m edial prefrontal 
cortex and am ygdala 45, 46. These an im als also  show different adaptations in meso- 
corticolim bic DA and acetylcholinergic neurons after exposure to cocaine, furth er 
enhancing their m otivational state to self-adm inister cocaine 45. Furtherm ore 
adm in istration  o f SSRI’s to these rats resulted in  decreased cocaine self-adm in istra­
tion, w hereas this effect could not be observed in  the less sensitive rats 46.
A common final pathway in the prefrontal cortex?
It has been suggested , th at all these d ifferent reinstatem ent m odels with 
d istin ct neurobiological correlates would fin ally  engage in  a com m on pathway, 
lead ing to reinstatem ent. The role o f the prefrontal cortex has been investigated in 
th is respect. In rats, effects on drug-prim ing and stress induced reinstatem ent 
were studied, after inactivation  o f the prelim bic, in fralim bic and orbitofrontal 
cortex 47. Especially  prelim bic and orbitofrontal inactivation  attenuated both drug 
p rim in g  and stress induced reinstatem ent o f cocaine seeking 47.
Role of brain memory systems
The m esolim bic DA system  appears to be the m ajor substrate for rew ard and 
reinforcem ent, both  for n atu ral and drug reinforcers 30. D rugs can  activate this 
b rain  rew ard pathw ay with a strength  and duration  th at exceeds any n atural 
stim ulus. The strong link  with brain  m em ory system s, especially  the hippocam pus, 
connects behaviour and environm ent, at tim e o f the u tilisation  o f drugs, with 
reinforcem ent. Consolidated into m em ory pathw ays, th is creates strong drug 
w anting and seeking behaviour, after exposure to drug related cues.
20 A nim al studies provided additional evidence th at DA release in the NAc is not
m ain ly  a sign al o f reward, but m ore a learn ing signal. Some evidence suggests that
DA release in  the Nac, after a rew arding stim ulus, habituates in tim e. Instead, the 
DA neurons fire  in  response to predictors o f rew ard 30. If a predicted rew ard is 
om itted, norm al levels o f fir in g  are suppressed, i f  rew ard exceeds expectation , 
fir in g  is enhanced 30. Specific in form ation  on cues, associated w ith reward 
intensity, are thought to be successively stored in the brain.
There is extensive evidence from  an im al literature th at DA interacts with
cortically  derived glu tam ate (NMDA), to produce enduring experience-dependent
and drug-dependent changes in neural circuitry, associated w ith craving and
relapse. A ccum ulating evidence suggests th at the N-methyl-D-aspartate (NMDA)
type o f g lu tam ate receptors is a particu larly  im portant site o f eth an ol’s action.
Several studies showed th at ethanol potently inhibits NMDA receptors (NMDARs) .y
■a
and prolonged ethanol exposition  leads to a com pensatory “up-regulation” o f ’g
NMDAR m ediated functions 48, 49. Therefore, alterations in  NMDAR function  are o
supposed to contribute to the developm ent o f ethanol tolerance, dependence and ”
relapse, as well as to the acute and late signs o f ethanol w ithdraw al 48, 49. 8
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Reorganization  o f neural circu itry  can  occur by intra-synaptic p lasticity  -g
(changes in tran sm itter release, num ber and function  o f receptors), changes in 
neuronal excitab ility  (changes in voltage dependent ion channels) and m orphologic ^
changes in inter-synaptic connections . There is evidence th at long term  •§
potentiation  (LTP) and depression (LTD) effects can  occur in m esolim bic DA •§
Ï-H
structures, as a consequence o f drug  adm in istration . In the Nac, LTP and LTD can  3
be elicited after activation  o f g lu tam ate receptors. Little is known on cellu lar 
m echanism s th at underlie LTP and LTD in  the NAc 30. It w ill be im portant to 
exam in e their role in  behaving an im als and hum ans, and their clin ical relevance 
for addiction  m edicine, and especially  which factors d irect the tran sition  from  
drug  use to abuse and addiction  30.
1
Molecular mechanisms
The m esolim bic system  and its forebrain  targets are p art o f the hum an reward 
pathway, and involved in m otivational behaviour and learn ing 50. As explained 
above, drugs are thought to activate th is system  w ith an overw helm ing strength 
and duration. W ith repeated exposure, th is leads to neuroadaptations in  the 
m esolim bic system  and probably in  other brain  regions as well. Changes in gene 
expression  have been thought to m ediate such enduring neuroadaptations. At the 
m olecular level the regulatory  genes, such as FosB and Cyclic-AMP Response- 
Element-Binding protein  (CREB), are o f special interest. Tem porarily alterations in 
expression  are thought to create perm anently  altered patterns o f synaptic 
connectivity, by rem odellation  o f synapses.
CREB regulates the transcrip tion  o f genes th at have a cyclic AMP binding site. 
Many such genes ex ist throughout the nervous system , including genes encoding 
for neuropeptides, n eu rotran sm itter producing enzym es, sign allin g  proteins and
those involved in  plasticity, grow th  and survival. Chronic opiate adm in istration  
leads to an upregu lation  o f the cyclic AMP pathway, probably because o f an  in itia l 
inhibition  o f adenylyl cyclase in various brain  regions, including the locus 
coeruleus, and nucleus accum bens 31,51. An increased cyclic AMP pathway, activates 
CREB, w ith consecutive increased expression  o f CREB contain ing genes in  these 
areas.
U pregulation  o f CREB in the locus coeruleus has been found to m ediate physical 
dependence and w ithdraw al in m ice 31, 51. Overexpression o f CREB in  the Nac is 
found to decrease the rew arding effects o f opiates and cocaine, m easured by a place 
preference parad igm  31, 51. Moreover, an an im al’s in terest for n atu ral reinforcers is 
dam pened by increased CREB function , and enhanced in  decreased CREB function  
51. This m ay reflect reduced interest in  n atu ral rew ards, as observed in  substance 
dependent patients 51. In an im als, stress also causes a com parable activation  of 
CREB in  the Nac 51. CREB activation  in  the Nac is therefore hypothesized to m ediate 
reduced sensitivity  to rew arding stim uli, which m ight m ediate anhedonia, as 
observed in substance dependent patients.
The longest-lasting m olecular change observed after repeated drug exposure is 
an  overexpression o f AfosB in the Nac and dorsal striatum , lastin g  for one or two 
m onths after drug w ithdraw al 31, 51. After drug adm in istration , several transcrip tion  
factors o f the Fos fam ily  are rapidly induced. Most are degraded rather rapidly as 
well. AfosB however, is rather stable and accum ulates w ith repeated drug exposure, 
to becom e the predom inant Fos-like protein  in these neurons 31, 51.
Induction o f AfosB in the Nac and dorsal stria tu m  o f transgenic m ice, has been 
shown to increase locom otor activity, conditioned place preference and self 
adm in istration  o f cocaine and m orphine 31, 51. Cocaine se lf adm in istration  and 
seeking in  reinstatem ent m odels were also  increased after AfosB induction  31, 51. 
Recently, expression  o f a AfosB antagonizing protein  (a dom inan t negative c-Jun 
m utant), has been shown to induce opposite effects in a place preference m odel 51. 
AfosB expression  m ight be a m olecular m echan ism , underlying sensitization  to 
drug  related cues, after repeated exposure.
One o f the proposed m echanism s, through  which AfosB induces a sensitized 
beh avioural state, are glu tam ate receptors. An AMPA receptor subunit (GluR2), is 
overexpressed after AfosB induction31, 51. AMPA receptors contain ing th is subunit, 
show reduced conductance levels after g lu tam ate binding, m ak in g  neurons less 
sensitive for glu tam ate, w hich m ay play a role in  sensitization  51. However, AFosB is 
involved in  the regulation  o f m any genes. Changes in  AMPA receptors are probably 
ju s t  one o f m any m echanism s involved 51.
Conclusion
22 Most an im al studies have focused on the neurobiological m echan ism s o f
relapse. The an im al m odels reviewed in th is study contribute to our knowledge o f
neurobiological correlates o f addiction. However, little  is known about individual 
d ifferences in proneness to relapse and the course o f addiction  in  general. Studies 
are needed th at focus on these indiv idual differences, leading to prognostic 
m arkers and targeted  pharm acotherapy.
A nim al m odels o f re in statem en t appear relevant for hum an relapse behaviour 
in  substance dependent patients. Indeed, p rim in g  doses o f cocaine and alcohol 
have shown to increase the desire for these substances in hum ans 38, 52. Exposure to 
stre ssfu l p ictures and p ictures o f drug  related cues, also  increase se lf reports of 
craving 38, 52.
However, the valid ity  o f an im al m odels o f re instatem ent for relapsing 
behaviour in  hum ans is under debate 36, 52. Face validity, agreem ent in  appearance 
o f the behaviour, seem s acceptable. It is questionable w hether se lf adm in istration  
in  an im als can  m odel loss o f control behaviour in hum ans. Aversive stim u li have 
been shown to suppress drug seeking in rats w ith lim ited  cocaine se lf adm in istration  
experience. After a m ore prolonged period o f cocaine consum ption, th is suppression 
is no longer observed, w hereas after prolonged sucrose consum ption  suppression 
by aversive stim u li rem ains 53. This m ay better re flect com pulsive drug  use, despite 
adverse consequences, as observed in  hum an addicts. In addition, it rem ains 
questionable w hether reinstatem ent o f drug tak in g  behaviour in  an im als equals 
self-reported craving, and relapse in  hum ans.
Predictive validity, pred ictin g intervention outcom e in  hum ans through 
an im al m odels, has produced little  agreem ent. Some m edication  effects have been 
predicted from  an im al m odels, for exam ple the p-opioid receptor antagonist 
naltrexone, th at is effective in reducing relapse in  hum an alcohol dependent 
patients. Few clin ical tria ls up to date have tested com pounds, that have been 
proven effective in  rein statem en t m odels.
There is lim ited  evidence for content validity, i.e. m echanistic resem blance. 
M olecular changes have been observed after exposure to drugs in an im als. It is far 
from  clear w hether th is is a consequence o f drug se lf adm in istration , or drug 
exposure per se. The relation  w ith a tran sition  o f controlled consum ption  to 
com pulsive drug  use, a h allm ark  in  addiction, is even less clear. Further research 
on an im al drug tak in g  behaviour is needed to bridge th is gap. More appropriate 
an im al m odels, w ith m ore prolonged drug  exposure and uncontrolled drug tak in g 
behaviour, should be used to unravel the relation  betw een the various transm itter 
system s involved, especially  DA and glutam ate, stru ctu ral changes, e.g. in the 
nucleus accum bens, and the underlying m olecular m echan ism s like, AfosB and 
CREB expression.
All three reinstatem ent m echan ism s d iscussed  above, appear to be 
com plem entary. This would m ean th at d ifferent m echan ism s are involved, in 
d ifferent types o f relapse. In hum ans, exposure to several relapse inducing 
situations, m ay also  have a com bined effect 28. In future, treatm ent m ay need to
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focus on all these different m echan ism s o f relapse. It rem ains unclear, which 
ind iv idual is m ore vulnerable to w hich type o f relapse. Translational should test 
th is hypothesis, by studying these d ifferent m echan ism s o f relapse in hum ans, and 
focus on the neurobiological m echanism s involved. W hether a fin a l common 
pathw ay eventually m ediates relapsing behaviour, needs to be studied . A nim al 
data  suggest an  im portant role for the prefrontal cortex.
Human neuropsychopharmacology
Hum an neuropharm acological research  tries to elucidate neurobiological 
and neurochem ical factors, involved in neuropsychiatric d iseases. Results from  
neuropharm acological studies could m ake an im portant contribution  to the 
understan din g o f inter-individual differences in the course o f addiction. Challenge 
and depletion studies, and studies involving peripheral m arkers could help to 
identify  b iological m echanism s, underlying substance dependence and relapse. 
This m ight identify  neurobiological indicators o f severity and prognosis o f the 
disease. Identification  o f addiction  subtypes, w ith possibly d istin ct pathophysiolo­
gy could be u sefu l to m atch therapy to indiv idual ch aracteristics in future.
Furtherm ore the duration  o f abstinence from  alcohol and illic it drugs was 
found to be longer for ind iv iduals who were non-sm okers or qu it sm oking during 
detoxification  treatm ent 54. Interestingly, resum ption  o f sm oking indicated a 
greater risk  for relapse 54. This m ight re flect cross sensitization  to prim in g dose 
induced relapse as observed in an im als.
Research into the neurobiology underlying these m echan ism s in hum ans 
could help answ er these questions. Here we report on articles th at focused on neu­
robiological m arkers related to addiction  severity and treatm ent outcom e. The 
search on Pubmed did not reveal any review articles on this issue. However, 
screening o f a ll hits resu lted in nine orig inal articles. Searching M edline and 
Psycinfo revealed another five orig in al articles. We found one review on m olecular 
m echanism s underlying com pulsive drug  use and its persistence. Finally  fifteen  
papers were included. Six dealt w ith cocaine, two with alcohol, five were on 
addiction  in  general and another two dealt with stress in  particu lar.
Hum an neuropharm acological research on addiction in  vivo has focussed 
m ain ly  on m echanism s o f drug action and changes induced by the use o f 
psychoactive drugs in relevant neural circuits. Also m any articles deal w ith the 
detection o f relapse u sing b iochem ical m arkers. The use o f psychopharm acological 
techniques in  the field o f addiction  research  has however been lim ited. Therefore 
also  orig in al articles on psychopharm acological research on addiction, appearing 
24 betw een 2000 and 2005 were reported. In addition references were screened for
relevant articles.
Dopamine (DA) system
Psychopharm acological ch allenge studies in alcohol dependent patients that 
focused on sensitivity to dopam inergic agents are few. In hum ans reduced DA 
function  has been found to be related to severe dependence and the risk  o f relapse.
The secretion o f prolactin  is under inh ibitory  in fluence o f tu beroin fu nd ibu lar DA 
neurons. Changes in  serum  prolactine levels are thus thought to re flect central DA 
activity. In addition, elevated prolactin  levels have been  found during outpatient 
treatm ent o f cocaine addicts 55-58. The level o f prolactin  was associated with 
addiction  severity as m easured by quantitative cocaine use and Addiction Severity 
Index scores 57,58. However baselin e prolactin  levels could not pred ict treatm ent 
outcom e 57.
Stim ulation  o f n eu roin fu nd ibu lar DA receptors stim ulates p itu itary  grow th 
horm one secretion. It has been shown that alcohol dependent patients show 
reduced grow th horm one responses to adm in istration  o f the dopam ine agon ist 
apom orphine (APO), com pared to healthy controls, p articu larly  during 
detoxification  59-62. Moreover, early relapse after in itia l detoxification  in  a clin ical 
sam ple has been shown to be related to a low grow th horm one response to APO, 
com pared to abstainers 59, 60. To w hat extend such hypothalam ically  m ediated 
endocrine m easurem ents re flect m esolim bic and prefrontal DA function , believed 
to be involved in  addiction pathophysiology, is unclear. Studies on the effect o f 
variation  in  the dopam ine D2 receptor gene on the grow th horm one response to 
APO have shown reductions in  grow th horm one response in  carriers o f the TaqA1 
varian t o f the DRD2 receptor gene 63. However, conflictin g resu lts on th is effect 
have been  reported 64.
Long term  drug  use resu lts in both tolerance (reduced effects w ith the sam e 
dose) and sensitization  (increased effect w ith the sam e dose). C linically  sensitization  
to psychosis inducing effects o f cocaine has been described. Cocaine is known to 
induce (paranoid) psychosis, especially  w ith long-term use. More than  h a lf of 
inpatien t cocaine dependent patients show paranoid psychosis 65, 66. H alf o f the 
patients reported psychosis to be induced by less drugs over tim e and m ore than 
h a lf  reported w orsening o f sym ptom s over tim e 65, 66. This sensitization  to psychosis 
inducing effects o f cocaine m ay reflect altered DA function . Sensitized patients 
were shown to have less severe cocaine dependence and reported less craving 66.
This m ay indicate a decrease in  use, to avoid (paranoid) psychosis 66. Previous 
studies have shown a trend for a greater num ber o f re-hospitalizations for sensitized 
patients 65. Reports on clin ical relevance as an  indicator o f addiction severity, 
craving, and relapse vu lnerability  need furth er study 65, 66.
Serotonin (5HT) system
The serotonin (5HT) tran sporter (5HTT) serves as a binding site for cocaine. The 25
exact role o f the 5HT system  in cocaine dependence however is not clear. Yet
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reductions in peripheral m easures o f 5HT function  have been shown to be 
associated w ith worse treatm ent outcom e. Binding o f titrated  paroxetine to 
platelets is used to determ ine the num ber o f peripheral 5HT tran sporter sites 
(Bmax). It is thought that a decreased density  o f tran sporter sites m ay be associated 
w ith reduced 5HT uptake and lead to decreased 5HT neurotran sm ission  67. Increased 
drop-out rates from  treatm ent and, a higher risk  for relapse were associated with 
reduced paroxetine b indin g on platelets. An association  w ith subjective reports on 
craving could not be found 68. Also sensation  seeking, im pulsivity  and aggression  in 
cocaine dependent indiv iduals had lower paroxetine b indin g 67, 68. These findings 
suggest a decreased 5HT n eurotran sm ission  in addiction, in  p articu lar  im pulsive 
and aggressive patients.
It has been studied whether substance dependent patients would benefit from  
treatm ent w ith serotonergic agents. F indings are in trigu in g. The response to 
serotonergic agon ists and agon ists seem  to d iffer am ong subgroups o f alcohol 
dependent patients. Since decreases 5HT function  was thought to be related to 
addiction, selective serotonin re-uptake inhibitors (SSRI’s) were thought to be effective.
Studies u sing sertralin e and fluoxetine have shown some ben eficial effects of 
SSRI’s over placebo only in alcohol dependent patients w ith a late onset (type I) of 
the d isease 2 3. Patients w ith early onset drin k in g  (type II) were even found to 
increase their d rin k in g behaviour after treatm ent w ith a SSRI 2 3.
Evaluating the effect o f ondansetron, a selective 5HT3 antagonist, resu lts were 
opposite. Type II alcohol addicted patients appeared to im prove sign ifican tly  
com pared to placebo 69. Though type I alcohol dependent patients did not deteriorate 
sign ificantly, their outcom e was worse com pared to placebo 69.
Glutamate
Despite the fin din gs on the role o f glu tam ate in the developm ent o f substance 
dependence in an im al studies, hum an  pharm acological studies on glu tam ate in 
substance dependence are lim ited. H um an studies m ainly  focus on the treatm ent 
o f  alcohol dependence w ith  acam prosate. A cam prosate is a g lu tam ate antagonist 
and has been shown to be an effective and safe treatm ent strategy  for supporting 
continuous abstinence after detoxification  in alcohol dependent patients 70-72. 
Moreover, it has been suggested th at m easu rin g cerebral g lu tam ate during alcohol 
w ithdraw al, u sing MR spectroscopy, m ay define subtypes o f alcoholics according to 
p articu lar  h igh cerebral g lu tam ate during acute alcohol w ithdraw al 73. This study 
is currently  in its recru itm en t phase, and resu lts are expected soon.
Hypothalamic Pituiary (HPA) axis
As observed in  an im als, in hum ans drug intake is also  under influence of 
26 stre ssfu l events 74. Firstly the vu lnerability  to becom e addicted is increased am ong
indiv iduals w ith a h istory o f early physical and sexual abuse. Furtherm ore these
ind iv iduals tend to have an earlier age o f onset o f substance abuse. Patients with 
deficient coping strategies, also  appear to use drin k in g and drug us as an alternative 
coping strategy to deal w ith stress. Secondly exposure to stress appears to increase 
drug  and alcohol in take am ong substance dependent patients.
Stress also  plays an im portant role in the detoxification  process 74. During 
w ithdraw al the stress system  (see an im al models) becom es activated, and levels of 
CRF in the cerebrospinal flu id , p lasm a ACTH, cortisol, norepinephrine and 
epinephrine increase. Stress and negative affect are often  reported reasons for 
relapse. Stress proved to be a sign ifican t predictor o f treatm ent outcom e after two 
years in  both alcohol and cocaine dependent patients 75. Coping w ith stress has also 
been found to be associated with relapse in  alcohol dependents, heroin  addicts, and 
cocaine abusers 74. Yet, the occurrence o f stre ssfu l life events only does not predict 
relapse. Individual resources for coping have been found m ore im portant for the 
likelihood to relapse 74. D isappointingly  cognitive beh avioural interventions 
designated to teach m ore adequate coping sk ills appeared not ben eficial over 
stan dard  drug  coun selling 74. This raises the question  w hat other m echan ism s 
underlie stress m ediated relapse in hum ans.
Reactivity o f the H ypothalam ic-Pituitary-Adrenal axis has been found to 
pred ict the duration  of rem ission  and necessity for continued therapy in  patients 
w ith depression 55, 56. A blunted stress horm one (cortisol) response to CRH 
adm in istration  is a reliable m arker for an  activated HPA-axis. Especially  in 
substance dependent patients with co-morbid depressive sym ptom s such 
neuroendocrine abnorm alities in the regulation  o f the HPA-axis m ay be clin ically  
relevant 55, 56.
A blunted cortisol response to CRH adm in istration  has indeed been found in 
polysubstance dependent ind iv iduals, but w ithout axis I p sychiatric co-morbidity 
55, 56. Previously also  elevated basa l levels o f cortisol have been found in  cocaine 
dependent ind iv iduals 55, 56. These fin d in gs suggest a centrally  activated stress 
system  in  substance dependent patients. HPA axis hyperresponsivity found in  drug 
free form er heroin addicts seem s to persist for m onths or years after cessation  of 
heroin  addiction, but appears to n orm alize during steady state p-opioid agonist 
treatm ent, such as m ethadone 76.
On the other hand a subgroup o f cocaine addicts has been found to show a 
hypoactive HPA axis. Reduced levels o f cortisol have been found in  cocaine addicts 
w ith a history  o f violence and aggression  77. Com parable fin d in gs were reported in 
ind iv iduals w ith an tisocial personalities 77. The cocaine dependent patients with 
reduced p lasm a levels o f cortisol, ind icating an hypoactive HPA-axis, were more 
likely to relapse alm ost im m ediately  after release from  the hospital 77.
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Conclusion
The observation  o f d istin ct neurobiological pathw ays to relapse in an im als 
m ight have relevance for the hum an situation  as well. It has been clearly shown 
th at d ifferent neuropharm acological system s are involved in different form s of 
relapse. The m ost im portant system s currently  identified  are the DA, 5HT, as well 
as the neuroendocrine stress system  (HPA axis).
Poor treatm ent outcom e has been associated w ith low levels o f DRD2 and 
reduced DA agon ist sensitivity, and decreased 5HT n eurotransm ission . Stress seems 
to induce relapse in hum ans as well as rein statem en t o f drug tak in g  behaviour in 
an im als. Moreover the stress system  appears ch ronically  activated in  substance 
dependent patients, which m ay p ersist for m onths after abstinence. On the other 
hand hypoactivity o f the HPA axis seem s to be a predictor o f poor treatm ent 
outcom e in  a subgroups o f cocaine addicts. An hypoactive HPA axis has been found 
in  patien ts w ith attention  deficit hyperactivity disorder, an tisocial personality  
disorder, and conduct disorder. Reduced HPA activity  m ay therefore indicate a 
subgroup o f patients w ith specific psychiatric co-morbidity.
It appears th at an hypoactive DA system  is associated w ith higher novelty 
seeking behaviour, and high h arm  avoidance. This m ay form  another subgroup of 
substance dependent patients w ith a specific clin ical presentation. However, 
im pulsivity, and sensation  seeking have also  found to be associated with 
hypoactivity o f the 5HT system . How these neural circu itries interact in addictive 
d isorders is not clear yet. One proposed hypothesis is a deficiency o f the brain  
rew ard system . This theory seem s to apply for early onset patients in  particu lar. 
Both DA and 5HT m ay interact on the m esolim bic rew ard system  to produce a less 
sensitive rew ard system . This would m ake an indiv idual m ore sensation  seeking 
and m ore vulnerable to develop substance dependence, and relapse.
Others studies found an hypoactive 5HT system in addicted patients to be 
associated with depressive symptoms. These patients, more likely having a late onset 
o f the disease may need a different treatm ent approach, with for exam ple selective 
5HT reuptake inhibitors. These have shown some effect in a group o f type I alcohol 
dependent patients, where type II alcohol addicted patients seemed to worsen on 
SSRI’s 2 3. On the other hand, when treated with the selective 5HT3 antagonist 
ondansetron only early onset alcohol addicts improved significantly over placebo 69.
Also evaluation  o f the hum an stress system  m ay have clin ical im plications. 
Patients w ith an hyperactive HPA axis m ay benefit from  treatm ent w ith  a CRH 
antagonist. P reclinical data  show im provem ent o f m aladaptive behaviours after 
treatm ent w ith a CRH antagonist. These patien ts m ay also  be m ore sensitive to 
stress induced relapse. More em phasis on psychotherapeutic interventions to 
im prove coping in stre ssfu l situations m ay also  be ben eficial for these patients. The 
28 clin ical relevance o f these d ifferent neurobiological pathways to relapse in
different subgroups of substance dependent patients needs furth er study.
Neuroimaging
Advances in  im agin g  techniques have m ade it possible to study brain  structure 
and fun ction al aspects in vivo. In addiction  research  m uch attention  has focused 
on m echan ism s o f action o f addictive drugs and the neurobiological consequences 
o f long term  drug use. Im aging studies have revealed areas in  the brain  involved in 
various stages o f the disease.
Stru ctural and fun ction al changes have been  studied u sing (functional)
M agnetic Resonance Im aging ((f)MRI), D iffusion  Tensor Im aging (DTI), Positron 
Em ission Tomography (PET) and Single Photon Em ission Com puted Tomography 
(SPECT). Data on the clin ical relevance o f neuroim aging data for the course of 
substance dependence are very scarce. In th is introduction  I therefore focus on the 
m ain  fin d in gs w ith  neuroim aging techniques w ith respect to the pathophysiology 
o f substance dependence.
Brain structure (MRI and DTI)
Stru ctural abnorm alities have been found in  patients dependent on or abusing 
various types o f drugs, including alcohol. Some o f these stru ctu ral changes tend to 
n orm alize during abstinence, w hereas others do not. The relevance o f these 
stru ctu ra l changes and their recovery for clin ical presentation , treatm ent and 
prognosis has to our knowledge not been  studied extensively yet.
MRI data  have shown reduced volum es o f grey and white m atter in the cerebral 
cortex, m ost pronounced in the fron tal lobes o f alcohol dependent patients 78-80.
Volume changes also  occur in  hippocam pus, thalam us, cerebellar cortex and 
corpora m am illaria . Long term  MRI studies o f alcoholics have shown cortical white 
m atter volum e as p articu larly  am enable to recovery w ith abstinence and vulnerable 
to furth er decline w ith continued drin k in g 78. Some studies have shown volume 
reductions in  chronic cocaine abusers in the fron tal lobes in p articu lar. These 
reductions in volum e affect both  white and grey m atter and seem  to correlate with 
the duration  o f abuse 81.
In addition  various general neuropathological changes have been observed in 
cocaine abusing subjects. Random ly d istributed focal white m atter hyperin tensi­
ties, found in  MRI studies, are thought to reflect ischem ic lesions due to cocaine 
abuse. These do not affect any brain  area in  p articu lar, m oreover they tend to 
increase w ith age 82.
In m etham phetam ine dependent subjects, neuronal dam age has been observed 
u sing m agnetic resonance spectroscopy (MRS). This is a MRI technique which 
detects concentrations o f n eu rotran sm itters or their m etabolites in  pre-selected 
brain  areas. Low levels o f N-acetylaspartate (NAA) were found in the basa l gan glia  
and prefrontal grey m atter 83. In the fron tal regions h igh levels o f choline (Cho) and 29
m yoinositol (Mi) were observed 83. Low levels o f NAA and h igh levels o f Cho and Mi
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are thought to reflect neuronal dam age. Studies w ith recently abstinent subjects 
have shown recovery o f dam age to borderline norm al levels 83.
A relatively new MRI technique, DTI, has recently been used to study effects of 
long term  alcoholism . DTI can  be used to study degradation  o f white m atter fibres. 
D isruptions o f fibre m icrostru ctu re  were found in  white m atter o f the front p art of 
the corpus callo su m  and in  the m ass o f white m atter that com poses the interior of 
the cerebral hem isphere. The m agn itude o f the dam age in these regions was 
associated w ith w orking m em ory and attention  deficits. This m ight have 
consequences for the likelihood o f relapse and abstinence 78.
Brain metabolism Positron Emission Tomography (PET and SPECT)
Using PET, alterations in regional blood flow  and m etabolism  can  be studied. 
PET studies into alcoholism  have been used to investigate both  acute and long term  
effects o f alcohol intake. Long term  changes in  alcohol use d isorders are considered 
m ore relevant for the course o f alcohol addiction, and only these w ill be discussed 
here.
Brain glucose m etabolism  in  alcohol dependent patients has been shown to be 
decreased through out the entire brain  80. These changes appear m ost pronounced 
in  the fron tal lobes and cerebellum  80. Regional cerebral blood flow  (rCBF) has also 
been  found to be reduced in these regions 80, 81. Decreases in  rCBF and m etabolism  
in  fron tal lobes precede shrinkage o f th at brain  area and are associated with 
cognitive im pairm en ts 79, 81. Im provem ent in  cognitive function  w ith in  the first 
weeks o f abstinence are accom panied by a p artia l reversal o f brain  shrinkage 79. 
Frontal lobe blood flow  also  appears to n orm alize sim ultaneously  79, 81. The duration 
to recovery varies from  4 m onths to 4 years, depending on the brain  region  under 
survey, im aging technique and duration  o f follow-up 79, 81. Relapse to alcohol 
ingestion  renews brain  shrinkage and rCBF reductions 79. Indeed alcohol dependents 
who rem ained abstinent betw een two PET scans (interval vary ing 10-32 months) 
showed increases in  glucose m etabolism  in the orbital and m edial areas o f the 
fron tal cortex, w hereas the relapsers showed decreased m etabolism  81.
The risk  o f relapse after detoxification  has been found to be associated with 
both the degree o f neuropsychological im pairm en t as well as frontal 
hypom etabolism , as m easured by PET 81. It rem ains to be elucidated w hether the 
observed deficits in both m etabolism  and cognitive perform ance only resu lt from  
chronic exposure to high levels o f alcohol in  the blood or also  re flect pre-morbid 
states o f increased vu lnerability  for the addictive properties o f alcohol and possibly 
relapse.
In active cocaine users m etabolic activity in the orbitofrontal cortex (OFC) and 
cin gulate gyrus are increased  84. D uring the fir st  weeks o f detoxification  cocaine 
30 dependent subjects show increased m etabolic activity in  the orbitofrontal cortex
and basa l gan glia  81, 84. In the group o f active cocaine users hyperactivity  in  the OFC
was found to be associated w ith increased se lf reports o f craving. Intravenous 
adm in istration  o f m ethylphenidate (MP) was shown to increase OFC m etabolism , 
only in  subjects th at reported intense craving after MP 84. The sam e has been shown 
for exposure to video’s o f drug paraph ern alia  and recall o f drug experiences 84. This 
indicates a involvem ent o f the OFC in  the process o f craving. To what extend this 
process is relevant for indiv idual prognosis is not clear yet.
Prolonged abstinence has been found to be associated w ith decreased 
m etabolism  in the fron tal cortex o f form er cocaine addicts 81 84. These reductions 
have been shown up to one and a h a lf  and three m oths o f abstinence 81, 84. In cocaine 
addicts long lastin g  neuro-cognitive deficits have been found th at are related to 
prefrontal dysfunction  81. These are hypothesized to be a consequence o f long term  
cocaine use and contribute to disinhib ition , im pulsivity, and attentional deficits, 
rendering an indiv idual m ore vulnerable to re-initiation o f drug abuse.
Glucose m etabolism  in the brain  has been found to be decreased in thalam ic 
and stria ta l brain  areas o f m etham phetam ine users after at least n ine m onths of 
abstinence. M etabolism  did recover in the thalam us, w hich was correlated with 
better perform ance in m em ory and attention  tasks. However stria ta l m etabolism  
did not recover even after prolonged abstinence. Since stria ta l activity  seem s to be 
involved in m ediatin g the rew arding effects o f drugs, th is m ight re flect an 
enduring anhedonic state after m etham phetam ine detoxification  85.
Chronic cannabis u sers have been shown to have lower baselin e cerebellar 
m etabolism  and greater increases o f activity in prefrontal and m esolim bic areas 
after adm in istration  o f delta-9-tetrahydrocannabinoid, the active com pound of 
cannabis. Early onset o f cannabis use is associated w ith stru ctu ral abnorm alities 
including reduced whole brain  volum e and percentage o f grey m atter 86. These 
fin d in gs are rather unspecific, the m eaning and their prognostic relevance rem ain  
to be studied.
In su m m ary  data  on brain  m etabolism  in  addiction to various substances have 
shown rem arkably consistent fin d in gs w ith regard  to the prefrontal cortex. 
Reduced PFC m etabolism  has been found across patients dependent on various 
substances. In addition  cognitive deficits related to fron tal dysfunction  have been 
found am ong substance dependent patients. It is thought that decreased PFC 
function  resu lts in reduced inh ibitory  control over behaviour as observed am ong 
substance dependent patients. This m ay account for in itiation  o f d rug  use and 
continued im pulsive drug  use. Once addicted, it m ay also  contribute to a h igh risk  
for relapse after detoxification , due to reduced response inhibition . Moreover 
hyperactivity  in  PFC regions has been suggested to be related to craving in active 
cocaine abusing subjects. The relevance o f a p rim in g  dose, exposure to drug related 
cues and recall o f drug  experiences as observed in  an im al studies has also  been 
shown in  hum ans. Reduced response inh ibition  m ay render an individual 
susceptible for re in statem en t o f drug consum ption.
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The use o f PFC m etabolism  indices in  clin ical decision m aking and treatm ent 
selection  appears feasible but is not extensively used in  practice yet. Further 
research  is needed to help identify ing patients at h igh risk  for relapse, using 
neuro-im aging techniques. This m ay im prove treatm ent outcom e when ‘h igh ’ risk 
patients can  be offered m ore intense treatm ent program m es.
Neutrotransmitter systems (PET and SPECT)
PET studies have been used in the evaluation  o f neurotran sm itter system s in 
substance dependence. Using radio  ligan d  tracers, binding capacity  can be studied 
for various tran sm itter system s. Changes in  b indin g capacity after an intervention, 
e.g. cue induced craving, can  be studied.
Chronic alcohol consum ption  appears to lead to a down regulation  o f the num ber 
o f GABA receptors and the ability  o f GABA to bind to these receptors. The alcohol 
w ithdraw al syndrom e is therefore thought to re flect generalized  neuronal hyper- 
exitab ility  due to reduced inhibitory activity throughout the brain  79.
Excitatory neurotran sm itter system s are in fluenced by chronic alcohol 
consum ption. In p articu lar  glutam ate, dopam ine and serotonin  system s have been 
shown to undergo alterations due to chronic excessive alcohol consum ption. 
Reductions in  g lu tam ate NMDA receptors m ay play a role in  m em ory deficits and 
learn in g problem s associated w ith chronic alcohol exposure. 5HT and DA activity 
have been shown to be im paired  by chronic excessive alcohol consum ption. Reduced 
5HT and DA function , probably are thought to re flect hypofunction  o f the brain 
rew ard system s 79.
Dopamine
In im agin g  research  the m esolim bic DA system  has received a lot o f attention. 
This p ar t brain  system , often referred to as the brain  rew ard system  is involved in 
reinforcem ent and attention  direction  81 84 84 87 88. D ysfunction o f th is brain  region 
w ould therefore resu lt in an anhedonic, state w ith increased salience attribution  
to drugs and drug related cues 81 84 87-89. Indeed PET and SPECT studies have shown 
reduced stria ta l DRD2 availab ility  in patients dependent on the m ost com m only 
abused drugs. This is in  line w ith fin d in gs o f reduced DA release in  the ventral 
stria tu m  after stim ulation  w ith a DA agonist in substance dependent ind iv iduals 84 
84, 85, to. Moreover a delayed recovery o f stria ta l DRD2 density  has been shown 
predictive o f subsequent poor treatm ent outcom e and in som e cases w ith early 
relapse in  alcohol dependents 85 90. Again th is paralle ls fin d in gs o f reduced DA 
agon ist reactiv ity  in  relapsing com pared to abstain in g alcohol addicts 62.
DA tran sporter availability, as m easured by ligan d  b indin g using PET, has been 
found to be reduced in chronic m etham phetam ine abusers and alcohol dependent 
32 patients 83 84 84 87 88. Moreover the m agn itude o f DA increases after adm in istration
o f m ethylphenidate, a DAT blocker, appears sm aller in substance dependent
patients com pared to healthy controls 84, 87' 88. Reductions in  DRD2 and DAT in  meth- 
am phetam ine users are shown to be reversible after 12-17 m onths o f abstinence; 
however neuropsychological perform ance did not equally  im prove 85. Recovery of 
DAT in alcohol dependent patients seem s to occur during the fir st  week of 
abstinence 84, 87, 88. DA system s outside the stria tu m  have been shown dam aged, 
especially  the anterior cin gulate and orbitofrontal cortex 85. Since these structures 
are thought to be involved in  inh ibition  and behavioural control, it is understandable 
th at substance dependent patients show high im pulsivity  and problem s in 
beh avioural control, related to drug  tak in g  behaviour in  p articu lar. This m ay m ake 
dependent ind iv iduals m ore vulnerable to relapse in  drug tak in g  behaviour.
In both  hum ans and an im als cues, ingestion  o f sm all am ounts o f a drug, and 
stress seem  to be able to provoke relapse. The m esolim bic DA system  m ay play an 
im portant role. Firstly  brain  activity  in the m esolim bic DA system  increased  after 
exposure to these stim uli. Secondly the am ount o f activity appears to correlate 
w ith subjectively reported craving. These fin d in gs m ay indicate increased salience 
attribution  to drug  related cues. The exact relation  to relapse however, rem ains to 
be elucidated 84, 85, 88.
Serotonin (5-HT)
Evidence for dysfunction  o f the 5-HT system  in addiction comes m ain ly  from  
an im al, genetic, and psychopharm acological research. Cognitive deficits, im pulsive 
responding in  p articu lar, have been  observed in  chronic m etham phetam ine users 
83. Im pulsivity  has been associated w ith  serotonergic dysfunction  83. Neuro-im aging 
research  could help unravellin g the neurobiological m echanism  behind these 
observations and its relevance for prognosis and treatm ent.
SPECT has been used to study effects on 5-HT neurons o f chronic excessive 
alcohol use. A defect in the gene encoding the serotonin transporter was associated 
with increased vulnerability  to the toxic effects of chronic alcohol abuse. Alcoholic 
carriers o f two copies o f the long allele o f the 5HT regulatory region showed a low 
availability  o f 5HT transporters, whereas their non alcoholic counterparts showed 
increased 5HT transporter availability  com pared to carriers o f the short allele. An 
interaction o f genetics and alcohol abuse m ay therefore resu lt in neuropharmaco- 
logical abnorm alities. Moreover low availability  o f brainstem  5HT transporters have 
previously been associated with increased anxiety and depression. In a subgroup of 
alcohol dependents this m ay contribute to an increased risk for relapse 79, 90.
Conclusion
N euroim aging has greatly  contributed to our in sigh t in  m echan ism s o f drug 
action and long term  consequences o f excessive drug  use. Even though different 
im agin g  techniques are used w ith in  different populations o f addicts (different 33
drugs, com orbidity patterns etcetera, resu lts are rather consistent. Areas associated
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with m otivational learning, goal directed behaviour, decision m aking and response 
inh ibition  seem  especially  involved. These areas include the AMG, ACC, dlPFC, OFC 
and ventral striatum .
Addiction is therefore hypothesized as a syndrom e o f im paired  response inhibition 
and increased salience attribution, in  ind iv iduals w ith reduced levels o f reward 
activity. This has im portant consequences for addiction  m edicine. Strategies for 
intervention should aim  at increasin g rew ard activity related to non-drug 
reinforcers, decrease the rew arding value o f drugs, strength en  inhibitory control 
and counteract on conditioned responses.
To w hat extent im agin g  studies can be used for ind iv idual m arkers o f prognosis 
and treatm ent selection  rem ains to be elucidated. C urrently studies are being 
undertaken  to com bine both genetic/genom ic and im aging techniques to unravel 
b iological alterations at a m olecular level. By com bining these strategies we will 
get a better in sigh t in inter-individual differences in  the m echan ism  o f addiction, 
and prognosis, which m ay in futu re drive treatm ent selection.
Human genetics
Genetic studies can  be divided into quantitative genetics and m olecular 
genetics. In heritab ility  studies the likelihood o f a certain  d isease to resu lt from  
heritable factors is calcu lated. The precise genetic variation  involved, can  be 
identified  by m olecular genetic studies.
Heritability of alcohol dependence
If the frequency o f a disorder is higher am ong siblings o f a patien t com pared to 
the frequency in  the general population  (the disorder runs in  fam ilies) th is may 
indicate a genetically  transferred  risk. Fam ily m em bers o f alcohol dependent 
patients indeed have tw ice the risk  o f subjects in  the general population  to become 
substance dependent (15.3% versus 8.7%) 91. In fir st degree fam ily  m em bers the risk 
to becom e alcohol dependent is tw ice th at o f m em bers in the second or th ird  degree 
(86% versus 45%) 92.
If the frequency o f a disorder is h igher am ong a m onozygotic co-twin o f a 
patient, sh arin g approxim ately 100% o f o f the DNA, com pared to the frequency in 
a dizygotic co-twin o f a patient, sh arin g approxim ately 50%, this is also  an 
indication  th at heritable factors are likely to be involved. The two largest tw in 
studies on alcohol (and drugs) dependence are the studies in  the V ietnam  Era Twin 
(VET) register en het V irgin ia Twin (VT) register 93-99. The VET register consists of 
8000 m ale tw ins that served in V ietnam  betw een 1956 and 1975. The VT register is 
34 a population  based register, consisting o f 800 fem ale and 1193 m ale tw ins. For
alcohol dependence the concordance (occurrence o f the disorders in both tw in
m em bers) in  m onozygotic tw ins is estim ated  at 30-60%, and 20-40% in  dizygotic.
H eritability  estim ates for alcohol dependence are calcu lated to vary  between 
40-70%. H eritability  estim ates are som ew hat lower in  the VET register , probably 
because o f a larger environm ental risk  factor occurring in  this sam ple: participation  
in  the w ar in  Vietnam .
Finally the frequency o f a disorder in adoptees can be com pared w ith the 
frequency o f the disorder in their b iological and their adopting parents. The 
b iological parents share 50% of the DNA, w hereas the adopting parents do not 
share genetic features, but only affect the environm ent. The relative risk  to becom e 
addicted when a b iological parent is addicted varies betw een .80 and 6.3 94. Moreover 
there is no such relation  betw een the risk  to becom e addicted when an adopting 
paren t is addicted 100-103. Note that a possible effect o f very early environm ental 
factors, e.g. antenatal factors, cannot be ru led  out.
Molecular genetic studies in alcohol dependence
M olecular genetic studies can  be devided in linkage and association  studies.
Linkage studies are used in  fam ily-based sam ples to test linkage to a d isease for 
chrom osom e regions that are shared m ore often am ong phenotypically  concordant 
relatives than  am ong ones who are phenotypically  discordant. These studies have 
been used to identify  chrom osom al regions o f in terest and hinted at specific genes 
th at are probably related to the disorder. In association  studies the frequency of 
such specific genetic variants is com pared betw een groups o f cases and controls, to 
test association  o f a genotype w ith the disease. Such studies use a candidate gene 
approach, but m ay also  use hypothesis free genom e wide association  (GWA) 
m ethods. In GWA studies the entire genom e is com pared betw een large groups of 
cases and controls. The technique for this type o f studies has been developed during 
the p ast decade. Results for alcohol dependence are therefore lim ited.
Linkage
In alcohol dependence few genom e linkages have been replicated in independent 
studies, probably because o f heterogeneity, both  at the level o f the genotype and 
the phenotype. However, linkage studies have identified  loci on chrom osom e 2 
(location o f the opioid receptor gene cluster), 4q  (location o f alcohol dehydrogenase 
gene cluster), 4p (GABA-A gene cluster), 9q (GABA-B gene cluster), 11p (DRD4 gene 
cluster) th at lin k  w ith alcohol dependence (for recent reviews see: Li 2009, Ducci 
2008, Ho 201015, 104-107.
|j-opioid receptor gene cluster:
A varian t in the opioid receptor gene located on chrom osom e 2 has been linked 
inconsistently  to alcoholism  and other addictions 15, 104, 106. Recent evidence supports 
th at th is locus also  predicts response to naltrexone in  clin ical tr ia ls  w ith Asp40 35
being associated w ith better treatm ent response 15, 104, 106.
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Alcohol dehydrogenase gene cluster:
The m ost convincing exam ples o f alcoholism -related genes are the alcohol 
dehydrogenase IB (ADH1B) and aldehyde dehydrogenase 2 (ALDH2) genes that encode 
for two enzym es catalyzing consecutive steps in alcohol degradation  15, 104, 106. Either 
h igher activity  o f ADH1B or lower activity  o f ALDH2 lead to accum ulation  of 
acetaldehyde follow ing alcohol assum ption  which, in  turn , causes an unpleasant 
and aversive response, term ed the flu sh in g  reaction. These genotypes are thus 
protective again st the developm ent o f alcoholism  15, 104, 106, 107.
GABA receptor gene clusters:
In hum ans, alcohol dependence has been linked to both  the chrom osom e 4 and 
chrom osom e 5 GABA clusters 15, 104, 106. Several lines o f evidence suggest th at GABA 
is involved in m any effects o f alcohol including tolerance, dependence and cross­
tolerance to benzodiazepines and barbiturates. Low alcohol sensitivity  related to 
GABA genotypes is predictive o f alcohol dependence in  hum ans 15, 104, 106.
D opam ine receptor D4 (DRD4) gene cluster:
The chrom osom e 11p telom ere region has been linked to addictions 15, 104-106. 
DRD4 lies on chrom osom e 11p, and a 16 am ino-acid repeat polym orphism  in DRD4 
has variably been associated w ith im pulsivity  and novelty seeking 15, 104-106. Since 
novelty seeking indiv iduals tend to experim en t w ith novel stim uli, including the 
use o f drugs o f abuse, novelty seeking is thougth  to be involved in  the developm ent 
o f addiction  for several drugs.
Genome wide association  (GWA)
GWA allow s the hypothesis-free m apping o f disease-causing loci w ith in  the 
genom e. W hereas whole-genome lin kage studies is pow erful in detecting effects of 
uncom m on and rare alleles present in  probands and their fam ilies, genom e wide 
association  studies, have greater power to detect effects o f relatively com m on 
alleles (m inor allele frequency >0.05). Only three genom e wide associations studies 
have been published to date.
The fir st study by Johnson  et al. identified 51 relatively sm all chrom osom al 
regions contain ing variants th at showed association  w ith  alcohol dependence 108. 
W ithin these chrom osom al regions 16 sim ple sequence len gth  polym orphism  
(SSLP) m arkers were identified that were previously linked to 
alcohol phenotypes providing additional levels o f support for the valid ity  o f the 
observed clustering.
A second study by Treutlin et al 2009 identified  genome-wide sign ifican t 
association  w ith 2 SNPs located in a chrom osom al region 2q35 109. Linkage and 
an im al studies also provide evidence for the presence o f susceptib ility  varian ts in 
th is chrom osom al region pred isposing an indiv idual to alcohol addiction. The PECR 
36 gene, w hich is located close to these SNPs, was identified as a plausible candidate
gene 109. However, expression  o f PECR is h ighest in  the liver, followed by the kidney,
m uscle tissue, the lungs, and the heart but barely in  the brain . If th is gene is 
involved in alcohol dependence, it m ust act in  the periphery rather than  in  the 
central nervous system  109.
In a genom e wide association  study perform ed by Bierut et al. none o f the top
15 association  sign als were replicated in  the independent datasets, nor did this 
study replicate the two genome-wide sign ifican t resu lts reported by Treutlein and 
colleagues or the fin din gs o f Johnson  et al. 110.
A ssociation  studies
In association  studies, the frequency o f a known specific genetic varian t (a 
candidate gene) is com pared betw een groups o f interest. If a gentic varian t is more 
com m on in the group o f patients, th is varian t is associated w ith the disorder.
V ariants in alcohol- and drug-m etabolizing enzym es as well as in several neu­
ro tran sm itter system s have been investigated. Here we focus on polym orphism s in 
genes related to the dopam ine pathway. Positive reports o f association  with 
substance dependence are sum m arized  below.
D opam ine receptors (DRD):
The dopam ine D2 (DRD2) TaqIA polym orphism  is the m ost studied polym orphism  
in  relation  to alcohol dependence. M eta-analyses have shown a sm all but sign ifican t 
association  o f alcohol dependence w ith  being hom ozygote or heterozygote for the 
A1 allele 111, 112. The odds ratio varies betw een 1.31 and 1.38, w ith an attributable 
risk  o f approxim ately 11% 111, 112. The strongest association  have been found in 
patients w ith severe, fam ilia l alcoholism , com pared to controls w ithout a fam ily  
h istory  o f d rug  abuse or dependence 112, 113.
Other dopam ine receptor types have also  been studied in  relation  to alcohol 
dependence, however data are lim ited. Some studies have shown an association  of 
variation  in the DRD1 and DRD4 genotypes w ith alcohol dependence 111. As indicated 
above, the personality  tra it novelty seeking m ay exp lain  p art o f th is association, 
since both genotypes have been im plicated in  novelty seeking 105. For the DRD3 
genotype only negative fin d in gs have been reported and for the DRD5 genotype 
there have been no reports in  alcohol dependent patients to date 111.
D opam ine tran sporter (DAT):
The DA transporter takes DA back up into the presynaptic neuron, and is the m ain 
term inator o f mesolimbic DA neurotransm ission. Some studies have shown relevance 
o f polym orphism s in the gene encoding the DA transporter in addiction. Most studies 
have studied a “variable number o f tandem  repeats” variant, consisting o f a 40 base 
pair repeat unit in exon 15. In some studied subjects carrying a 9-repeat allele showed 
reduced DA transporter availability compared to 10-repeat homozygotes up to 22% 114.
The 9-repeat allele is also associated with alcohol dependence, complicated by 
withdrawal seizures and delirium  114. Carriers o f the 9-repeat allele are also more 37
prone to m etham phetam ine and cocaine induced psychosis 115.
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Catechol-O-Methyl Transferase (COMT):
Catechol-O-m ehyltransferase (COMT) is the m ajor enzym e in  the breakdow n of 
DA in  the prefrontal cortex. A Val158Met substitu tion  in the gene encoding COMT 
is related to the activity o f the COMT enzym e. The presence o f a h igh activity  (Val) 
allele pred icts lower fron tal cortical DA in both healthy subjects and several 
psychiatric populations 17, 63, 104, 116-119. In line w ith these observations, the Val158 
allele has been linked to inefficien t fron tal lobe function.
In certain  populations, including polysubstance abusers, heroin and alcohol 
dependent patients, the Val158 allele is associated w ith vu lnerability  to addiction 
through  im pulsivity  or dyscontrol 17, 117. However, the Met158 allele, although 
associated w ith better cognitive perform ance, is associated w ith decreased stress 
resiliency and increased  anxiety. in populations o f addicts in  whom  anxiety  is a 
m ore salien t p red isposing cause -for exam ple, in  late-onset alcoholics and social 
drinkers- the Met158 allele is m ore com m on 17, 63, 104, 117.
The association  o f the COMT Val158Met genotype w ith substance dependence may 
thus depend on the psychiatric co-morbidity. The Val allele m ay be associated with 
substance dependence in  populations w ith high levels o f im pulsivity  or disorders 
w ith im paired  behavioral control. The Met allele may be associated w ith substance 
dependence in populations with high levels of anxiety or anxiety disorders 17, 63, 104, 117.
A comprehensive model of addiction
Findings from  an im al studies, pharm acological studies, neuro-im aging studies 
and genetic studies on addiction can  be sum m arized  in the three stage m odel of 
the developm ent o f addiction. Each stage is thought to be m ediated by discrete 
circu its in the brain  (see Figure 2 and 3) 120. The fir st  stage is the binge/intoxication 
stage, the second is the w ithdraw al/negative affect stage, th ird  is the preoccupation/ 
anticipation  stage.
D uring the binge/intoxication stage, re in forcing effects o f drugs engage 
rew ard-related neurotran sm itters in the nucleus accum bens and then engage 
stim u lus-respon se habits that depend on the dorsal striatum . Two m ajor neuro­
tran sm itters m ediatin g the rew arding effects of drugs of abuse are dopam ine and 
opioid peptides. An early neuroadaptation , com m on to all drugs o f abuse and 
observed after a single in jection  of cocaine, is increased excitability  o f the 
m esolim bic dopam ine system , reflected in long-term potentiation  dependent on 
changes in g lu tam ate activity. The activation  of dopam ine and glu tam ate 
contributes to increased excitab ility  o f the ventral stria tum  120.
D uring the w ithdraw al/negative affect stage, the negative em otional state of 
38 w ithdraw al engage the activation  o f the extended am ygdala. The extended
am ygdala is com posed o f several basa l forebrain  structures, including the bed
Figure 2 Schem atic draw ing describing the sequential and cum ulative effects 
o f neuroadaptive changes hypothesized to contribute to the neuro­
p lasticity  that prom otes com pulsive drug-seeking 120
N euro plasticity w ith increasing use
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nucleus o f the stria  term in alis, central nucleus o f the am ygdala, and possibly the 
m edial portion of the nucleus accum bens. Major n eurotran sm itters in the extended 
am ygdala hypothesized to have a function in negative reinforcem ent are cortico­
tropin-releasing factor, norepinephrine, and dynorphin 120.
The preoccupation/ anticipation  stage involves the processing of conditioned 
reinforcem ent in the baso lateral am ygdala and the processing of contextual 
in form ation  by the hippocam pus. Executive control depends on the prefrontal 
cortex and includes representation  of contingencies, representation of outcom es, 
and their value and subjective states associated w ith drugs (e.g. craving). The 
subjective effects term ed drug craving in hum ans involves activation of the orbital 
and anterior cin gulate cortices and tem poral lobe, including the am ygdala. A m ajor 
neurotran sm itter involved in the craving stage is glutam ate localized in pathways 
from  frontal regions and the basolateral am ygdala that project to the ventral 
stria tum  120.
In the fin al stage the engagem ent of ventral striatal-pallidal-thalam ic loops is 
hypothesized to translate to the dorsal striatum  to contribute to engagem ent of 
habits and autom aticity that resem ble com pulsive-like behavior. As com pulsivity 
evolves into fullblow n addiction, loss o f function  occurs in the frontal cortex
system s that control executive function , contributing to poor decision-m aking and 
gain  o f function  in the brain  stress system s but contributing to incentive salience 
for drugs over n atu ral reinforcers 120.
In summ ary, it seems that the mesolimbic dopam inergic pathway mediates the 
acute rew arding aspects o f drug intake and conditioned learning associated with 
craving and relapse, whereas adaptations in the m esocortical and am ygdala 
glutam atergic pathway mediates the conscious aspects of drug intake, craving, loss of 
inhibitory control, and continued drugacquisition behaviors at the expense of 
biologically relevant ones and despite catastrophic negative consequences 121-123. Besides 
these fundam ental circuits, other brain  regions and systems likely have modulatory 
functions in the addictive process, such as brain stress systems (ie, changes in adreno­
corticotropic hormone, corticosterone, and CRF), the insula (modulation o f internal 
em otional responses and autonomic activity in drug craving), the thalam us (filtering 
functions), the cerebellum, and the subthalam ic nuclei 121, 123.
Conclusion and recommendations
In th is review we have explored literature on neurobiological predictors o f the 
course o f addiction. There is a grow ing bulk  o f literature on neurobiological aspects 
o f substance dependence. However little  is known on indiv idual neurobiological 
features involved in  prognosis, relapse risk, and treatm ent outcom e. Since we have 
included reviews only, recent new fin din gs on th is issue m ay have rem ained 
und iscussed . In order to dam pen th is gap, orig in al reports of recent new fin din gs 
are d iscussed  shortly in  the general discussion . Another draw back o f u sing review 
articles is the often lim ited  in form ation  on statistics o f the orig inal findings. 
C orrelations m entioned in th is article are therefore m ostly not quantified .
Various neurobiological correlates o f addiction  have been found during the 
p ast decades. These involve dysfunctioning in  neurotran sm itter system s and 
changes in brain  arch itecture, as w ell as d ifferences in  genetic make-up and gene 
expression . We have tried  to give an overview of the m ost im portant fields o f neu- 
robiological research  on addiction. These include data  from  an im al studies and 
hum an  research. Regarding the latter we have divided the review into neuropsy- 
ch opharm acological, neuro-im aging and genetic studies.
A general draw-back o f the studies th at we cam e across during the review ing 
process is the short duration  o f follow-up. If lon gitudinal data  were collected at all, 
the duration  o f follow-up is generally  short, betw een 3-6 m onths. In studies on 
predictors on the course of addiction, a m ore prolonged study design  (at least one 
year) should be applied.
40 A nother general problem  in  our view is the defin ition  o f the course o f the
disease. Prospective studies often  take duration  to fir st  relapse as an  outcome
Figure 3 Comprehensive model of neurobiology of addiction at different stages 120
G reen/blue arrow s: g lu tam aterg ic  p ro jectio n s; oran ge arrow s: d o p am in erg ic  p ro jection s; p in k  
arrow s: GABAergic p ro jection s. Acb, n u cleu s accu m ben s; BLA, b a so la te ra l am y gd ala ; VTA, v en tra l 
tegm en ta l a rea ; SNc, su b stan tia  n ig ra  p ars co m p acta ; VGP, v en tra l g lobus p a llid u s; DGP, d o rsa l 
g lobu s p a llid u s; BNST, bed n ucleus o f  the str ia  te rm in a lis ; CeA, cen tra l n ucleu s o f the am y gd ala . NE: 
n orep in ep h rin e ; CRF: co rtico tro p in -re leasin g  facto r; PIT: Pavlovian  in stru m e n ta l tran sfe r  (adapted  
from  Koob et al, 2010).
1
T3art
tgo
41
m easure. However, th is appears not to be a stan dard ised  criterion: the criterion 
m ost often used is the duration  o f abstinence defined as the fir st  day drin k in g  five 
units o f an alcoholic beverage for alcohol dependents, and rein statem en t o f drug 
use for other types o f addiction. Other options used are to calcu late the am ount of 
drugs (including alcohol) consum ed at fixed tim e intervals or to estim ate the total 
duration  o f abstinence over a given tim e window. For a better com parison  o f study 
resu lts it would be m ore appropriate to define one m easure for follow-up and use it 
consistently.
Animal studies
The p ast decades a lot o f an im al research  in addiction has been  undertaken. 
R einstatem ent m odels seem  relevant for the study o f relapse in hum ans. Face 
valid ity  appears quite good. Predictive, and content valid ity  need furth er study. 
Few com pounds that appear prom ising in an im al studies are tested in hum ans. 
H um an research w ith a tran slation al approach m ay find new effective m edications 
to treat substance dependent patients.
A nim al m odels o f addictive behaviour are m ostly  based on a sim ple self 
adm in istration  parad igm . New an im al m odels that use a loss o f control and 
com pulsive consum ption  p arad igm  after m ore prolonged drug exposure m ight 
better re flect addictive behaviour in hum ans. These m odels should therefore be 
used preferentially  when conducting an im al research  on addiction.
Genetic an im al research, for exam ple u sing knock out m ice often doesn ’t take 
environm ental m an ipulations in  consideration. It has however been  shown, that 
expression  o f a phenotype in  both an im als and hum ans is m ore likely a consequence 
o f an interaction  betw een genetic and environm ental factors, which both should 
be m odelled in an im als.
A nim al studies have revealed d ifferent m echanism s o f reinstatem ent, 
resem bling relapse m echan ism s in  hum ans. Sm all drug doses, drug related cues 
and stress all seem  to be involved in inducing rein statem en t and relapse. A nim al 
research  has clearly shown d istin ct neurobiological m echan ism s for these form s of 
reinstatem ent.
In hum ans d ifferent relapse inducing factors often occur sim ultaneously. 
To what extent these d ifferent m echan ism s of re instatem ent also occur in relapse 
in hum ans needs furth er study. Future studies should also  search for individual 
vu lnerabilities for each type o f relapse. This m ay gain  our in sigh t in  an ind iv id ual’s 
risk  for relapse and prognosis.
To what extent these observations have relevance for d irectin g pharm acother­
apy also  needs to be investigated. Multiple pathways o f relapse m ay provide m ultiple 
drug  targets as well. The value o f com bining different pharm acotherapeutic agents 
42 in the prevention of relapse rem ains to be studied. Treatm ent outcom e m ight
im prove when m edication  is adjusted to an indiv idual pathophysiological charac-
teristics. For exam ple, it m ay be shown th at patients vulnerable for stress induced 
relapse m ay benefit from  CRF antagonists in particu lar.
U ltim ately fin d in gs from  an im al studies should be translated  into the hum an 
situation . Studies u sing such tran slation al approach are scarce. It rem ains to be 
studied w hether consistent fin d in gs in an im al studies hold when applied to 
hum ans.
Human neuropsychopharmacology
Little psychopharm acological research  into addiction  has been perform ed. 
However various studies have revealed in terestin g observation on the neurophar­
m acology o f addiction in  hum ans. Especially  the brain  rew ard pathw ay (m ainly 
DA), stress system  and serotonin  system  have been studied. To what extent 
d isturbances in these d ifferent neurobiological pathways indicate d ifferent 
subgroups o f substance dependent patients need furth er study.
Patients w ith d istin ct clin ical features m ay have d istin ct neuropharm acologi- 
cal profiles. Behavioural m easures and co-morbid psychiatric diseases should be 
taken  into consideration  when conducting such studies. D opam inergic and 
serotonergic dysfunctions seem  to be predictive for a chronic course o f the disease. 
The role o f the HPA axis is less clear.
Future research  should incorporate neuropharm acological profiles in the 
evaluation  o f treatm ent efficacy. C hallenge and depletion studies as w ell as 
peripheral biom arkers appear prom ising m ethods for identification  o f subgroups 
o f patients. Subgroups o f dependent patients m ay thus be identified th at benefit 
from  specific treatm ent strategies. M ethods for evaluation  o f DA, and 5HT systems 
as well as HPA axis activity have been well established, but need furth er study.
Follow-up studies should also use endophenotypes to correlate behavioural 
outcom e m easures w ith neurobiological changes over tim e. Recovery o f neurobio- 
logical adaptations w ith prolonged abstinence and its relevance for individual 
prognosis and relapse risk should be investigated further, as w ell as its relation  to 
cognitive and executive function.
43
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Current thesis
In the overview presented above, several areas o f beurobiological addiction 
research can be identified. Im portant gaps in the scientific knowledge on substance 
dependence deal w ith the lack of translation al research, the lack o f gene 
environm ent interaction  studies, heterogeneity of the phenotype and lim ited  data 
on the course of substance dependence (short duration o f lon gitudinal studies and 
diverse defin itions o f relapse). On the other hand, various lines o f research, 
including an im al, neuroim aging, have consistently pointed tow ard an im portant 
role for the brain  dopam ine system  in the developm ent o f substance dependence.
In th is thesis I focus on dopam ine pathways found to be involved in alcohol 
dependence. I focus on alcohol dependence because th is is by far the m ost common 
type of substance use disorder in The Netherlands. In addition, alcohol dependent 
patients enter treatm ent quite regularly, so inclusion o f a sam ple large enough for 
th is research appeared to m ost feasible when including alcohol dependent patients.
The dopam ine pathways we studied are the salience pathway, involved in the 
early stages o f alcohol dependence (including the ventral striatum ), the behavior 
m onitoring pathway (including the anterior cingulate cortex) and the behavior 
inhibition  pathway (the prefrontal cortex), involved in the advanced stages of 
alcohol dependence (see Figure 4).
Figure 4 D opam ine pathways in alcohol dependence: the salience pathway 
(including the ventral striatum ), the behavior m onitoring pathway 
(including the anterior cingulate cortex) and the behavior inhibition 
pathw ay (the prefrontal cortex)
44
One o f the m ost extensively studied  pathw ays in  substance dependent patients 
is the m esolim bic dopam ine pathw ay (with dopam inergic neurons in  the ventral 
tegm en tal area projecting to the ventral striatum , including the nucleus 
accum bens). Potentially addictive drugs, such as alcohol, stim ulate the m esolim bic 
dopam ine pathw ay by the release o f extracellu lar dopam ine in  the ventral striatum .
The drug  induced release o f dopam ine is associated w ith its positive rew arding 
effects. The release o f dopam ine in  the ventral stria tu m  triggered  by drugs o f abuse 
surpasses physiologic variation  in  the dopam ine system  associated w ith natural 
saliency and rew ard 120, 123-126. This w ill facilitate the consolidation  o f m em ory traces 
connected to the drug, so th at these w ill trigger dopam ine release w ith future 
exposure to stim u li associated w ith these drug-cues 120, 123-126.
It has repeatedly been shown th at subjects dependent on a variety  o f drugs, 
including alcohol, exh ibit sign ifican t reductions in stria ta l dopam ine D2 receptor 
availability. This is thought to contribute to the decreased sensitivity for natural 
rein forcers in  addicted indiv iduals, w ith reduced interest for environm ental 
stim uli. Because drugs are m uch m ore potent at stim u latin g  dopam ine regulated 
rew ard circu its than  n atu ral reinforcers, drugs would still be able to activate the 
depressed rew ard circuit, possibly pred isposing addicted subjects for seeking drug 
stim ulation  as a m eans to tem porarily  activate the depressed rew ard circuit.
Studies in  healthy volunteers on the role o f dopam ine in the prefrontal cortex have 
shown th at op tim al levels o f dopam ine are crucial for op tim al cognitive 
perform ance, including inh ibitory  control, w orking memory, cognitive flex ib ility  
and reinforcem ent learn ing. Both too low and too h igh levels o f dopam ine appear 
to have detrim ental effects on prefrontal cortex function ing, which has been 
explained by an “inverted U”-shaped relationship  betw een prefrontal cortex 
fun ction in g and prefrontal dopam ine levels 1 127-131.
In substance dependent patients a reduced activity in the prefrontal cortex has 
been shown, as m easured by reductions in  regional brain  glucose m etabolism  124-126,
132-135. Since the prefrontal cortex is involved in  inhibitory control and em otional 
processing, it is thought th at abnorm alities in dopam ine regulation  at the level of 
the prefrontal cortex in  addicted subjects could underlie their loss o f control over 
drug  intake and their poor em otional self-regulation 124-126, 132435.
At the level o f the anterior cin gulate cortex, dopam ine is involved in  the 
m onitoring o f behavior. Fast detection o f errors is crucial for efficien t goal-directed 
behavior. There is am ple evidence that the anterior cin gulate cortex (ACC) plays an 
im portant role in  error m onitoring 136. Error-related ACC activity is also  reflected 
in  a response-locked event-related potential, known as the error-related negativity 
or ERN, elicited im m ediately  follow ing erroneous responses 137-139. The dom inant 
view on the neurochem ical m echan ism s underlying the ERN assigns a m ajor role
to dopam ine 137-140. 45
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D im inished error m onitoring, as reflected  in  decreased ERNs or error-related 
hypoactivity o f the ACC, has previously been dem onstrated in  abstinent cocaine 
and opiate dependent patients, as well as in  current alcohol and cocaine dependent 
patients 14M44. D im inished m onitoring o f behaviour, due to hypodopam inergic 
fun ction in g at the level o f the anterior cin gulate gyrus, has been hypothesized to 
underlie continued excessive use o f drugs in  face o f its adverse consequences 141-144. 
D opam ine fun ction in g in  alcohol dependence m ay thus be affected at the level of 
the striatum , as w ell as at the level o f the prefrontal cortex and the cingulate 
gyrus. D opam ine m ay play a role in  the early phases o f the developm ent o f substance 
dependence through  the salience pathw ay (striatum ), and the m ore advanced stage 
o f addiction  through the executive fun ction in g pathw ay (prefrontal cortex) and a 
behavioral m onitoring pathw ay (anterior cin gulate gyrus).
Vulnerability factor or scar: 
animal models of (alcohol) dependence
As explained above, abnormalities in the brain dopamine systems have been found 
in alcohol dependent patients. This raises the question to what extent these biomarkers 
are pre-morbid vulnerability markers for the disorder, or the consequence o f excessive 
drug use, i.e. state or trait markers. In other words: “Is it cause or consequence?”
Reduced fun ction in g o f the brain  rew ard system  m ay on the one hand m ake an 
ind iv idual m ore vulnerable to develop alcohol dependence due to decreased 
sensitiv ity  to n atu ra l incentives. On the other hand, long term  alcohol use may 
alter the fun ction in g o f the brain  rew ard system , as the indiv idual progresses from  
the early stage to m ore advanced stages o f dependence. The sam e can  be argued  for 
the observed reductions in  PFC dopam ine functioning.
The only way to reliably identify  a causal re lation  betw een a (risk) factor and a 
d isease is by use o f a prospective interventional experim en tal study design. Studies 
th at m an ipulate at a genetic or environm ental level are d ifficu lt to perform  in 
hum ans. However, in an im als such interventional experim ents have been 
perform ed. A nim al m odels of substance dependence have been widely used to 
study the association  betw een prem orbid variation  in  the dopam ine system  and 
the vu lnerability  to se lf adm in ister drugs of abuse, and the effect o f drug use on 
the brain  dopam ine system.
Self adm in istration  o f alcohol and other addictive drugs, is n atu rally  observed 
in  an im als. This provides a good opportun ity  to study the n atu ral course o f drug 
abuse and addiction, u sing an im al m odels. A nim al m odels used to study substance 
dependence have m ain ly  studied voluntary se lf adm in istration , tran sition  to 
46 uncontrolled drug tak in g  behavior and rein statem en t o f drug se lf adm in istration
after a period o f abstinence.
Perhaps the best exam ple o f such an im al studies is the work o f the group of 
Nader in  m acaques 145-147. Using neuroim aging techniques, they m easured dopam ine 
D2 receptor density before and during cocaine se lf adm in istration , and after 
detoxification  from  daily  cocaine use. At baseline, they found n atu ral variation  in 
dopam ine D2 receptor availab ility  betw een an im als, before cocaine adm in istration .
They showed th at an im als w ith lower dopam ine D2 receptor density at baseline 
se lf adm in istered  m ore cocaine when given free access to the drug. Prolonged 
cocaine use m arkedly reduced the density  o f dopam ine D2 receptors. W hen anim als 
had a longer period o f cocaine se lf adm in istration  (up to one year), these reductions 
were only p artia lly  reversible.
These fin din gs suggest th at n atu rally  occurring variation  in the brain  
dopam ine system  m ay be a vu lnerability  factor for the use o f drugs and possibly 
dependence. The use o f drugs itse lf  fu rth er dow nregulates the dopam ine system.
This resu lts in  a vicious cycle o f increasin g vu lnerability  to excessively se lf 
adm in ister drugs, m ak ing it a se lf perp etu atin g  disorder.
An im portant question  is what factors influence prem orbid variation  in  the 
brain  dopam ine system ? One o f the an im al m odels for the vu lnerability  for drug 
se lf adm in istration  has been the apom orphine (APO) sensitivity m odel in  rats 148-150.
It has repeatedly been shown th at the sensitiv ity  to the dopam ine agon ist APO 
differs betw een different strain s o f an im als 148. For exam ple W istar rats and 
Sprague-Dawley rats show a large increase in stereotypes gnaw ing behavior after 
APO adm in istration , w hereas Fisher and ACI rats are relatively im m une for the 
effects o f APO on gnaw ing.
W ithin a single stra in  from  one breeder large differences in  APO susceptibility  
can  also  be observed. Based on a large series o f experim ents, the susceptib ility  to 
APO w ith in  breeding colonies o f W istar rats appear to follow a bim odal variation  
148. The sensitiv ity  to the effects o f APO is related to several behavioral ch aracteris­
tics o f the rats. For exam ple, an im als th at have a low sensitiv ity  to APO show 
decreased explorative behavior in the open field, increased freezin g response when 
exposed to an intruder and increased  se lf adm in istration  o f alcohol and cocaine, 
com pared to the an im als w ith a h igh sensitivity to APO 150, 151.
Selective breed ing experim ents in  rats have shown th at APO sensitivity  is 
stably tran sm itted  over several generations 150, 151. It is thought that th is reflects a 
genetic transm ission  o f APO sensitivity  and its behavioral correlates. On the other 
hand, experim ents w ith postn ata l m an ipulation  o f the environm ent have yielded 
evidence th at experiences early in ch ildhood (i.e. cross-fostering or m aternal 
deprivation) have long-lasting effects on APO sensitivity  in rats, depending on the 
APO sensitivity  at baselin e 150, 151. Low APO sensitivity  in  rats, a possible neurobio- 
logical vu lnerability  factor for excessive substance use, m ay thus arise from  an 47
interaction  betw een genetic and environm ental factors.
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Aims of thesis
Based on the review o f the literature on neurobiological aspects o f alcohol 
dependence, as sum m arized  above, several areas o f research  can  be identified . The 
three m ain  issues th at I w ill focus on deal w ith the lack o f translation  o f an im al 
studies into hum an  situation , the d ifficu lty  o f the broad phenotype o f substance 
dependence and the lack o f environm ental factors in  neurobiological studies. Thus, 
the overall a im  o f th is thesis is to explore neurobiological aspects o f alcohol 
dependence by investigating gene environm ent interaction  and various 
interm ediate phenotypes in  alcohol dependent patients.
I w ill address the follow ing specific aim s:
1. To study a tran slation al in term ediate phenotype (apom orphine sensitivity) in 
alcohol dependence (chapter 2,3).
2. To study interm ediate phenotypes th at im prove genetic association  fin din gs in 
alcohol dependence (chapter 4,5).
3. To study interaction between indentified relevant alcohol genes and environmental 
factors in  alcohol dependence (chapter 6).
4. To study alternative interm ediate phenotypes th at help to delineate the broad 
phenotype o f alcohol dependence (chapter 7, 8, 9).
Outline of thesis
Chapter 1 provides a state o f the art su m m ary  o f b iological m echanism s 
underlying vu lnerability  for substance dependence and the propensity  to relapse. 
The background inform ation  in  chapter 1 can  be regarded as a startin g  poin t for 
th is research project. Based on th is in form ation  some potentially  interesting 
interm ediate phenotypes and genotypes related to brain  dopam ine fun ction in g 
were identified , to be subsequently studied in  th is thesis.
One prom ising an im al m odel o f addiction encountered in the literature is the 
sensitiv ity  to the dopam ine agon ist APO. A nim als w ith low sensitivity  to APO self 
adm in ister m ore alcohol com pared to APO sensitive an im als. In order to translate 
th is an im al m odel for addiction  vulnerability  to hum ans the fir st  step was to find 
a way to apply analogous m ethodology in hum ans. In chapter 2 we explore whether 
APO sensitivity  can  indeed be adequately m easured in hum ans. Pharm acokinetic 
and pharm acodynam ic properties o f both sublin gual and subcutaneous 
adm in istration  o f APO were analyzed, in order to find the op tim al m ethodology 
for the m ain  study in alcohol dependent patients and healthy controls.
48 The n ext step was to test the interm ediate phenotype o f APO sensitivity  in
alcohol dependence. In chapter 3 I present data on the effects o f APO on cognitive
perform ance in  alcohol dependent patients and a group o f m atched healthy 
controls.
A question  th at rem ained is to what extend dysfunctioning o f the dopam ine 
system  as encountered the literature is a consequence o f long term  excessive 
alcohol use, or m ay be a pre-morbid vu lnerability  factor. In an im als APO sensitivity 
is tran sm itted  over generations. This suggests a possible genetic m echan ism . I 
continued w ith testin g the role o f genetic factors in APO sensitivity, fir st  in  healthy 
controls (chapter 4), next in alcohol dependent patients (chapter 5). Several genetic 
variants involved in  dopam ine fun ction in g have previously been described. In the 
current study three genes w ith com m on varian ts (polym orphism s) were selected 
based on previous studies show ing a relation  w ith either substance dependence or 
dopam ine function ing, i.e. com m on polym orphism s in the genes encoding the 
enzym e Catechol-O-M ethyltransferase (COMT), the dopam ine D2 receptor (DRD2) 
and the dopam ine tran sporter (DAT).
Chapter 4 shows the effect o f a polym orphism  o f the gene encoding the COMT 
enzym e in  APO sensitivity in healthy controls, u sing a task  th at requires prefrontal 
cortex fun ction in g (the AX-CPT). APO sensitivity can be m easured u sing d ifferent 
outcom e m easures as shown in  chapter 2. The effects o f APO on these d ifferent 
outcom e m easures are hypothesized to re flect dopam ine sensitivity in d ifferent 
brain  pathw ays. Genes involved at d ifferent levels in  the dopam ine pathw ay m ay be 
involved in  d ifferent m easures o f APO sensitivity.
Chapter 5 shows the relation  o f two selected polym orphism s in  genes involved 
in  the dopam ine pathw ay w ith the two different outcom e m easures o f dopam ine 
sensitivity, and its relation  w ith alcohol dependence. Finally  we tested the 
previously identified  genotypes (DRD2 and COMT) in  a gene environm ent interaction  
m odel.
Chapter 6 shows the interaction  betw een exposure to adverse experiences 
during ch ildhood and the DRD2 and COMT genotypes.
After the study o f the tran slation al in term ediate phenotype (i.e. APO sensitivity) 
we also  tested some other poten tial interm ediate phenotypes th at m ay help to 
delineate the broad phenotype o f alcohol dependence. An im portant issue to take 
into consideration is th at alcohol dependence is often associated w ith  psychiatric 
co-morbidity. Both in ternalizin g m ental disorders, like anxiety  and depression, 
and extern aliz in g  disorders, such as ADHD and an tisocial personality  disorder are 
com m on am ong alcohol dependent patients. Psychiatric co-m orbidity m ay be 
related to the pathophysiology underlying the alcohol use disorder.
In Chapter 7 we tested the way the brain  m onitors behavior in alcohol dependent 
patients and healthy controls, and its relation  w ith co-morbid psychiatric disorders.
Further, in  chapter 8 we explored the role o f co-morbid psychiatric disorders in  the 49
course o f alcohol dependence after clin ical detoxification.
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In Chapter 9 we present the th ird  in term ediate phenotype. This is the acoustic 
startle  response, a m easure o f excitab ility  o f the brain . Previously it has been 
suggested that variation  in  the acoustic startle  response m ay be a stable interm ediate 
phenotype, w ith a strong heritability. However, in alcohol dependence a state 
dependent effect o f w ithdraw al or scarring effect o f previous detoxifications has 
also  been suggested . We tested the acoustic startle  response in  two groups of 
alcohol dependent patients (early and late onset), after protracted w ithdraw al, to 
test w hether alterations in the acoustic startle  re flect a trait, state or scar.
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Abstract
D ysfunction o f brain  dopam ine system s is involved in  various neuropsychiatric 
disorders. C hallenge studies w ith dopam ine receptor agonists have been perform ed 
to assess dopam ine receptor function ing, c lassically  u sing the release o f grow th 
horm one (GH) from  the h indbrain  as p rim ary  outcom e m easure. The objective o f 
the current study was to assess dopam ine receptor fun ction in g at the level o f the 
forebrain.
Fifteen healthy, m ale volunteers received apom orphine su b lin gu ally  (2mg), 
subcutaneously  (0.005mg/kg), and placebo in  a balanced, double blind cross-over 
design. Outcome m easures were p lasm a GH levels, perform ance on an AX 
continuous perform ance test and prepulse inh ibition  o f the acoustic startle.
The relation  betw een central outcom e m easures and apom orphine levels observed 
in  p lasm a and calcu lated  in the brain , was m odelled u sing a tw o-com partm ental 
pharm acokinetic-pharm acodynam ic analysis.
After adm in istration  o f apom orphine p lasm a GH increased, perform ance on the 
AX continuous perform ance test deteriorated, p articu larly  in participan ts w ith low 
baselin e perform ance. Apom orphine disrupted PPI on h igh intensity  (85dB) 
prepulse tria ls and im proved PPI on low intensity  (75dB) prepulse trials, p articu larly  
in  p articipan ts w ith low baselin e PPI. High cognitive perform ance at base lin e was 
associated w ith reduced baselin e sensorim otor gating. N europhysiological 
m easures correlated best w ith  calcu lated  brain  apom orphine levels, after 
subcutaneous adm in istration .
M odulation o f the effect o f apom orphine by baselin e perform ance levels provides 
evidence for an inverted U-shape relation  betw een prefrontal dopam ine fun ction in g 
and cognitive perform ance, and m esolim bic dopam ine fun ction in g and 
sensorim otor gating. Future apom orphine ch allenge tests preferen tially  use 
m ultip le outcom e m easures, after subcutaneous adm in istration  o f apom orphine.
60
D ysfunctioning o f dopam inergic n eurocircu itry  has been im plicated in various 
neuropsych iatric disorders, including substance dependence, Tourette’s syndrom e, 
sch izophren ia and others (see 1 for a com prehensive review). Pharm acological 
ch allenge tests u sing dopam ine receptor agon ists provide a u sefu l tool for 
investigating sensitivity o f brain  dopam ine receptors. C lassically, the release of 
grow th horm one (GH) after adm in istration  o f a dopam ine agonist, e.g. apom orphine 
(APO) or brom ocriptine, has been used to assess central dopam ine sensitivity, 
show ing reduced plasm a GH levels in  patients su fferin g from  alcohol dependence, 
m ajor depression and sch izophren ia 2-4.
The GH response to APO is m ediated by dopam ine receptors in  the h indbrain  
(pituitary) region, whereas prefrontal and m esolim bic dopam ine n eu rotran sm is­
sion are m ore relevant for hum an behaviour, and neuropsychiatric disorders 5 6. 
This report describes a dopam ine-challenge in healthy hum an volunteers, using 
three indices o f dopam ine function : p lasm a GH levels, perform ance on a continuous 
perform ance test and prepulse inh ibition  o f the acoustic startle  response.
D opam ine is involved in  cognitive function ing, including perceptual speed, 
(spatial) w orking m em ory and response inh ibition  7-9. Deficits in  cognitive 
perform ance on various cognitive tasks have been described in  disorders w ith a 
decrease in  prefrontal dopam ine function ing, such as ADHD and sch izophren ia 10. 
Evidence from  both an im al and hum an studies, u sing pharm acological stim ulation  
o f dopam ine receptors, suggests th at both too little  and too m uch stim ulation  of 
dopam ine im pairs cognitive perform ance 11-13.
Individuals w ith poor baselin e perform ance on an N-back task , w ith  presum ed 
suboptim al prefrontal dopam ine function ing, im proved after adm in istration  o f 
the dopam ine agon ist D -am phetam ine, w hereas ind iv iduals w ith high baseline 
perform ance deteriorated 14, 15. Using the dopam ine agon ist brom ocriptine, sim ilar 
fin d in gs have been found on a variety o f cognitive tasks, including the W isonsin 
Card Sorting Task (set sh iftin g  task), the Stroop task  (interference task) and Corsi 
Block Tapping Task (spatial span  task) 16, 17.
In addition, am phetam ine im proved perform ance on a continuous perform ance 
task  in ind iv iduals scoring low on novelty seeking, w ith presum ed low levels of 
dopam ine, and im paired  perform ance in  ind iv iduals scoring h igh on novelty 
seeking, w ith presum ed h igh dopam ine levels 18. Thus, a specific level o f dopam ine 
appears necessary  for op tim al fun ction in g o f the prefrontal cortex, follow ing an 
inverted U dose-response curve 11, 13, 19, 20.
A dm in istration  o f the dopam ine agon ist APO has been shown to d isrupt 
perform ance on a w orking m em ory task  in  healthy hum an volunteers, probably by 
altered brain  activity in the dorso lateral prefrontal cortex 21-23. We selected the AX 
continuous perform ance test (AX-CPT), because previous pharm acological studies
Introduction
2
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w ith dopam inergic m edication  (apom orphine and cabergoline) have shown clear 
effects on task  perform ance u sing th is task  24, 25. We hypothesized that 
adm in istration  o f APO to healthy controls would change task  perform ance, 
depending on baselin e task  perform ance, such th at perform ance im proves in those 
subjects w ith low baselin e perform ance, and deteriorates in those w ith high 
baselin e perform ance.
Prepulse inh ibition  (PPI), the phenom enon th at a startle  response elicited by a 
sudden intense stim ulus (noise burst) is inhibited, when it is preceded by a weaker 
stim ulus, has also  been shown to be related to dopam ine function ing. Reductions 
o f PPI have been shown in  disorders in which an increase in  dopam ine fun ction in g 
has been hypothesized, such as sch izophrenia, obsessive com pulsive disorder and 
tic disorder (see B raff et al 2001 for a review on PPI parad igm s in  hum ans). Moreover 
dopam ine agon ists have been  shown to reduce PPI in  an im als and hum ans (see for 
furth er reviews: B raff et al, 2001, Swerdlow et al 2000, Swerdlow et al. 2001). An 
inverted-U association  betw een PPI levels and dopam ine fun ction in g has been 
hypothesized, since the disruptive effects o f the dopam ine agon ist pergolide and 
am an tad in e on PPI in  hum ans have been shown only in  subjects w ith h igh baselin e 
PPI levels, suggesting excessive dopam inergic stim ulation  in  subjects w ith high 
levels o f baselin e PPI 26, 27.
Although the neuronal c ircu itry  underlying PPI is extensive, there is a large 
am ount o f evidence ind icating th at the APO induced deficit in PPI depends 
predom inantly  on stim ulation  o f m esolim bic dopam ine receptors in  the nucleus 
accum bens 28, 29. We expected adm in istration  o f APO to change PPI, depending on 
baselin e levels o f PPI, such th at PPI increases in  those subjects w ith  low baseline 
PPI, and reduces in  those w ith h igh baselin e PPI.
The relationship between APO levels in blood and brain, and GH release was first 
explored by Aymard et al. 30. They showed that APO levels in the second com partm ent 
(i.e. the concentration o f APO in cerebrospinal fluid, CSF), correlated better with 
p lasm a GH levels than  APO levels in  the first com partm ent (i.e. the concentration of 
APO in plasma) 30, 31. As shown by Hofstee et al. (1994) APO levels in CSF can be reliably 
calculated from  plasm a APO concentrations, using pharm acokinetic m odelling 31. 
We m easured plasm a APO levels and calculated APO levels in the CSF, and 
hypothesized that central effects o f APO can best be modelled using calculated APO 
levels in the CSF, com pared to observed APO levels in the plasm a. We used both 
subcutaneous (s.c.) and sublingual (s.l.) adm inistration  o f APO in order to be able to 
m odel the central effect o f APO in different kinetic profiles and to assess which mode 
o f adm in istration  was m ost appropriate for use in a challenge test.
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Methods and materials
Design
A double-blind, placebo controlled ch allenge study was perform ed in  fifteen  
healthy m ales, u sing a balanced, cross-over design  w ith three treatm ent conditions 
in  a double-dum m y approach: APO 2 m g s.l./placebo s.c., APO 0.005 m g/kg s.c./ 
placebo s.l., and placebo s.l./s.c.. Low doses o f APO were used, because o f poor 
tolerability  at higher doses (nausea, vom iting and collapse, unpublished pilot 
studies). The study protocol was approved by the regional eth ical board.
Participants
Participants were recru ited through  advertisem ents in  regional new spapers 
and at the cam pus o f Radboud University Nijm egen. After w ritten  inform ed 
consent, p articipan ts were screened for any m edical condition, including laboratory 
abnorm alities, and the use o f m edication  or drugs w ith in  2 m onths prior to the 
study. Auditory acu ity  was evaluated during m edical exam ination , by use o f tun in g 
fork tests (Weber, Rinne and Swabach) and w hisper tests.
Psychiatric h istory was assessed using the Dutch version o f the Mini International 
N europsychiatric Interview  for psychiatric disorders version 2.1 and the Dutch 
version o f the ADHD rating scale 32-34. To assess h istory  o f drug  and alcohol use we 
used the Dutch version o f the Addiction Severity Index (EuropASI), section 4 35, 36. 
Participants w ith any psychiatric (family) history, including substance use 
d isorders and habitual sm oking (daily nicotine use) were excluded. Out o f 16 
screened ind iv iduals, 15 were eligible, m ean age (SD) 25.2 (5.9) years. Participants 
were not allowed to sm oke or use caffeine during study m ornings, or take alcohol 
two days before study days.
Measurements 
Plasma apomorphine (APO) and growth hormone (GH) levels
To assess p lasm a APO and GH levels, blood (4ml) was taken. After centrifugation , 
2.0m l sam ples were kept on ice and stored at -30°C. APO levels were assessed  by 
h igh pressure liquid chrom atography (HPLC), w ith electrochem ical detection 37. GH 
levels were assessed by Radio Im munoAssay, u sing an tiseru m  raised  in gu in ea pig. 
The 1st (80/505) in ternational stan dard  for GH was used for the stan dard curve, with 
a detection lim it o f 1.6 mIU/L. Two Participants w ith baselin e GH levels >10 U/l were 
excluded from  analysis. Plasm a APO levels were available for nine o f fifteen  
ind iv iduals, due to contam ination  o f the antioxidant in  one series o f batches.
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AX continuous performance task (AX-CPT)
In the AX-CPT single white letters were consecutively shown on a black screen 
(in terstim ulus interval=1300 ms). Participants were in structed  to give a target 
response (right button  press) after the probe ‘X ’, i f  preceded by a cue ‘A’, or a 
non-target response (left button press) after any other com bination o f letters 38. To 
increase task  d ifficulty , two d istracter letters were presented betw een cue and 
probe 38. To increase sensitivity  for im pulsive response styles (com m ission errors) 
70% were target tr ia ls  39. Responses were scored in  a w indow betw een 100 and 2000 
m s, after stim ulus onset. Perform ance during each session was calcu lated  as the 
m ean reaction tim e and accuracy on AX tria ls  (the percentage com m ission  errors). 
Non responses (omissions) were not taken  into account, given the low num ber (<1%). 
A m edian  sp lit on baselin e accuracy was used to divide h igh and low baseline 
perform ers 16.
Prepulse inhibition (PPI)
Reflex eye b link responses were m easured as electrom yographic activity over 
the righ t orbicu laris oculi m uscle, w ith a sam pling frequency (Fs) o f 1000 Hz 38. 
Background sound consisted o f 70 dB white noise, pulse-alone tria ls o f 105 dB white 
noise bursts, w ith in stan t rise tim e. Prepulse tria ls consisted o f either 75 or 85 dB 
w hite noise bu rsts preceding 105dB pulses. Pulse duration  was 20 m s for prepulses 
and 40 m s for startle  pulses. In terstim ulus interval was 100ms, in tertria l intervals 
ranged betw een 8-12 sec random ly. Each PPI m easurem ent started  w ith 15 
habituation  tr ia ls  (105 dB PA trials), th at were subsequently excluded from  the 
analysis, followed by 12 tria ls o f each type (105 dB, 85/105 dB, 75/105 dB) in  a 
pseudo-random  order.
Data clean ing was perform ed off-line w ith MIDAC softw are (testorganizer- 
MIDAC polygraphy m odule, In strum entation  Service, UMC St Radboud, Nijmegen), 
w ith  a response window from  20-150 ms after stim ulus onset. Startle responses 
w ith  an inconstan t baselin e 20 m s before the stim ulus, w ith a response to the 
prepulse, or tr ia ls  in which no startle  response was detected were excluded from  
furth er calcu lations.
The average am plitude o f startle  responses was calcu lated  for each tr ia l type 
(105dB, 75/105 dB and 85/105 dB) per startle  session (i.e. 6 sessions per treatm ent 
condition). Percentage PPI was calcu lated  for 75/105 dB and 85/105 dB tria ls, per
startle  session , as follows: |(Mamplitude PA-Mamplitude PP)/(Mamplitude PA)] 100%. A
m edian  sp lit on baselin e PPI (both 75/105dB and 85/105dB) was used to divide high 
and low baselin e sensorim otor gaters 26, 27.
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Procedure
Study m ornings started  at 8.30h a.m., w ith  a stan dard ized ligh t breakfast. 
M easurem ents were perform ed once before and five tim es after drug  adm in istration , 
startin g  w ith blood sam pling, followed by a nine m inute startle  session and 
consecutively ten m inutes AX- CPT, each cycle lastin g  20 m inutes (figure 1). 
Treatm ent conditions were ten to twenty-five days apart.
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Figure 1 O utline o f study days
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Data analysis
SPSS (version 16.0) under W indows, was used for statistica l analysis, w ith a  set 
at .05 (two-sided). The effect o f APO on GH, perform ance on the CPT-AX and acoustic 
startle  was analyzed u sing GLM repeated m easures ANOVA, w ith treatm ent (APO 
s.l., APO s.c., and placebo) and tim e (baseline, T1, T2, T3, T4,T5) as w ithin-subject 
factors. Scores on each outcom e m easure at baseline, were used to divide subjects 
by m edian  sp lit into low and h igh perform ers, so that we could exam in e the effect 
o f APO on these two groups, for each outcom e m easure, w ith group as a between- 
subject factor. In order to control for a learn ing effect over the d ifferent sessions, 
order was entered as a betw een-subjects factor in  the analysis o f the AX-CPT. Since 
both the factors tim e and treatm ent have two or m ore degrees o f freedom , Green- 
hous-Geisser correction was used, epsilon  values and adjusted p-values are 
reported.
Post-hoc, we analyzed sim ple contrasts to baseline, in order to identify  the 
specific tim e points w ith the largest effect o f APO on the outcom e m easure after 
both s.c. and s.l. adm in istration  o f APO, only i f  the om nibus test showed a 
sign ifican t interaction  effect. To asses the relation  betw een baselin e task 
perform ance on the AX-CPT and baselin e PPI we com puted Pearson’s correlation  
betw een speed and accuracy on the AX-CPT and PPI on 75/105 and 85/105dB.
Individual curves o f APO levels in  the fir st  and second com partm ent were 
fitted  in a previously validated algorithm  in  MW/Pharm, a softw are package 
developed to study the clin ical effect o f APO, e.g. in  patients su fferin g from  
Parkinson ’s d isease (m edi\w are, version 3 . 60 ) 31,31,40, 41. Individual fits were based on 
plasm a APO levels, indiv idual pharm acokinetic param eters (volume o f distribution , 
rate constants for elim ination  and intercom partim en tal exchange, renal function  
and BMI), and population  kinetics. We com puted Pearson’s correlations betw een 
the central outcom e m easures and tim e locked APO levels both  in the fir st  and 
second com partm ent (plasm a and CSF).
Results
Plasma apomorphine (APO) and growth hormone (GH) levels
Both s.c. and s.l. adm in istered  APO resulted in  detectable p lasm a APO levels 
(Fig. 2). Due to technical issues APO levels were only available for nine o f fifteen  
participan ts. GH levels increased after adm in istration  o f APO, see Table 1 and 
Fig. 3 (F(10,12)= 8.4, p<.001). Posthoc analysis showed the effect o f APO was m ainly  
at 50 m inutes after s.c. adm in istration  (F(1, 12)=18.3, p=.001).
AX continuous performance task
Baseline task  perform ance did not d iffer betw een treatm ents (com m ission 
errors: F(2,14)=0.6, p=.547; reaction tim e: F(2,14)<.01, p=.977). There was no effect of 
order on task  perform ance (F(3.3,14)=.6,p=.611). There was no difference in age or 
APO levels betw een the m edian  split groups (see supplem entary table 1a). The 
percentage com m ission  errors increased after APO, p articu larly  in  subjects with 
m ore error responses at baseline, see Table 1 and Fig. 4a (F(3.2,14)=3.5, p=.030). 
Mean reaction tim e on AX-trials increased after APO, in subjects w ith slow baseline 
responses, see Table 1 and Fig. 4b (F(4.2,14)=2.9, p=.030).
Posthoc analysis showed that the effect o f APO on both error percentage and 
reaction  tim e was m ain ly  at 40 m inutes after s.c. adm in istration  (error percentage: 
F(1, 14)=38.1, p<.001, reaction tim e: F(1, 14)=21.6, p=.001).
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Table 1 Results: baselin e values and effect o f treatm ent w ith apom orphine 
(APO), on p lasm a grow th horm one (GH) levels, perform ance on the 
AX-continuous perform ance task (AX-CPT) and prepulse inhibition (PPI)
Outcome m easure M ean at baseline 
(SD)
F-Statistic
(df)
e-value p-value
GH NA
-Time 13.4(1.8, 12) .36 <.001
-Treatment 10.9(1.7, 12) .87 .001
-Time*Treatment 8.4(2.7, 12) .27 <.001
CPT-AX, reaction  tim e (msec) 347.91ms (66.61)
-Time 2.1 (3.3, 14) .67 .107
-Treatment 2.7 (1.9, 14) .96 .090
-Time*Treatment 1.7 (4.2, 14) .42 .157
-Time*Treatment*Baseline 2.9 (4.2, 14) .030
CPT-AX, com m ission  errors (%) 4.8% (5.4)
-Time 1.0 (3.3, 14) .67 .399
-Treatment 0.4 (1.4, 14) .71 .580
-Time*Treatment 0.5 (3.2, 14) .32 .675
-Time*Treatment*Baseline 3.5 (3.2, 14) .030
PPI 75/105dB (%) 9.7% (22.6)
-Time 1.1 (3.7,14) .73 .381
-Treatment 2.2 (1.6,14) .78 .143
-Time*Treatment 1.7 (5.0,14) .50 .161
-Time*Treatment*Baseline 2.8 (5.0,14) .024
PPI 85/105dB (%) 22.2% (24.6)
-Time 2.5 (3.5, 14) .70 .040
-Treatment 3.5 (1.5,14) .75 . 050
-Time*Treatment 1.5 (4.9, 14) .49 .154
-Time*Treatment*Baseline 1.4 (4.9, 14) .182
Tim e: m a in  e ffec t  o f tim e , trea tm en t: m a in  e ffec t  o f trea tm en t, T im e*T reatm en t: Tim e by 
Treatm ent in te ractio n  effec t, T im e*T reatm en t*B aselin e : Tim e by T reatm en t by base lin e  
p erfo rm an ce  in teractio n  effect.
Prepulse inhibition (PPI)
The num ber o f excluded tria ls increased betw een baselin e and T5; from  13% to 
26% for 75/105dB (F(5, 14)=4.7, p=.001), from  35% to 48% 105dB (F(5, 14)=4.8, p=.001), 
and from  24% to 32% 85/105dB (F(5, 14)=3.0, p=.018). This is m ain ly  caused by an 
increase in  the num ber o f non responses. The num ber o f excluded tr ia ls  did not 
d iffer over the three drug conditions (105dB trials: F(10, 14)=1.1, p=.331, 75/105dB
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Figure 2 Results: p lasm a apom orphine (APO) concentration and APO levels 
as estim ated in  the second com partm ent, after oral (2mg) and 
sub lin gual (0.005mg/kg) adm in istration
2.0 
S ' 1.5
2 io 
<
0.5
0.0+
plasma APO 2mg s.l.
-A-  plasma APO 0.005mg/kg s.c.
'  ' : - A - ' ' 'v brain APO 2mg s.l.
# ___A' - a - brain APO 0.005mg/kg
Figure 3 Results: P lasm a grow th horm one levels, before and after
sub lin gual (2mg) and subcutaneous (0.005mg/kg) adm in istration  
o f apom orphine (APO)
APO 2mg s.l.
-A- APO 0.005mg/kg s.c. 
Placebo
tria ls: F(10, 14)=0.5, p=.853, 85/105dB tria ls: F(10, 14)=0.5, p=.900), ind icating no 
difference in  habituation  to the startle  stim ulus over all treatm ent conditions. For 
the resu lts o f analysis o f startle  am plitudes, see supplem entary table 2 and 
supplem entary figures 1a-c).
Baseline PPI did not d iffer betw een treatm ents (PPI 75/105dB: F(2,14)=0.4, 
68 p=.686, PPI 85/105dB: F(2,14)<0.1, p=.911). There was no difference in age or APO
levels betw een the m edian  split groups (see supplem entary table 1b). PPI decreased
Table 2 Mean correlations betw een central outcom e m easures (plasm a GH 
levels, and perform ance on the AX-continuous perform ance task 
(CPT-AX) and apom orphine (APO) levels in  p lasm a and as calcu lated  in 
the second com partm ent
GH, 
M ean R (sd)
AX-CPT, m ean R (sd) 
Reaction tim e 
E rrors
PPI, m ean  R (sd) 
75/105dB 85/105dB
APO 0.005m g/kg s.c. (N=8) (N=9) (N=9) (N=9) (N=9)
1st com partm ent 0.20 (0.30) 0.41 (0.48) 0.58 (0.37) .289 (.25) -.175 (.44)
2nd com partm ent 0.58 (0.20) 0.45 (0.44) 0.58 (0.37) .282 (.35) -.178 (.39)
APO 2m g s.l. (N=5) (N=5) (N=5) (N=5) (N=5)
1st com partm ent 0.01 (0.27) 0.46 (0.43) 0.33 (0.37) .074 (.41) -.192 (.33)
2nd com partm ent 0.30 (0.41) 0.43 (0.43) 0.46 (0.36) .137 (.22) -.373 (.32)
2
Figure 4 Results: Perform ance on AX-continuous perform ance task  (CPT-AX), 
before and after su b lin gu al (2mg) and subcutaneous (0.005mg/kg) 
adm in istration  o f apom orphine (APO)
a) Percentage commission errors on CPT-AX, by baseline task  performance
APO 2mg s.l. poor perf 
- A-  APO 0.005mg/kg s.c. poor perf 
placebo poor perf
APO 2mg s.l. high perf 
- A-  APO 0.005mg/k s.c high perf 
placebo high perf
b) Reaction tim e on CPT-AX, by baseline task performance
2mg s.l. poor perf 
- A-  0.005mg/kg s.c. poor perf 
- I -  placebo poor perf
2mg s.l. high perf 
- A-  0.005mg/kg s.c. high perf 
placebo high perf
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after adm in istration  o f APO for high intensity  prepulse tria ls (85/105dB), see Table 
1 and Fig. 5a (F(1.5, 14)= 3.5, p=.050). Baseline PPI did not m odulate the effect o f APO 
on PPI in h igh intensity  prepulse tria ls (F(4.9,14)=1.4, p=.182). PPI increased after 
adm in istration  o f APO for low intensity  prepulse trials, in  subjects w ith low 
baselin e PPI, see Table 1 and Fig. 5b (F(5.0,14)=2.8, p=.024). Posthoc analysis showed 
th at the effect o f APO on PPI was m ain ly  at 30 m inutes after s.c. adm in istration  
(85/105dB: F(1, 14)=6.0, p=.030; 75/105dB: F(1, 14)=10.1, p=.008). Baseline PPI levels 
for low intensity  prepulse tria ls were inversely correlated w ith baselin e accuracy 
on task  perform ance (75/105dB: R=-.59, p=.021).
Figure 5 Results: percentage prepulse inh ibition  (PPI), before and after
sub lin gual (2mg) and subcutaneous (0.005mg/kg) adm in istration  of 
apom orphine (APO), on 75dB and 85dB prepulse tria ls
a) Percentage PPI on 75dB prepulse trials, by high vs. low baseline levels o f PPI
APO 2mg s.l. (high) 
-A- APO 0.005mg/kg s.c.
(high)
Placebo (high)
APO 2mg s.l. (low) 
-A- APO 0.005mg/kg s.c.
(low)
-1- Placebo (low)
b) Percentage PPI on 85dB prepulse trials
30H
APO 2mg s.l. 
-A- APO 0.005mg/kg s.c. 
Placebo
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PK/PD analysis
The effect o f APO on the outcom e m easures showed close resem blance w ith the 
k inetics o f APO (Fig 2-5). The relation  betw een APO levels and the observed effects 
could best be m odelled u sing S-curves (Fig 6). Central m easures correlated best 
w ith APO levels in  the second com partm ent after s.c. adm in istration , GH levels and 
accuracy on the AX-CPT in p articu lar  (Table 2).
Figure 6 Results: relation  betw een apom orphine (APO) levels in  the first
en second com partm ent (blood and brain) and tim e locked p lasm a 
grow th horm one (GH) levels and error percentage on the 
AX-continuous perform ance task  (AX-CPT)
a) GH after 0.005mg/kg APO s.c. 
30n
A A
I
(3
20
10
APO 0.005mg/kg s.c. comp I 
A APO 0.005mg/kg s.c. comp II
A A
A A
A A'
0.0 0.5 1.0
APO concentration
1.5
b) Error percentage on AX-CPT after 0.005mg/kg APO s.l.
£  10 
2 
0
AA
APO 0.005mg/kg s.c. comp I 
A APO 0.005mg/kg s.c. comp II
A
A
0.0 0.5 1.0
APO concentration
1.5
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Supplementary table la
Results: com parison o f age, APO kinetics and GH levels for m edian split groups for PPI 75/105dB and PPI 85/105dB
Low PPI75 
Mean (SD)
High PPI75 
Mean (SD)
F-statistic p-value Low PPI85 
Mean (SD)
High PPI85 
Mean (SD)
F-statistic p-value
Age (yrs) 24(3.4) 27(7.5) 0.7 .411 26 (4.0) 25 (3.0) 0.1 .746
Apo max
-s.c. 2.0 (0.7) 1.6 2.0 (0.5) <0.1 .975 2.1 (0.7) 1.8 (0.5) 0.3 .595
-s.l. (0. 9) 0.9 (0.3) 1.0 .374 1.1 (0.3) 1.6 (1.2) 0.4 .583
GH max
-s.c. 25.9 (20.5) 31.0 (36.5) 0.2 .702 36.0 (26.1) 21.3 (21.9) 0.5 .497
-s.l. 16.3 (11.5) 17.8 (13.7) <0.1 .830 16.0 (9.0) 15.3 (20.0) <0.1 .961
Baseline startle
105dB 885(449) 924 595 (306) 2.1 .173 737(173) 532 (147) 2.4 .193
75/105dB (436) 794 499 (279) 4.9 .046 756 (190) 382 (57) 10.7 .031
85/105dB (305) 444 (280) 5.3 .038 778 (73) 252 (78) 73.2 .001
Supplementary table lb
Results: com parison o f age, APO kinetics and GH levels for m edian split groups for AX-cpt reaction tim e and AX-cpt accuracy
Fast responders 
Mean (SD)
Slow responders 
Mean (SD)
F-statistic p-value Poor accuracy 
Mean (SD)
High accuracy 
Mean (SD)
F-statistic p-value
Age (yrs) 26(7.5) 25(3.7) 0.2 .641 25(7.4) 27(2.6) 0.4 .520
Apo max
-s.c. 2.0 (0.8) 1.9 (0.4) <0.1 .914 1.6 (0.5) 2.2 (0.5) 2.8 .136
-s.l. 2.0 (1.4) 1.0 (0.3) 2.3 .204 2.0 (1.3) 1.0 (0.3) 2.4 .195
GH max
-s.c. 37.1 (21.2) 13.0 (14.9) 4.9 .050 32.8 (21.2) 22.0 (23.5) 0.8 .400
-s.l. 21.6 (11.1) 9.2 (9.4) 4.3 .062 20.9 (14.0) 12.2 (7.3) 1.9 .200
Supplementary figure 1a.-c
Results: acoustic startle  am plitude, before and after sub lin gual (2mg) and 
subcutaneous (0.005mg/kg) adm in istration  o f apom orphine (APO)
a) Startle amplitude after 105dB trials
-» AP02mgs.l.
* APO 0.005mg/kg s.c. 
Placebo
Time
b) Startle amplitude after 85/105dB trials
- •  AP02mgs.l.
* APO 0.005mg/kg s.c. 
Placebo
Time
c) Startle amplitude after 75/105dB trials
- •  AP02mgs.l.
A APO 0.005mg/kg s.c. 
▼ Placebo
Time
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Supplementary table 2
Results: baselin e values and drug effects after adm in istration  o f APO on the 
acoustic startle  am plitude.
Startle  am plitude M ean at baseline 
(SD)
F-Statistic
(df)
p-value
105dB 749.62mV (419.79)
-Time 6.4(5,14) <.001
-Drug 0.1(2,14) .713
-Time*Drug 1.7(10,14) .093
85/105dB 630.50mV (361.23)
-Time 3.3(5,14) .010
-Drug 1.6(2,14) .213
-Time*Drug 2.0(10,14) .037
75/105dB 729.09mV (415.67)
-Time 5.9(5,14) <.001
-Drug 0.1(2,14) .849
-Time*Drug 1.0(10,14) .454
Tim e: m a in  effec t o f tim e , D rug: m a in  e ffec t  o f d ru g , T im e*D rug: Tim e by D ru g in te ractio n  effect, 
u sin g  rep eated  m e asu re s  ANOVA
Adverse events
Nausea was reported by five participan ts, betw een 10 and 40 m inutes, only 
after s.c. adm in istration  o f APO. Yawning and w eariness were reported in  all 
conditions (placebo: 7 participants, APO s.l. 10 participants, APO s.c. 12 participants).
Discussion
A dm inistration  o f the d irect dopam ine receptor agon ist APO to healthy 
ind iv iduals resu lted in increased p lasm a GH levels and disrupted  perform ance on 
the AX-CPT, as predicted. APO im proved PPI in prepulse tr ia ls  o f low intensity  
(75/105dB), in  subjects w ith poor baselin e sensorim otor gating, and disrupted  PPI 
in  high intensity  prepulse tria ls (85/105dB).
Elevated levels o f p lasm a GH after adm in istration  o f APO are in  line with 
previous studies that have shown GH responses after com parable doses o f APO in 
healthy controls and patients su fferin g from  schizophrenia, m ajor depression and 
alcohol dependence 4. The dose o f APO currently  adm in istered appears to be 
su ffic ien t to stim ulate central dopam ine receptors.
The observed deterioration in  cognitive perform ance after APO is in line with 
74 other studies, show ing decreased cognitive perform ance after adm in istration  o f
APO and the dopam ine agon ist pram ipexole 25, 42. Since dopam ine receptors in the
PFC are located both at the presynaptic and postsynaptic neuron, one could 
speculate th at the disruptive effect on cognitive perform ance is caused by decreased 
dopam ine fun ction in g after stim ulation  o f presynaptic dopam ine receptors, or 
excessive dopam ine fun ction in g after stim ulation  o f postsynaptic dopam ine 
receptors 43, 44.
In th is study p articipan ts w ith poor baselin e cognitive perform ance, were 
m ost sensitive to the deteriorating effects o f APO on cognitive perform ance.
Healthy ind iv iduals w ith low baselin e cognitive perform ance, w ith presum ed 
lower levels o f prefrontal dopam ine function ing, being m ore sensitive to the 
detrim en tal effects o f APO on cognitive perform ance suggests that stim ulation  of 
presynaptic dopam ine receptors, and subsequently reduced dopam ine n eu rotran s­
m ission  in  the PFC is involved.
The observation  o f PPI disruption  in h igh intensity  prepulse tria ls after 
adm in istration  o f APO, versus PPI enhancem ent in low intensity  prepulse tria ls , is 
in  line w ith previous fin d in gs w ith the dopam ine agon ists pergolide and PHNO in 
rats 45, 46. This paradoxical fin d in g  has been hypothesized to resu lt from  either 
agon ist action on dopam ine receptors located pre and post synaptically, or at 
d ifferent p arts in  the startle  neurocircuitry , or from  agon ist action on different 
neurochem ical subclasses o f dopam ine receptors, e.g. D3, D4 45, 46.
Although dopam ine receptors are located in  several d ifferent brain  areas, there 
is su bstan tial evidence from  preclin ical research, su ggesting that the fin a l pathw ay 
in  the disruptive effect o f APO on PPI is dependent on stim ulation  o f dopam ine 
receptors in  the nucleus accum bens. Local application o f dopam ine agon ists in the 
nucleus accum bens, but not in  the n eostriatu m  or the orbitofrontal cortex, reduces 
PPI 47, 48. Interestingly, w ith in  the prefrontal cortex dopam ine antagonists rather 
th an  agonists appear to decrease PPI 49, 50. More im portantly, Swerdlow and 
colleagues also  showed th at the PPI disruptive effects o f system ically  applied 
dopam ine agon ists can  be blocked by b locking dopam ine transm ission  in  the 
nucleus accum bens 51. These data  suggest th at the effects o f dopam ine agon ists on 
PPI are predom inantly  m ediated via the m esolim bic, nucleus accum bens, dopam ine 
receptors. However, it cannot be ru led out th at the disruptive effect o f APO on PPI 
m ay be m ediated by dopam ine receptors in  the m edial prefrontal cortex 52, 53.
At low prepulse intensities, APO im proved sensorim otor gatin g in participan ts 
w ith suboptim al baselin e levels o f PPI, w ith  presum ed suboptim al m esolim bic 
dopam ine function ing. This suggests that stim u lation  o f postsyn aptic dopam ine 
receptors, and subsequently increased m esolim bic dopam ine n eurotran sm ission  is 
involved. In contrast, base lin e levels o f PPI did not m odify  the response to APO in 
h igh intensity  prepulse tria ls . PPI on h igh intensity  prepulse tr ia ls  is rather robust, 
and likely less sensitive to the effect o f baselin e PPI on APO sensitivity. Yet, at low 
prepulse intensities, PPI m ay be dependent on a m ore narrow  optim um  of 75
m esolim bic dopam ine functioning.
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The observed negative correlation  betw een baselin e cognitive perform ance 
and baselin e PPI on low intensity  prepulse tria ls, supports a previously suggested 
reciprocal relation  betw een prefrontal and subcortical dopam ine n eu rotran sm is­
sion 54' 55. Participants w ith high baselin e cognitive perform ance, i.e. presum ed 
optim al prefrontal dopam ine function ing, showed im paired  levels o f sensorim otor 
gating, i.e. presum ed suboptim al m esolim bic dopam ine function ing. Moreover, 
subjects sensitive to deteriorating effects o f APO on cognitive perform ance, 
appeared to be less sensitive to the PPI enhancing effects o f APO. This again  
supports the idea that w hereas cognitive perform ance is m ore related to cortical 
dopam inergic system s, PPI is m ore m ediated via m esolim bic dopam inergic system s. 
Several additional issues regard in g PPI need to be considered. First, the num ber o f 
excluded startle  tria ls in th is study (20%), is h igh com pared to literature (5%) 26, 38, 56, 
57. Moreover, the num ber o f excluded tr ia ls  increased over consecutive startle  
sessions. This m ay resu lt from  both habituation  and w eariness o f the participan ts, 
due to repeated m easurem ent sessions. Though there was no effect o f treatm ent on 
the num ber o f excluded tria ls , habituation  effects m ay have in fluenced the 
observed effects o f APO on PPI. Im portantly, we used a low dose o f APO (0.005 mg/ 
kg s.c. or 2 m g s.l.), com pared to an im al literature (e.g. 0.5 mg/kg). D irect translation  
o f the cu rrent fin din gs to an im al fin d in gs is therefore lim ited.
The effect o f APO on the central outcom e m easures closely follows the kinetics 
o f APO. In line w ith our hypotheses we found the best correlation  betw een central 
outcom e m easures and calcu lated  APO levels in the second com partm ent (CSF), 
after s.c. adm in istration . APO levels in  the second com partm ent show an S-curve 
relation  w ith  central outcom e m easures, w hereas p lasm a APO concentrations (first 
com partm ent) show a poor correlation, due to a large counter-clock hysteresis 
curve. The use o f tw o-com partm ental PK/PD m odelling m ay provide fu rth er in sigh t 
in  true pharm acodynam ic differences in  dopam ine receptor sensitivity  betw een 
groups, tak in g  into account pharm acokinetic d ifferences. Since correlation  
coefficients were rather low, factors other th an  APO levels m ay contribute to the 
observed changes in  central outcom e m easures, like w eariness, m otivational 
decline, habituation  to the acoustic startle  and a learn ing effect on the AX-CPT. In 
addition, PK/PD analyses were based on a lim ited  num ber o f participan ts. Future 
studies are needed to confirm  the current fin din gs.
Conclusions
Baseline perform ance m odulated the effect o f APO on task  perform ance and 
PPI. This provides furth er evidence for the hypothesized inverted U-shape relation  
betw een prefrontal dopam ine fun ction in g and cognitive perform ance, and 
m esolim bic dopam ine fun ction in g and sensorim otor gating. The current findings
also  suggest a reciprocal relation  betw een prefrontal and m esolim bic dopam ine 
functioning.
More studies on the relation  betw een the central effects o f APO and levels o f 
APO in  the CSF are needed. Future APO ch allenge studies into dopam ine 
dysfunctioning in  neuropsychiatric d isorders preferably use m ultiple outcom e 
m easures, after s.c. adm in istration .
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The dopam ine agon ist apom orphine differen tially  affects cognitive perform ance 
in  alcohol dependent patients and healthy controls
Abstract
Background
Reduced m etabolic activity in fron tal brain  regions, and reduced stria ta l dopam ine 
receptor densities have been shown in alcohol dependent patients. Little is known 
on fun ction al changes in the fronto-striatal-thalam ic dopam inergic n eurociru itry  
in  these patients. The objective o f th is study was to assess sensitivity o f prefrontal 
dopam ine receptors in  alcohol dependent patients.
Experim ental procedures
Male alcohol dependent patien ts (N=40) and healthy controls (N=39) perform ed an 
AX continuous perform ance test before and after adm in istration  o f the DA agon ist 
apom orphine (0.005mg/kg). Results
At baselin e alcohol dependent patients were slower and less accurate com pared to 
healthy controls. After adm in istration  o f apom orphine, perform ance im proved in 
alcohol dependent patients and deteriorated in  healthy controls.
Conclusions
Reduced cognitive perform ance in  alcohol dependent patients com pared w ith 
healthy controls m ay indicate dopam ine dysfunctioning at the prefrontal level. 
Im provem ent o f cognitive perform ance in alcohol dependent patients after 
adm in istration  o f apom orphine and deterioration in healthy controls provides 
evidence for an  inverted U-shape relation  betw een dopam inergic fun ction in g and 
cognitive perform ance.
84
D ysfunction o f the m esolim bic dopam ine (DA) system  is thought to play an 
im portant role in  substance dependence \  Reinforcing effects o f drugs o f abuse are 
contingent upon a m esolim bic increase in dopam ine, exceeding th at o f n atural 
rew arding events. Im aging studies have shown reduced stria ta l DA D2 receptor 
densities in patients w ith alcohol or substance dependence 2. A reduced grow th 
horm one (GH) response after adm in istration  o f the DA receptor agon ist 
apom orphine (APO), reflects a decreased hypothalam ic DA receptor sensitiv ity  in 
recently detoxified alcohol dependent patients 3' 4. However, little  is known on 
fun ction al changes in the fronto-striatal-thalam ic DA neurociruitry. This is the 
fir st  report on the sensitiv ity  o f DA receptors in  alcohol dependent patients, u sing 
a prefrontal cognitive outcom e m easure in  a DA ch allenge test.
DA function  in  the prefrontal cortex is involved in  cognitive perform ance, 
including perceptual speed, (spatial) w orking m em ory and response inhibition  5-7. 
D eficits in  cognitive perform ance have been described in d isorders w ith a decrease 
in  DA function ing, such as Parkinson ’s d isease and ADHD but also  in disorders in 
w hich an increase in DA fun ction in g has been hypothesized, such as sch izophren ia 
and H untington ’s d isease 1 8. This suggests th at a specific level o f DA is necessary 
for an op tim al fun ction in g o f the prefrontal cortex and striatum , as described by 
an inverted U-shape curve 9 10. Indeed, APO has been shown to d isrupt cognitive 
perform ance in  an im als and healthy hum an  volunteers, probably by an alteration  
o f brain  activity in the prefrontal and cin gulate cortex 11-13.
Perform ance on the AX-continuous perform ance test (AX-cpt), has been shown 
to re flect m ultiple cognitive dom ains, including inhibition, attention  and working 
m emory, that are to a large extend dependent on DA function  in the fronto-striatal- 
th alam ic n eurocircu itry  9 10, 14, 15. We report on the effect o f the DA agonist APO on 
cognitive perform ance in  alcohol dependent patients, com pared w ith healthy 
controls. We hypothesized that alcohol dependent patients w ill be less sensitive to 
the d isruptin g effects o f APO on cognitive perform ance.
Experimental procedures
Subjects
Male alcohol dependent patients (according to DSM-IV, N=40), age 44.8 years (SD 
8.9), applying for inpatient detoxification , were tested after one m onth o f controlled 
abstinence. Healthy controls, age 42.9 years (SD 10.6), w ithout a (family) h istory of 
substance abuse or dependence, were recru ited through advertisem ents in  regional 
new spapers (N=40).
Introduction
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After w ritten  inform ed consent, p articipan ts were screened on m edical illness 
and axis I psychiatric d isorders, u sing the Dutch version o f the Mini International 
N europsychiatric Interview  for psychiatric d isorders version 2.1 and the Dutch 
version o f the ADHD rating scale 16-18. Patients th at required  treatm ent (like mood 
or anxiety  disorders), psychotic vu lnerability  (except a single drug-induced 
psychosis) or Korsakov’s syndrom e (1 patient) were excluded (Fig. 1). M edication was 
allowed, except for agents w ith dopam inergic activity, e.g. m ethylphenidate, 
antipsychotics (2 patients), sedatives, or when m edication  was changed during 
three m onths prior to the study (see Table 1). Participants were not allowed to 
sm oke or use caffeine contain ing drinks on study days (use o f caffeine and nicotine).
Figure 1 Consort Flow Chart
Patients Controls
To assess sociodem ographic ch aracteristics and history  on drug and alcohol use 
we used the Dutch version o f the Addiction Severity Index (EuropASI), sections 2 
and 4 19-21. Patients had a lower level o f education (Table 1). All participan ts were 
asked for their preferred hand for fine and m ajor m otor activities. There was no 
86 difference w ith respect to dexterity  betw een groups (Table 1).
The study was approved by the regional m edical eth ical board.
Table 1 D em ography (ASI section 2), h istory  o f drug  abuse (ASI section 4), for 
alcohol dependent patients and healthy controls
Patients (N=36) 
Mean (SD)
C ontrols (N=39) 
Mean (SD)
Test sta tistic P-
value
Age (years) 43.8 (8.9) 42.9 (10.6) T=-.41 .681
Education level (%)*
-Low 39% 8% C2=18.60 <.01
-Intermediate 42% 23%
-High 19% 69%
Dexterity (%) 12% 5% C2=1.70 .19
Age alcohol use disorder 23 (8) 1 NA NA NA
(age in years)
Duration o f illness (years) 18 (10) NA NA NA
Co-morbid use o f
-stim ulantia (%) 0 0 NA NA
- cannabis (%) 0 0 NA NA
- opiates (%) 3% 0 NA NA
(1 patient, prior
to admission)
- hallucinogens (%) 0 0 NA NA
-nicotine 38% 17% C2=4.65 .031
-caffeine 100% 98% C2=1.02 .312
Co-morbid psychiatric
diagnosis
-Mood disorders 3% (1 patient 0 C2=1.07 .302
with depression)
-Anxiety disorders 5% (2 patients 0 C2=2.16 .142
w ith soc. phob.)
-ADHD 13% 0 C2=5.60 .018
Use o f medication
-SSRI’s 8% 5% C2=.278 .598
*H igh est d ip lom a ob ta in ed : low level o f  ed u cation  is  p r im ary  an d  seco n d ary  sch ool, in term ed ia te  
level o f edu catio n  is  v o ca tio n a l ed u cation , h igh  level o f  edu cation  is  h igh er p ro fessio n a l edu cation , 
un iversity . NA=not ap p licab le
Measurements
Participants perform ed the AX-cpt for ten m inutes, once before and tw ice after 
(20 and 40 m inutes) subcutaneous adm in istration  o f APO (0.005mg/kg). In the task, 
single letters were consecutively shown in  white on a black screen, participan ts 
were in structed  to give a target response (press righ t button) after the probe ‘X ’ in 
com bination w ith the cue ‘A’, or a non-target response (press left) after any other 
com bination o f letters, w ith an in terstim ulus interval o f 1300 m sec, described by 
van der Linden (2006)22. To increase task  difficulty , two distracter letters were
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presented in red betw een cue and probe. To increase sensitivity  for im pulsive 
response styles (com m ission errors), 70% were target tr ia ls  14. Responses were scored 
in  a response window betw een 100 and 2000m s, after stim ulus onset.
Statistical assessment
Data were analyzed u sing SPSS version 14.0. One patient and one control subject 
were excluded from  analysis, because o f fa ilu re  to com prehend the task  properly. 
D ependent variables were speed and accuracy. Accuracy was com puted as the 
percentage error responses (com m ission errors) from  the total responses. Non 
responses, om ission  errors, were not taken  into account, given the low num ber in 
both groups (1%).
Baseline differences betw een groups were com puted u sing an unpaired  T-test. 
The response to APO was analysed u sing a general lin ear m odel repeated m easures 
ANOVA, w ith tim e as w ithin-subject factor and group as betw een-subject factor 
(alpha (two-sided)=0.05). Since there was a sign ifican t difference in  use o f nicotine, 
ADHD, and level o f education betw een groups, we added these as co-variates.
Table 2 Results: Perform ance on AX-CPT before and after APO in detoxified 
alcohol dependent patients and healthy controls
Patients (N=36) 
M ean (SD)
Controls (N=39) 
M ean (SD)
Test sta tistic P-
value
Speed:
Reaction tim e (ms)
-Baseline 376.6 (77.1) 336.8 (61.9) T=-2.49 .015
-20 m inutes after APO 361.4 (72.0) 351.6 (74.0) T=-.58 .562
-40 minutes after APO 369.4 (81.4) 351.2 (78.8) T=-.98 .331
Interaction effect
(Time x group) F(1,2)=3.574 .034
Error responses (%)
-Baseline performance 6.8 (6.2) 3.9 (2.8) T=-2.57 .013
-20 m inutes after APO 5.7 (4.8) 6.1 (7.5) 7.2 .788
-40 minutes after APO 5.8 (5.4 ) 5.2 (5.4) T=-4.94 .623
Interaction effect
(Time x group) F(1,2)=3.177 .045
88
Results
AX-CPT
At baselin e alcohol dependent patients perform ed worse on AX tria ls in term s o f 
speed and accuracy, com pared to healthy controls (376.6 ms. vs. 336.6 m s. T= -2.49, 
p=.015; 6.8% errors vs. 3.9%, T=-2.57, p=.013). See Fig. 2).
Figure 2 Reaction tim e and perform ance on the AX-cpt before and after 
adm in istration  o f APO
Reaction time on AX-trials
400n
350-
I
controls 
- patients
300J
baseline 20 minutes 40 minutes
Errors on AX-trials
s 3-
U 2-
1-
0-I---------1------------------ 1----------------------------- 1-------
baseline 20 minutes 40 minutes
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Response to APO
There was no m ain  effect o f tim e on perform ance (speed: F(1,2)=.221, p=.803; 
accuracy: F(1,2)=.257, p=.774), there was a sign ifican t interaction  effect betw een 
group and tim e w ith  respect to speed and accuracy (F(1,2)=3.574, p=.034; F(1,2)=3.177, 
p=.045). W ithin group analysis showed a decrease in  perform ance in  the control 
group (accuracy: T=1.81, p=.039; speed: T=1.69, p=.050) and no statistica lly  
sign ifican t change in alcohol dependent patients (accuracy: T=1.38, p=.087; speed: 
T=1.43, p=.081).
Specific contrast analysis showed the interaction  effect was m ain ly  due to the 
effect 20 m inutes after APO in healthy controls (speed: F(1,73)=5.40, p=.023; 
accuracy: F(1,73)=4.50, p=.037). Adding the level o f education, habitual n icotine use 
and ADHD as co-variates did not alter the resu lts (level o f education: speed: 
F(1,2)=7.21, p=.009; accuracy: F(1,2)=5.06, p=.028; habitual n icotine use speed: 
F(1,2)=4.75, p=.010; accuracy: F(1,2)=4.26, p=.022 ; ADHD speed: F(1,2)=3.47, p=.034; 
accuracy: F(1,2)=4.07, p=.047).
Discussion
This is the fir st  report on the effect o f a dopam ine agon ist on cognitive 
perform ance in alcohol dependent patients, com pared w ith  healthy volunteers. 
Our hypothesis th at alcohol dependent patients are less sensitive to the disruptive 
effects o f APO on cognitive perform ance was confirm ed. Actually, patients tended 
to im prove perform ance. The observed deterioration  in  perform ance in  controls, 
w ith presum ed optim al DA function ing, and im provem ent in  patients, w ith 
im paired  dopam ine function ing, is in line w ith an inverted U-shape relationship  
betw een prefrontal DA function  and cognitive perform ance9.
The m agn itude o f the effect o f APO seem s reduced in alcohol dependent 
patients com pared to healthy controls, re flecting a reduced central sensitivity to 
APO, at the level o f the prefrontal cortex. This is in line w ith previous fin d in gs o f a 
reduced grow th horm one response to APO, and reduced stria ta l DA D2 receptor 
density  in  alcohol dependent patients 1 3 4. As dopam ine affects other n eu rotran s­
m itter system s as w ell (such as the serotonin  system) differences in these system s 
m ay also contribute to the observed differences betw een patients and healthy 
controls.
V ariations in central DA function , associated w ith alcohol dependence in  hum ans, 
and increased se lf adm in istration  o f alcohol and drugs in  an im als, have been 
shown to be related to heritable factors, as w ell as environm ental influences, such 
as cross fostering or m aternal deprivation23-26. W hether DA dysfunction  is a risk  
90 factor for, or consequence o f prolonged excessive alcohol use in hum ans (or both)
needs furth er study.
Our fin d in gs o f alcohol dependent patients perform ing worse on the AX-cpt, 
com pared to healthy controls at baseline, after controlling for the level o f education, 
are in line w ith previous fin din gs, show ing im paired  executive perform ance in 
alcohol dependent patien ts27,28. Im paired perform ance m ay indicate a hypo or 
hyper function  o f the fronto-striatal-thalam ic DA n eurocircu itry  in  alcohol 
dependent patients. However, cognitive im pairm en t in alcohol dependent patients 
has also been shown to be associated w ith reductions in  the volum e o f grey m atter 
in  prefrontal brain  areas (up to 20%)27,28. A lthough patients w ith neurological 
abnorm alities were excluded from  participation , reduced perform ance m ay still be 
a consequence o f m inor brain  dam age due to excessive alcohol use.
Alcohol dependence is often accom panied by other psychiatric sym ptom s, like 
depression and attention  deficit. It cannot be ru led out th at these psychiatric 
sym ptom s also  influence the observed DA dysfunction. Participants w ith serious 
psychiatric sym ptom s were excluded, yet selection o f p articipan ts w ithout any 
psychiatric sym ptom s would have been im practicable. Since p articipan ts were not 
allowed to smoke or drin k  caffeine during the study, acute effects o f these 
substances on task  perform ance do not confound the resu lts. Moreover, controlling 
for nicotine use did not alter the resu lts. Thus w ithdraw al effects o f n icotine are 
also  unlikely  to have confounded the resu lts. There was no difference in  the use of 
m edication  betw een groups, yet serotonin m edication  can influence cognitive 
perform ance as well, and interactions w ith APO are possible. Since th is study 
included m ales only, new studies are needed to exam ine i f  these resu lts can  be 
generalized  to fem ales.
In sum m ary, these resu lts provide fu rth er evidence for a dysfunction  o f the 
fronto-striatal-thalam ic DA n eurocircu itry  in alcohol dependent patients. Our 
resu lts w arrant fu rth er study, to address the question  to w hat extend DA 
dysfunction  in  these brain  areas is cause, or consequence o f addiction, by exam in in g  
the role o f genetic and environm ental factors in central DA function  and alcohol 
dependence.
91
A
po
m
or
ph
in
e 
in 
al
co
ho
l 
de
pe
nd
en
t 
pa
ti
en
ts
Reference List
92
1) Volkow  ND, Fowler JS , W ang GJ, Sw an son  JM , Telang F. D opam in e in  d ru g  abu se  an d  ad d ictio n : 
re su lts  o f im a g in g  stu d ie s  an d  trea tm en t im p lica tio n s. Arch Neurol 2007 N ovem ber;64(11):1575-9.
2) Volkow  ND, Fowler JS , W ang GJ, Sw anson  JM. D opam in e in  d ru g  abuse  an d  add ic tio n : re su lts  from  
im a g in g  stu d ie s  an d  trea tm en t im p lica tio n s. Mol Psychiatry  2004  June;9(6):557-69.
3) H einz A, L ichten berg-K raag B, B aum  SS et al. Evidence for p ro lon ged  recovery  o f d o p am in erg ic  
tran sm iss io n  a fter  d e to x ific a tion  in  alco h o lics w ith  poor trea tm en t outcom e. J  N eural Transm  Gen 
Sect 1995;102(2):149-57.
4) Sch m id t LG, D ettlin g  M, G rae f KJ et al. R educed d o p am in erg ic  fu n ctio n  in  a lco h o lics is  re la ted  to 
severe depen den ce. Biol Psychiatry  1996 F eb ru ary  1;39(3):193-8.
5) B ack m an  L, G in ov art N, D ixon  RA et al. A ge-related  co gn itive  d e fic its  m ed ia ted  by ch an ges in  the 
s tr ia ta l  do p am in e  system . Am J  Psychiatry  2000 April;157(4):635-7.
6) C ropley VL, F u jita  M, In n is RB, N ath an  PJ. M olecu lar im a g in g  o f the d o p am in erg ic  sy stem  an d  its 
a sso c ia tio n  w ith  h u m an  cogn itive  fu n ction . Biol Psychiatry  2006 May 15;59(10):898-907.
7) Reeves SJ, G rasby PM, H ow ard RJ, B an tick  RA, A sse lin  MC, M ehta MA. A p o sitro n  em issio n  
tom ograp h y  (PET) in v e stiga tio n  o f the role o f  str ia ta l  do p am in e  (D2) receptor av a ilab ility  in sp a tia l 
cog n ition . N euroim age  2005 O ctober 15;28(1):216-26.
8) Iversen  SD, Iversen  LL. D opam in e: 50 y ears in  p erspective . Trends Neurosci 2007 M ay;30(5):188-93.
9) C ools R, Barker RA, S ah a k ian  BJ, R obbins TW. E n h an ced  or im p a ire d  co gn itive  fu n ctio n  in 
P ark in so n ’s d isea se  as a fu n ctio n  o f  d o p am in erg ic  m ed ica tio n  an d  ta sk  d em an ds. Cereb Cortex  2001 
D ecem ber;11(12):1136-43.
10) V ijayraghavan  S, W ang M, Birnbaum  SG, W illiam s GV, A rn sten  AF. Inverted-U dopam ine D1 receptor 
actions on prefron tal neurons engaged  in w orking mem ory. N at Neurosci 2007 March;10(3):376-84.
11) F letcher PC, Frith  CD, G rasby PM, Friston  KJ, D olan  RJ. Local an d  d is tr ib u te d  e ffec ts  o f  ap om orp h in e  
on fron to-tem p o ral fu n ctio n  in  acu te u n m ed ica ted  sch izo p h ren ia . J  Neurosci 1996 N ovem ber 
1;16(21):7055-62.
12) F riston  KJ, G rasby PM, Bench CJ et al. M easu rin g  the n eu ro m o d u la to ry  e ffec ts o f d ru g s  in  m an  w ith  
p o sitro n  em issio n  tom ography. Neurosci Lett 1992 Ju ly  6;141(1):106-10.
13) G rasby PM, Friston  KJ, Bench CJ et al. The e ffec t  o f  the do p am in e  ag o n ist , ap o m o rp h in e , on reg io n a l 
ce rebral b lood flow  in  n orm al volu n teers. Psychol Med 1993 A u gust;23(3):605-12.
14) Braver TS, B arch  DM, Keys BA et al. C on tex t p ro ce ssin g  in  older ad u lts : ev idence for a th eory  re la tin g  
cogn itive  con tro l to n eu rob io logy  in  h ealth y  ag in g . J  Exp Psychol Gen 2001 D ecem ber;130(4):746-63.
15) Braver TS, B arch  DM. A th eo ry  o f co gn itive  con tro l, ag in g  co g n ition , an d  n eu ro m o d u latio n . Neurosci 
Biobehav Rev 2002 Novem ber;26(7):809-17.
16) Sh eeh an  DV, Lecrubier Y, Sh eeh an  KH et al. The M in i-In tern ation al N eu ro p sy ch iatr ic  Interview  
(M.I.N.I.): the developm en t an d  v a lid a tio n  o f a stru c tu re d  d iag n o stic  p sy ch ia tr ic  in terv iew  for 
DSM-IV an d  ICD-10. J  Clin Psychiatry  1998;59 Suppl 20:22-33.
17) v an  V liet I, de B eurs E. [The M IN I-International N eu ro p sy ch iatr ic  In terview . A b r ie f s tru c tu re d  
d iag n o stic  p sy ch ia tr ic  in terv iew  for DSM-IV en ICD-10 p sy ch ia tr ic  d isorders]. Tijdschr Psychiatr 
2007;49(6):393-7.
18) S an d ra  Kooij JJ , M arije  BA, S w in k els SH, Bekker EM, de N, I, B u ite laar  JK. R eliab ility , v a lid ity , an d  
u t ility  o f in stru m e n ts  for se lf-rep ort an d  in fo rm an t rep o rt  co n cern in g  sym ptom s o f ADHD in  ad u lt 
p a tie n ts .J  A tten D iso rd  2008 January;11(4):445-58.
19) M cLellan AT, K ushner H, M etzger D et al. The F ifth  E d ition  o f the A d diction  Severity  Index. J  Subst 
A buse Treat 1992;9(3):199-213.
20) M cLellan AT, Luborsky L, C acc io la  J et a l. New d ata  fro m  th e A d dictio n  Severity  Index. R eliab ility  
an d  v a lid ity  in  th ree  centers. J  Nerv Ment D is 1985 July;173(7):412-23.
21) L an ge lan d  W, v an  den  BW, D raijer N, H artgers C. S en sitiv ity  o f the A d diction  Severity  Index  physical 
an d  se x u a l a ssa u lt  item s: p re lim in a ry  fin d in g s on gender d ifferen ces. Eur A ddict Res 2001 
D ecem ber;7(4):193-7.
22) v an  der LD, M assar SA, S ch elleken s AF, E llen broek  BA, V erkes RJ. D isru p ted  sen so rim o to r g a t in g  due 
to m en ta l fa tig u e : p re lim in a ry  evidence. Int J  Psychophysiol 2006 O ctober;62(1):168-74.
23) Nader MA, Czoty PW. PET im agin g  o f dopam in e D2 receptors in m onkey m odels o f cocaine abuse: 
genetic p red isp osition  versu s environm ental m odulation . Am J  Psychiatry 2005 August;162(8):1473-82.
24) Ellenbroek BA, van der Kam  EL, van der Elst MC, Cools AR. Individual d ifferences in d ru g  dependence 
in  rats: the role o f genetic factors an d  life events. Eur J  Pharm acol 2005 D ecem ber 5;526(1-3):251-8.
(25) v an  der Kam  EL, E llen broek  BA, C ools AR. G ene - en v iro n m en t in te ractio n s determ in e  th e  in d iv id u a l 
v a r ia b ility  in  cocain e  se lf-ad m in istra tio n . N europharm acology  2005 A pril;48(5):685-95.
(26) Savitz  J, So lm s M, R am esar R. The m o lecu lar  gen etic s o f  co g n ition : d op am in e , COMT an d  BDNF. 
Genes B rain  Behav  2006 June;5(4):311-28.
(27) C h an rau d  S, M arte lli C, D ela in  F et al. B rain  m orp h om etry  an d  co gn itive  p erfo rm an ce  in  detox ified  
a lcoh ol-depen d en ts w ith  p reserv ed  p sy ch o so c ia l fu n c tio n in g . N europsychopharm acology  2007 
February;32(2):429-38.
(28) H arper C, M atsu m oto  I. E th an ol an d  b ra in  d am age . Curr Opin P harm acol 2005 February;5(1):73-8.
93
A
po
m
or
ph
in
e 
in 
al
co
ho
l 
de
pe
nd
en
t 
pa
ti
en
ts

4
Effects of the COMT Val158Met genotype on 
prefrontal dopamine sensitivity
Arnt F.A. Schellekens, M.D.1A' 1B' 1C, Barbara Franke1A1D1C, Sharon H oppenreijs1A, 
A rm and W.A.A. van O osterw ijck1A, Bart A. Ellenbroek, Ph.D. 2,
Cor A.J. de Jong, M.D., Ph.D.1B, Jan  A lexander Cools1C, K. Buitelaar, M.D., Ph.D.1C, 
Robbert-Jan Verkes, M.D., Ph.D.1A,1C
1 R adboud U n iversity  N ijm egen  M edical C en tre, D on ders In stitu te  for B rain , C ogn ition  an d  B eh aviour, 
N ijm egen , The N eth erlan ds
A D ep artm en t o f  P sych iatry
B N ijm egen  In stitu te  for Science P ractition ers in  A d d iction  
C D ep artm en t o f C ogn itive  N eu roscience  
D D ep artm en t o f  H u m an  G en etics
2 Evotec AG, H am bu rg , G erm an y
Adapted from  the paper COMT Val158Met genotype m odulates prefrontal 
dopam ine sensitivity, subm itted for publication
Abstract
Background
The n eu rotran sm itter dopam ine (DA) is involved in cognitive function ing. This 
involvem ent is hypothesized to follow an inverted-U relationship, where both too 
low and too h igh prefrontal DA levels reduce cognitive perform ance. Previous 
studies have shown th at variation  in the gene encoding COMT (an enzym e that 
m etabolizes DA in the prefrontal cortex) affects perform ance on various cognitive 
tasks. However, fun ction al in vivo studies on the relation  betw een DA, the functional 
COMT Val158Met polym orphism  and cognition are scarce. We exam ined the effect 
o f the selective, d irect DA agon ist apom orphine on perform ance on a continuous 
perform ance test, expectin g increased task  perform ance in hom ozygotes for the 
high activity COMT (Val) allele and decreased perform ance in carriers o f the low 
activity  COMT (Met) allele.
Methods
Healthy m ale volunteers (N = 98) perform ed an AX-continuous perform ance test 
before and after apom orphine adm in istration  (0.005 mg/kg). The COMT Val158Met 
polym orphism  was genotyped using Taqm an-based analysis. Specificity for the 
effect o f COMT genotype on APO responsiv ity  was assessed by testin g a genetic 
polym orphism  (3’ UTR VNTR) o f the DA tran sporter (SLC6A3/DAT1), the m ain  
regulator o f DA levels in the striatum .
Results
The COMT Val158Met genotype did not affect baselin e task  perform ance. Subjects 
w ith high activity COMT indeed im proved perform ance on the task  upon 
apom orphine adm in istration , w hereas perform ance in carriers o f the low activity 
COMT deteriorated. There were no effects o f the DAT1 polym orphism  on apom orphine 
responsivity.
Conclusions
Our resu lts show th at the COMT Val158Met genotype affects prefrontal DA 
functionality , as reflected  in cognitive function ing. F indings are consistent with 
the inverted-U shape hypothesis o f DA function  in the prefrontal cortex and 
cognitive perform ance in vivo.
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Introduction
Genetic variation  in COMT, especially  the Val158Met polym orphism , has been 
im plicated in prefrontal cortex functioning, executive functioning in particu lar 1 2.
Results from  pharm acological experim ents in rats and in vitro experim ents and 
observations in  knockout m ice and post-m ortem  hum an brain  tissue have led to 
the general hypothesis that the effect o f the COMT Val158Met genotype on cognition 
is m ediated by an alteration  in prefrontal dopam ine (DA) fun ction in g 2-5.
The COMT gene encodes the enzym e catechol-O-m ethyltransferase th at breaks 
down DA, adren aline and n oradrenaline 2-5. COMT is expressed in various tissues 
throughout the body, w ith h ighest activity  in  the liver, kidney, gastro in testin al 
tract and in  various p arts o f the brain  (including the prefrontal cortex)6, 7.
COMT Val158Met resu lts from  a single nucleotide polym orphism , leading to a 
Val to Met substitu tion  at position  158 o f the (membrane-bound) enzym e. In vitro 
studies and observations in  post-m ortem  hum an brain  tissue have shown that this 
substitu tion  resu lts in a 40% reduction  in  the activity  o f the enzym e at body 
tem perature 8 9. C arriers o f the Met allele are therefore thought to have increased 
levels o f DA in  the prefrontal cortex (among other places in the brain). This is 
consistent w ith observations by Gogos and coworkers in COMT knock-out mice, 
w hich showed increased DA levels in the prefrontal cortex 10. Other studies in  COMT 
knock-out m ice and rats treated w ith COMT inh ibitors also  found increased 
prefrontal DA levels, but only after ch allenge w ith the DA precursor L-dopa 6 11-13.
Despite the preclin ical and post-m ortem  evidence for an effect o f COMT on 
prefrontal DA levels and prefrontal cortex function , hum an  in vivo studies on the 
relation  betw een COMT Val158Met, fun ction al DA m easures and cognitive 
perform ance are scarce. The Met allele has been linked to m ore efficient prefrontal 
cortex processing, w hile perform ing a cognitive task  4. Moreover, Met allele carriers 
have better cognitive perform ance, particu larly  on tasks that rely on working 
m em ory and attentional control (for a review see 2 14, 15.
U sing hum an in vivo positron  em ission  tom ography (PET) in  healthy controls a 
recent study extends th is hypothesis in  the hum an  situation  by show ing that 
carriers o f the Val/Val genotype show higher prefrontal binding o f a tracer for the 
DA D1 receptor, indicative o f low DA tone 16. A study on prefrontal DA D2 receptor 
availab ility  reported no effect o f the COMT Val158Met genotype 17.
One study tested the role o f DA fun ction ality  in the effect o f the COMT Val158Met 
genotype on cognition, by ch allenging the DA system  w ith the ind irect DA agonist 
dextro-am phetam ine in  healthy volunteers. In th is study, adm in istration  o f dex- 
tro-am phetam ine disrupted  perform ance on a w orking m em ory task  (N-Back task) 
in  carriers o f the low activity Met/Met genotype, w hereas perform ance im proved in 
carriers o f the h igh activity Val/Val genotype 18. These data  have been m odeled 97
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cognitive perform ance. The inverted-U m odel exp lain s th at a rightw ard sh ift in DA 
sign alin g  is ben eficial to Val/Val genotype carriers (with presum ed lower DA levels 
in  the PFC), but not to M et-carriers (with presum ed h igher DA levels)19. This m odel 
su ggests that adm in istration  o f an DA agon ist to Met-carriers leads to DA overstim ­
u lation  and thus a decrease in  cognitive perform ance.
A m phetam ine is a non-selective, ind irect catecholam ine agon ist affectin g both 
DA and n oradrenaline n eurotran sm ission . Since COMT breaks down noradrenaline 
as w ell as DA, an effect o f the COMT Val158Met genotype on am phetam ine 
responsiv ity  m ay have been m ediated by either DA or noradrenaline in  the study by 
M attay et al.. To specifically  investigate the relation  betw een DA functionality, 
COMT Val158Met and cognitive function ing, we therefore perform ed a study using 
the selective DA agon ist apom orphine (APO). APO is a selective, d irect DA agon ist 
used to treat Parkinson ’s d isease and to study DA fun ction in g in both  an im als and 
hum ans 20-25. In previous studies, we showed th at APO disrupts cognitive 
perform ance on a continuous perform ance task  (the AX-cpt) in healthy volunteers 
26. The AX-cpt is often  used to m easure attentional control and w orking m em ory 
27-30. The effect o f the COMT Val158Met genotype on inter-individual differences in 
the effects o f APO on cognitive perform ance on the AX-cpt is unknow n.
The current paper reports on the relationship  betw een the COMT Val158Met 
genotype and the effect o f the selective, d irect DA agonist APO using perform ance 
on the AX-cpt as read-out. We hypothesized th at APO would im pair perform ance in 
carriers o f the low activity Met-allele (due to excessive prefrontal DA levels) and 
im prove perform ance in carriers o f the h igh activity Val-allele (due to optim ized 
prefrontal DA levels). To test the specificity  o f the fin d in gs for the COMT Val158Met 
genotype, we also  tested the effect o f genetic variation  in the DA tran sporter gene 
(the variable num ber o f tandem  repeats (VNTR) polym orphism  in  the 3’ u ntran slated  
region  (UTR) o f the SLC6A3/DAT1 gene 31 on APO responsivity. Since the DA transporter 
m ain ly  controls stria ta l DA levels, and task  perform ance on the AX-cpt is related to 
prefrontal DA fun ction in g we hypothesized that SLC6A3/DAT1 genotype would not 
be related to the effect o f APO on task  perform ance 8 32-34.
Materials and Methods
Subjects
Healthy volunteers (N = 103), aged betw een 18 and 55 years, were recruited 
through  advertisem ents in  regional new spapers. In order to avoid possible 
confounding effects o f gender and variation  in m en strual cycle on cognitive 
perform ance and DA function ing, only m en were included 35-40. All were o f European 
Caucasian  ethnicity  o f regional descent. Exclusion criteria were psychiatric h istory
and fam ily  history  and any physical illness contra-indicating DA stim ulation .
Psychiatric (family) h istory  was assessed using the Dutch version o f the Mini 
International N europsychiatric Interview  for psychiatric disorders (MINI) version 
2.1 and the Dutch version o f the ADHD rating scale 41-43. The Dutch version o f the 
Addiction Severity Index (EuropASI), section 4, was used to assess the (family) 
h istory  o f drug  and alcohol use 44, 45. Four p articipan ts were excluded because o f a 
psychiatric fam ily  history. Participants were screened for physical illness. One 
partic ip an t was excluded because o f repeatedly elevated liver enzym es.
To avoid both acute and w ithdraw al effects o f n icotine and caffeine, participan ts 
were asked not to smoke or consum e caffeine-contain ing drinks on the m orning of 
experim en tal testin g (from two hours prior to m easurem ents) 46-49. The study was 
approved by the regional m edical eth ical board . All p articipan ts gave w ritten 
inform ed consent.
Cognitive performance measurement
Cognitive perform ance was assessed  u sing a ten m inute AX-cpt. The task 
consisted o f single letters consecutively shown in  white on a black screen, w ith  an 
inter-stim ulus interval o f 1300 m s, as described by van der Linden and co-workers 
(2006). Participants were in structed  to give a target response (right button press) 
after the probe ‘X ’ appeared preceded by the cue ‘A’, or a non-target response (left 
button  press) after any other com bination o f letters. Responses were scored in  a 
w indow  betw een 100 and 2000 ms after stim ulus onset. To increase working 
m em ory load, two d istracter letters were presented in  red betw een cue and probe 
and to increase m easurem ent sensitiv ity  for inhibitory control, 70% of the tria ls 
were target tria ls 28-30, 50, 51.
Participants perform ed a practice session prior to three test sessions, i.e. once 
before and tw ice after (20 and 40 min) subcutaneous adm in istration  o f the direct 
DA agon ist APO (0.005mg/kg). Our previous resu lts had shown that under placebo 
condition task  perform ance on the AX-cpt was stable over six  repetitive sessions 
and th at a learn ing effect occurs m ain ly  during the ten m inute practice session 
preceding study m easurem ents 26. Therefore we chose not to include a control 
condition.
Genotyping of COMT Val158Met and SLC6A3/DAT1 3' UTR VNTR
Blood was taken  by venapuncture and DNA was isolated u sing standard 
protocols. M olecular analyses were perform ed in  a CCKL-accredited laboratory at 
the D epartm ent o f H um an Genetics o f the Radboud University M edical Centre in 
Nijm egen, The Netherlands. The COMT Val158Met polym orphism  was genotyped 
u sing Taqm an-based analysis 52. Genotyping was carried  out in a volum e o f 10 |jl 
contain ing 10 ng o f genom ic DNA, 5 j l  o f ABgene M asterm ix (2x) (ABgene Ltd., 99
H am burg, Germany), 0.125 j l  o f the Taqm an assay (assay ID: Taqm an assay:
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C__25746809_50; reporter 1: VIC-A-allele; Applied Biosystem s, Nieuwerkerk a/d
Ijssel, The Netherlands) and 3.875 |jl o f H2O. A m plification  was perform ed on a 
7500 Fast Real-Time PCR System, startin g  w ith 15 m in  at 95° C, followed by 50 
cycles o f 15 s at 95°C, 1 m in  at 60° C. Genotypes were scored u sing the algorithm  
and softw are supplied by the m an ufactu rer (Applied Biosystems).
The 40 base-pair variable num ber o f tandem  repeat (VNTR) polym orphism  in 
the 3 ’ UTR of the gene encoding the DA tran sporter (SLC6A3/DAT1) was genotyped as 
described elsew here 31. To investigate the random  genotyping error rate in the two 
assays, the lab included 5% duplicate DNA sam ples, which showed 100% consistency 
in  genotype called. In addition, 4% blancs were included, which were all negative.
Statistical Analysis
Data were analyzed using SPSS version 16.0 (alpha (two-sided) = 0.05). Dependent 
variables were reaction  tim e and percentage com m ission  errors on the AX-cpt. 
Non-responses on the AX-CPT (om ission errors) were not taken  into account given 
the low num ber (< 1%).
D ifferences betw een genotype groups in baselin e speed and accuracy were 
com puted u sing u n ivariate analysis o f variance (ANOVA), w ith  COMT Val158Met and 
SLC6A3/DAT1 genotype as independent variables. D ifferences in  APO response 
betw een genotype groups were com puted u sing repeated m easures ANOVA, with 
TIME as a w ith in  subject factor (with three levels: once before and tw ice after APO 
adm in istration), and COMT Val158Met genotype (with three levels: Val/Val, Val/Met 
and Met/Met) and SLC6A3/DAT1 genotype (with three levels: R9/R9, R9/R10, R10/R10) 
as betw een subject factors. In order to correct for effects o f sphericity only Green- 
house-Geisser corrected p-values are reported.
Results
Genotypes and task  perform ance were available for 98 subjects. Table 1 shows 
the characteristics o f the study population . Genotype frequencies were in Hardy 
W einberg equilibriu m  (COMT: c2(df = 2) = 0.5, p = 0.479; SLC6A3/DAT1: c 2(df = 2) = 0.5, p 
= 0.495J and sim ilar to those reported in other European sam ples 53. The Val/Val 
genotype was observed in 22 ind iv iduals (22%), the Val/Met genotype was present in 
53 ind iv iduals (54%) and 24 subjects (24%) were hom ozygous for the Met-allele. For 
SLC6A3/DAT1, the R10/10 genotype was observed in 53 ind iv iduals (54%), R10/9 was 
present in 37 individuals (37%) and 9 subjects (9%) were homozygous for the R9-allele.
Performance on AX-cpt
Neither the COMT Val158Met, nor the SLC6A3/DAT1 genotype was associated with 
AX-cpt perform ance at baseline (for error percentage: COMT Val158Met genotype:
T ab le  1 Demographic characteristics and distribution o f SLC6A3/DAT1 genotype
per COMT Val158Met genotype (Val/Val, Val/Met, Met/Met carriers)
Val/Val 
(N=22) 
M ean (SD)
Val/Met 
(N=53) 
M ean (SD)
Met/Met 
(N=23) 
Mean (SD)
Test
sta tistic
p  value
Age (years) 41 (11) 38 (11) 34 (10) F(1,98)=2.5 n.s.
Education level (%)*
-Low 16% 10% 27% C2=6.0 n.s.
-Intermediate 74% 66% 46%
-High 10% 24% 27%
Habitual smoking 14% 10% 17% C2=0.9 n.s.
SLC6A3/DAT1
-R10/10 50% 51% 61% C2=1.3 n.s.
-R9/10 41% 38% 35%
-R9/9 9% 11% 4%
*H igh est d ip lom a ob ta in ed : low  level o f ed u catio n  is  p r im ary  sch ool, in term ed ia te  level o f education  
is  seco n d ary  sch ool, h igh  level o f ed u catio n  is h igher p ro fe ssio n a l ed u cation , u n iversity , n .s.=  p>.10
F(2, 95) = 1.0, p = 0.381, SLC6A3/DAT1 genotype: F(2, 95) = 1.1, p = 0.318; for reaction time: 
COMT Val158Met genotype: F(2 95) = 0.7, p = 0.482, SLC6A3/DAT1 genotype: F(2 95) = 1.6, 
p = 0.208, Table 2). However, COMT Val158Met genotype strongly affected APO 
responsivity, Figure 1. According to the om nibus test for the repeated m easures 
analysis, accuracy and reaction tim e deteriorated after APO adm in istration  (error 
percentage: F(2 95) = 5.7, p = 0.004; reaction tim e: F(2 95) = 6.0, p = 0.016). The COMT 
Val158Met genotype affected APO responsivity for accuracy, but not for reaction tim e 
(interaction TIME*COMT Val158Met genotype: F(4 93) = 3.2, p = 0.021; F(4 93) = 0.4, 
p = 0.783, respectively). In carriers o f the Met/Met and the Val/Met genotype accuracy 
deteriorated after APO adm in istration  (F(2 22) = 3.7, p = 0.032; F(2 52) = 9.3, p < 0.001, 
respectively), whereas APO improved perform ance in  carriers o f the Val/Val genotype 
(time effect: F(221) = 4.6, p = 0.023). The SLC6A3/DAT1 genotype was not associated with 
the effect of APO on task perform ance (interaction TIME*SLC6A3/DATî genotype: error 
percentage: F(4 93) = 1.2, p = 0.298; reaction tim e: F(4 93) = 0.8, p = 0.529).
Posthoc analysis o f specific contrasts showed that the m axim u m  effect o f APO 
on task  perform ance occurred 40 m inutes after adm in istration  (error percentage: 
F(1,96) = 8.0, p = 0.005; reaction  tim e: F(196) = 4.4, p = 0.013). The effect o f COMT 
genotype on APO responsiv ity  was also  m ax im al at 40 m inutes (error percentage: 
F(2,95) = 4.6, p = 0 .0 1 2 ).
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Table 2 Perform ance on the continuous perform ance test (AX-CPT) before and after adm in istration  o f apom orphine per 
COMT V all58M et genotype (Val/Val, Val/Met, Met/Met) and SLC6A3/DATîgenotype (R10/10, R10/9, R9/9).
Task Performance Val/Val 
(N=22) 
Mean (SD)
Val/Met 
(N=53) 
Mean (SD)
Met/Met
(N=23)
Mean
(SD)
Test
statistic
P
value
R10/10 
(N=52) 
Mean (SD)
R10/9 
(N=37) 
Mean (SD)
R9/9 
(N=9) 
Mean (SD)
Test
statistic
P
value
baseline
-Reaction tim e (ms) 
-Errors(%)
340 (62) 
3.5 (4.7)
327(56) 
2.8 (2.9)
340 (60) 
3.8 (2.8)
F(l,96)=0.7
F(l,96)=0.9
n.s.
n.s.
324(51) 
2.9 (3.6)
339 (63) 
3.1 (2.6)
358 (77) 
4.8 (4.2)
F(l,96)=1.6
F(l,96)=1.2
n.s.
n.s.
20 m inutes after 
APO
-Reaction tim e (ms) 
-Errors(%)
351 (72) 
3.1 (1.7)
341 (89) 
5.2 (6.5)
367(110) 
6.7 (7.7)
F(l,96)=0.7
F(l,96)=2.0
n.s.
n.s.
334(83) 
5.1 (6.5)
359 (96) 
4.2 (4.0)
400 (102) 
8.6 (10.3)
F(l,96)=2.4
F(l,96)=2.4
n.s.
n.s.
40 m inutes after 
APO
-Reaction tim e (ms) 
-Errors(%)
(350 (73) 
2.2 (1.9)
341 (62) 
4.7 (4.8)
(368 (128) 
7.4 (9.2)
F(l,96)=0.9
F(l,96)=4.7
n.s.
.011
337 (86) 
5.4 (7.0)
353 (79) 
4.2(3.3)
403 (87) 
7.7 (6.9)
F(l,96)=1.8
F(l,96)=2.3
n.s.
n.s.
n.s.=p>.10
Discussion
This is the fir st  report on the COMT Val158Met genotype m odulating the effect 
o f a selective, d irect DA agon ist on cognitive perform ance. Perform ance deteriorated 
in  carriers o f the low activity  Met-allele and im proved in hom ozygotes for the high 
activity  Val-allele. Genetic variation  in  the DA tran sporter gene (SLC6A3/DAT1) was 
not related to the effect o f APO on task  perform ance, confirm ing specificity  o f the 
fin d in gs for the COMT Val158Met genotype.
Figure 1 The effect o f apom orphine on cognitive perform ance per COMT 
Val158Met genotype (Val/Val, Val/Met, Met/Met)
time after APO
Met/Met homozygotes 
- *  Val/Met heterozygotes 
O Val/Val homozygotes
The fin d in g  o f an  effect o f the COMT Val158Met genotype on APO responsivity 
confirm s and extends resu lts o f a previous study show ing th at the non-selective, 
ind irect catecholam ine agon ist dextro-am phetam ine had detrim en tal effects on 
cognitive perform ance in carriers o f the COMT Met/Met genotype and was beneficial 
to Val/Val genotype carriers. Since a d irect DA agon ist was used in  the current 
study, it is unlikely  th at the effect o f APO on cognitive perform ance is m ediated by 
other neurotran sm itter system s than  the prefrontal DA system.
The data  also  fit w ith the proposed inverted-U dose-response curve m odel o f DA 
action on cognitive perform ance, as d iscussed  in  the introduction  and shown in 
Figure 2 18, 19, 54. Slow DA breakdow n in carriers o f a Met-allele m ay be associated 
w ith h igh tonic prefrontal DA levels resu ltin g  in  an excess in  phasic stim ulation  of 
postsynaptic DA receptors after APO adm in istration , w ith a consequent decrease in 
PFC fun ction in g and task  perform ance 18, 19.
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F ig u r e  2 Inverted U-shape model o f the effect of apomorphine on cognitive
perform ance per COMT Val158Met genotype (Val/Val, Val/Met, Met/Met)
Given the short duration  o f action o f APO (Tmax=30 m inutes, T =60 minutes), 
we were not able to test m ultiple cognitive dom ains in this study. The AX-cpt that 
w as used, m easures both  attentional control and w orking memory. It is not possible 
to d isentangle the role o f the COMT Val158Met genotype and related alterations in 
DA fun ction in g betw een these cognitive dom ains. Future studies m ay use a direct 
DA agonist with a longer duration  o f action (e.g. brom ocriptine) in order to perform  
m ultip le tasks m easu rin g different cognitive dom ains, and furth er specify  the 
effect o f the COMT Val158Met genotype on prefrontal DA fun ction ality  and 
cognition.
To avoid confounding effects o f tobacco or caffeine use on task  perform ance 
p artic ip an ts were not allowed to smoke or drin k  caffeine during the m orning prior 
to study. Furtherm ore, there was no difference in habitual caffeine or tobacco use 
betw een COMT genotype groups. It is therefore unlikely  th at nicotine or caffeine 
w ithdraw al biased  our fin d in gs. Since the study included m ale subjects only, future 
studies should assess whether these effects also  hold for fem ales, tak in g  effects of 
horm onal changes during the m en strual cycle into account. To w hat extend 
horm onal changes in  m en are also involved in  alterations in  brain  DA fun ction in g 
is unknow n.
The lack o f an effect o f the COMT Val158Met genotype on baselin e task 
perform ance on the AX-cpt m ay indicate that the AX-cpt is not specific enough to 
detect an effect o f the COMT Val158Met genotype on cognitive perform ance. Most 
104 fin d in gs o f COMT Val158Met genotype on cognitive fun ction in g have been reported
u sing the N-Back task  (predom inantly w orking m emory) and the W isconsin Card
Sorting Test (WCST; predom inantly  w orking m em ory and set sh ifting) . There has 
been only one sm all size study (23 participants), show ing an effect o f the COMT 
Val158Met genotype in an attentional control task  (sim ilar to our task), i.e. the 
Flanker task, in w hich a target stim ulus is surrounded by a series o f congruent or 
incongruent stim u li 2 15. It m ay w ell be th at the COMT Val158Met genotype and 
related alterations in  prefrontal DA fun ction ality  is m ore relevant for working 
m em ory than  for attentional control.
On the other hand, the lack o f a COMT effect on baselin e task  perform ance in 
th is study m ay also  be related to a ceiling effect, due to low baselin e error rates. 
Despite adding two distracter letters betw een cue and probe and setting the 
num ber o f target tr ia ls  at 70%, the baselin e error rate was only 3.4%. Previous 
studies reportin g a lack o f a COMT Val158Met genotype effect on the N-back task 
and low dem and attentional tasks suggested that an effect o f the COMT Val158Met 
genotype m ay only be detected u sing tasks w ith h igh cognitive loads 18, 54.
In the literature there is a debate about m in im al sam ple sizes in  genetic 
endophenotype studies 5 55, 56. For classic association  studies approxim ately 500 
cases and controls are needed to detect a m in im u m  risk  ratio o f 2.0 55, 57. However, 
when studying quantitative endophenotypes, it is suggested th at sam ple sizes of 
approxim ately  50-100 p artic ip an ts are su ffic ient to report fin d in gs th at are 
relatively consistent 55. According to these criteria, our study was well-powered for 
the analyses perform ed.
In sum m ary, the present study is the fir st  report o f in vivo m odulation  of 
prefrontal DA fun ction ality  in hum ans by the COMT Val158Met genotype directly  
related to cognitive function ing. Pharm acological ch allenge studies w ith selective, 
d irect DA agon ists u sing cognitive tasks relying on w orking m em ory and attentional 
control are a u sefu l tool to study DA fun ction ality  in vivo. Further studies exam in in g 
the relationship  betw een the COMT Val158Met genotype and altered prefrontal DA 
fun ction in g in neuropsychiatric disorders, such as attention  deficit hyperactivity 
disorder, substance dependence and sch izophrenia, u sing th is m ethodology, are 
w arranted.
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Reduced dopamine sensitivity as intermediate 
phenotype in alcohol dependence, 
and the role of the COMT Val158Met and 
DRD2 Taq1A genotypes
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Adapted from  Schellekens et al. Archives o f General Psychiatry 2011, The COMT 
Val158Met and DRD2 TaqlA  genotypes in  alcohol dependence, reduced dopam ine 
sensitiv ity  as in term ediate phenotype
Abstract
Context: Alcohol dependence is a com m on neuropsych iatric disorder w ith  high 
heritability. However, genetic association  studies on alcohol dependence are often 
troubled by non-replication. The use o f in term ediate phenotypes m ay help to 
understand the m ode o f action o f various candidate genes and im prove the repro­
ducibility  o f association  studies.
Objective: To test central dopam ine sensitivity  as an interm ediate phenotype for 
alcohol dependence. We specifically  tested the hypothesis that the dopam ine genes 
COMT Val158Met and DRD2 TaqlA  affected dopam ine sensitivity.
Design & Setting: case-control pharm acogenetic ch allenge study. Alcohol dependent 
patients adm itted for detoxification  were com pared to healthy controls m atched 
for age and level o f education. Participants: Patients (N=110) were a consecutive 
sam ple, healthy controls (N=99) were recru ited through  advertisem ents in regional 
news papers.
Intervention: A dopam ine ch allenge test was perform ed u sing the dopam ine agonist 
apom orphine (0.005m g/kg, subcutaneously). Outcome m easures were p lasm a 
grow th  horm one levels and perform ance on a continuous perform ance task. 
Results: Central dopam ine sensitivity is reduced in alcohol dependence and th is is 
m odulated by dopam inergic genes. Specifically, DRD2 TaqlA  genotype affected 
dopam ine sensitivity m easured w ith grow th horm one levels and COMT Val158Met 
genotype affected dopam ine sensitivity  m easured w ith cognitive perform ance. In 
a logistic regression  analysis reduced dopam ine reactiv ity  on both m easures 
predicted alcohol dependence, w ithout an additive effect o f the genotypes (COMT 
Val158Met and DRD2 TaqlA).
Conclusions: These fin din gs suggest that COMT Val158Met and DRD2 TaqlA  affect the 
interm ediate phenotype o f central dopam ine sensitivity. These genes m ay confer 
their risk on alcohol dependence through  reduced dopam ine sensitivity  in  the 
prefrontal cortex and the h indbrain , respectively.
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Introduction
Alcohol dependence is considered a chronic relapsing neuropsychiatric disorder 
with a m ultifactorial aetiology 1 2. Heritability estim ates are as high as 60%, w ith m any 
genes exp lain in g only a fraction  o f the heritab ility  3 4. Attem pts to delineate genetic 
contributions have m et w ith  lim ited  success. There is an ongoing search for 
in term ediate phenotypes in  alcohol dependence to abet genetic research  5-11.
Fundam ental to the in term ediate phenotype concept is the assum ption  that 
variation  in  an interm ediate phenotype depends upon variation  in fewer genes 
th an  the m ore com plex d isease phenotype, and is therefore m ore tractable in 
genetic analysis 11 . In a recent paper, a plea was m ade to adhere to interm ediate 
phenotypes known to be involved in the pathophysiology o f the disorder, in order 
to m in im ize the risk o f pleiotropic fin d in gs 9. The selection o f an interm ediate 
phenotype should then be based on convergent evidence, from  a variety o f studies 
from  hum an epidem iology to experim en tal neuroscience and an im al research 12.
In alcohol dependence, evidence from  various lines o f research indicates that 
alterations in at least two dopam ine pathways are involved in the pathophysiology 1 
13-15. The first is the mesolimbic dopam ine pathway, often referred to as the “reward” 
pathway. Alcohol generates its reinforcing effect by increasing the firing rate of 
dopam ine neurons in the ventral tegm ental area, leading to enhanced dopamine 
activity in the ventral striatum  16. Reduced densities o f striatal dopam ine receptors 
have been observed in alcohol-dependent patients 1 14. Reduced sensitivity to the 
dopam ine receptor agonist apomorphine, indexed by the growth hormone (GH) 
response, has repeatedly been observed in alcohol-dependent patients 17-21. Reduced 
dopam ine receptor sensitivity is thought to reduce the sensitivity o f addicted subjects 
to “n atural” reinforcers. This may increase the vulnerability to develop alcohol abuse, 
since alcohol consumption would compensate for this “reward deficiency” 1 13, 14, 21-23.
The second dopam ine pathway involved in alcohol dependence is runn ing from  
the ventral tegm ental area to the prefrontal cortex (PFC), often referred to as the 
“inhibitory control” pathway 14, 24, 25. Drug abusers show lower glucose m etabolism  in 
the PFC 1 14. Moreover, alcohol-dependent patients appear less sensitive to the effects 
o f the dopam ine receptor agonist apom orphine on perform ance on tasks requiring 
PFC functioning 20. It has been suggested that PFC and m esolim bic dopam ine 
dysfunctioning are interrelated, resu lting in a double handicap in alcohol 
dependence, including deficient reward processing and behavioral control 1 14, 26, 27.
Based on the evidence presented above, the m easurem ent o f dopam ine receptor 
sensitivity, u sing a ch allenge w ith a dopam ine agonist, m ay be a u sefu l phenotype 
for genetic studies o f alcohol dependence 28. Indeed, studies in  an im als and hum ans 
have shown that variation  in dopam ine sensitivity  is h ighly heritable 29-31, and 
predicts se lf adm in istration  o f substances as cocaine and alcohol 15, 30. Yet, genetic 113
studies u sing th is dynam ic in term ediate phenotype are relatively scarce.
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The dopam ine D2 receptor gene (DRD2) and its genetic polym orphism  TaqlA 
(rs1800497) is among the m ost extensively studied genetic variants in alcohol 
dependence. Some studies have shown that the DRD2 TaqlA genotype is associated with 
a 30% reduction in dopam ine D2 receptor density in the striatum  of healthy volunteers 
32, 33. Meta-analyses have shown an increased risk o f alcohol dependence for carriers of 
the A1 allele, though odds ratios are sm all (OR-range: 1.22-1.9) 34-36. Some studies have 
tested the role of DRD2 genotype in in vivo dopam ine sensitivity, m easured by the GH 
response to the dopam ine agonist apomorphine. In alcohol-dependent patients, a 
genotype in linkage disequilibrium  with the TaqlA genotype (A/A genotype) has been 
found to be associated with reduced GH responses to apomorphine 37. However, m ost 
studies failed to show such association for the DRD2 TaqlA genotype itself 18, 37-39. Several 
issues with respect to these studies should be taken into consideration. First is the 
often low statistical power. Sample sizes vary between eighteen and 97 subjects, with 
only the latter having enough power to detect any genotype effect 18, 38, 39. Second is the 
absence o f a healthy control group in m ost dopam ine challenge studies 18, 38. It has been 
suggested that genes whose expression is altered by chronic excessive alcohol intake, 
encode proteins that affect apomorphine induced GH release 38, 40. Any relation between 
genes and dopam ine sensitivity in alcohol dependent patients should therefore be 
confirm ed in a healthy control group. Third is the tim ing o f m easurem ents with 
respect to alcohol detoxification 18, 38. Previous studies have shown a strong influence 
o f detoxification on the GH response to apomorphine in alcohol dependent patients 18. 
An interm ediate phenotype should ideally be state independent 7 41, 42. In the only study 
that showed an association between DRD2 TaqlA and reduced GH response to 
apomorphine, m easurem ents were perform ed on alcohol-dependent patients, on day 
one o f detoxification 43. Thus, the usefulness o f the GH response to apomorphine, as an 
interm ediate phenotype for alcohol dependence, in relation to DRD2, is yet to be 
confirm ed in a substantially large sample, after conclusion o f in itial detoxification, 
including a healthy control group.
Another dopam inergic gene repeatedly studied in  alcohol dependence is the 
Catechol-0-Methyl Transferase (COMT). The COMT enzym e encoded by th is gene 
m etabolizes dopam ine, adren alin  and noradrenalin , and is the m ain  factor 
controlling dopam ine levels in  the PFC. A com m on fun ction al single nucleotide 
polym orphism  in  the coding region o f the COMT gene, induces a valine to 
m ethionine substitu tion  (Val158Met; rs4680), and is associated w ith a 40% 
reduction in enzym e activity 44, 45. COMT genotype affects reactiv ity  to the 
adm in istration  o f dopam ine agon ists in  healthy volunteers on tasks that rely on 
PFC fun ction in g 46, 47. COMT genotype has been associated w ith (subtypes of) alcohol 
dependence, w ith a higher frequency o f the Met allele in  type I alcohol-dependent 
patients 48-50. However, also negative association  resu lts have been reported 51-54.
114 COMT genotype is thus an interesting candidate to study in  relation  to the effects of
apom orphine on cognitive perform ance in alcohol dependence.
The current study was designed to study the fun ction al consequences o f risk  
alleles along the dopam ine pathway, u sing altered cognitive perform ance and 
neuroendocrine param eters after a ch allenge w ith the dopam ine receptor agon ist 
apom orphine as fun ction al in vivo in term ediate phenotypes for alcohol dependence. 
The hypotheses were th at 1) alcohol-dependent patients show reduced reactiv ity  to 
the dopam ine agon ist apom orphine com pared to healthy controls, 2) genetic 
variation  in the DRD2 and COMT genes affects apom orphine reactivity, and 3) 
dopam ine receptor sensitivity  is a better predictor o f alcohol dependence than  the 
dopam inergic, addiction-related genes.
E
Methods
Subjects
In a case-control design, a consecutive series o f male alcohol-dependent patients 
(diagnosed according to the DSM-IV criteria), adm itted to our detoxification clinic, 
were compared to healthy, m ale controls, matched for age and level of education. We 
selected males only, in order to avoid potential confounding effects o f the m enstrual 
cycle on dopam ine functioning in fem ales. In addition, in The Netherlands the m ajority 
o f alcohol dependent patients adm itted to a detoxification clinic are male. Controls 
were recruited through advertisements in regional newspapers. Exclusion criteria 
consisted o f current or past neuropsychiatric disorder related to dysfunction o f the 
dopam ine system (like psychosis, Korsakoff’s syndrome, Parkinson’s disease), 
non-European ancestry, language disabilities interfering with written informed 
consent and any m edical condition interfering with apomorphine adm inistration 
(recent cardiac disease, allergy). Healthy controls with a psychiatric history or 
psychiatric fam ily history (including substance dependence) were excluded. A total of 
110 eligible patients and 99 healthy controls could be recruited. See Table 1 for a 
description o f both groups and supplem entary figure 1 for a consort flow chart.
To assess drug and alcohol dependence we used the Dutch version o f the 
Addiction Severity Index (EuropASI), section 4 55. The ASI is a reliable tool for the 
assessm ent o f alcohol and drug dependence in c lin ical sam ples 56, 57. Lifetim e 
occurrence o f axis-I d isorders was assessed  u sing the Dutch version o f the Mini 
International N europsychiatric Interview  for psychiatric d isorders version 2.1 and 
the Dutch version o f the ADHD rating scale 58-60.
In order to avoid effects o f n icotine and caffeine use or w ithdraw al, participan ts 
were not allowed to smoke or use caffeine-contain ing drinks on the m orning of 
experim en tal testing, w ith in  two hours prior to m easurem ents as assessed  by 
self-report 61, 62. Patients were tested after one m onth o f controlled abstinence based 
on daily  self-report and regu lar breath  tests, and after at least one week w ithout 115
use o f benzodiazepines.
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Supplementary figure 1
Consort flow chart o f participants in the study
The study was approved by the regional m edical eth ical board  ((METiGG), protocol 
271, P04.0388L. All p articipan ts gave w ritten  inform ed consent.
Genotyping of COMT rs4680 G>A (Val158Met) and DRD2 TaqlA rs1800497 C>T
Blood was taken  by venapuncture and DNA was isolated u sing standard 
protocols. M olecular analyses were perform ed in  a CCKL accredited laboratory at 
the D epartm ent o f H um an Genetics o f the Radboud University M edical Centre in 
Nijm egen, The Netherlands. The DRD2 TaqlA  rs1800497 and COMT rs4680 
polym orphism s were genotyped using Taqm an-based analysis 63. Genotyping was 
carried  out in  a volum e o f 10 |jl contain ing 10 ng o f genom ic DNA. For DRD2, 5 |jl o f 
Taqm an M asterm ix (2_; Applied Biosystems), .125 j l  o f the Taqm an assay (assay ID: 
Taqm an assay:C_7486676_10; reporter 1: VIC-A-allele, reverse assay; Applied 
Biosystem s) and 3.875 j l  o f H2O were added. For COMT, 5 j l  o f ABgene M asterm ix 
116 (2x) (ABgene Ltd., H am burg, Germany), .125 j l  o f the Taqm an assay (assay ID: 
Taqm an assay: C__25746809_50; reporter 1: VIC-A-allele; Applied Biosystem s,
Table 1 Dem ographic characteristics, distribution  o f genotypes, traum a scores 
and apom orphine levels for healthy controls and alcohol-dependent 
patients
Healthy controls 
(N=99) 
M ean (SD)
Alcohol- 
dependent 
patien ts (N=108) 
M ean (SD)
Test
sta tistic
F/C2
p  value
Age (years) 39 (9) 41 (11) F(1,98)=2.6 .107
Education level (%)*
-None
-Basic
-Low
-Intermediate
-High
1 (1%)
7 (7%) 
41 (41%) 
34 (34%) 
16 (16%)
4 (4%)
15 (14%) 
46 (43%) 
28 (26%)
16 (15%)
C2=5.1 .274
Substance use (current) 
-Habitual smoking 
-habitual caffeine use 
-SSRI use
42 (42%) 
95 (96%) 
3 (3%)
73 (68%) 
106 (98%) 
11 (10%)
C2=14.0
C2=.9
C2=4.1
<.001
.337
.054
Psychiatric co-morbidity
-depression
-anxiety disorder
-OCD
-ADHD
- 29 (27%) 
17 (16%) 
2 (2%) 
10 (9%)
C2=28.4
C2=16.7
C2=1.8
C2=9.5
<.001
<.001
.178
.002
Co-morbid substance use 
(past)
-stimulants
-opioids
-cannabis
-hallucinogens
- 11 (10%) 
9 (8%) 
38 (35%) 
6 (6%)
*H igh est d ip lom a ob tain ed : none is  p rim ary  school w ith  no d ip lom a’s, basic is secon d ary  school, low 
level o f edu cation  is  low er vocation al education , in term ed iate  level o f edu cation  is h igher vocational 
education , h igh  level o f  edu cation  is h igher p ro fession al education/ university.
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Nieuwerkerk a/d Ijssel, The Netherlands) and 3.875 |jl o f H2O were added.
A m plification  was perform ed on a 7500 Fast Real-Time PCR System, startin g  with 
15 m in  at 95° C, followed by 50 cycles o f 15 s at 95°C, 1 m in  at 60° C. Genotypes were 
scored u sing the algorithm  and softw are supplied by the m an ufactu rer (Applied 
Biosystems).
To investigate the random  genotyping error rate in  the two assays, the lab 
included 5% duplicate DNA sam ples, which showed 100% consistency in genotype 117
called. In addition, 4% blancs were included, which were all negative.
Apomorphine challenge
Central dopam ine sensitivity  was m easured u sing a ch allenge w ith the dopam ine 
receptor agon ist apom orphine (.005 mg/kg, subcutaneously). Outcome m easures 
were the neuroendocrine response, indexed by p lasm a GH levels and the effect on 
cognitive perform ance on a continuous perform ance test. Sam ples for GH testing 
were taken  at baselin e and 30, 50 and 70 m inutes after apom orphine adm in istration ; 
the cognitive task was perform ed at baseline; 20 and 40 minutes after adm inistration.
Plasma apomorphine and GH measurement
Blood (4 ml) was take to assess p lasm a apom orphine and GH levels. After 
centrifugation , sam ples o f 2.0 m l were kept on ice and stored at 30°C. Apom orphine 
levels were assessed by high-pressure liquid chrom atography w ith electrochem ical 
detection 64. Plasm a GH was m easured by Radiolm m unoAssay, u sing an antiseru m  
raised  in gu in ea pig. One case was excluded from  analysis because o f a baselin e GH 
level above the detection lim it o f 1.6 ng/m l. Before Jan u ary  2006 we used the 1st 
(80/505) in ternational stan dard  for GH for the stan dard  curve; after Jan u ary  first 
2006, the 2nd (98/754) in ternational stan dard  was used. W ithin and betw een 
coefficients o f variation  were 7.1% and 10.5%, 4.3% and 8.2%, 5.4% and 10.9% at 
levels o f 6.0, 10.8 and 35.2 mlU/L, prior to and after Jan u ary  2006, respectively.
Cognitive performance measurement
Cognitive perform ance was assessed u sing the AX continuous perform ance 
task  (AX-CPT). This task  consists o f single letters consecutively shown in  white on a 
black screen w ith an inter-stim ulus interval o f 1300 ms, as described previously 65. 
Participants were in structed  to give a target response (right button  press) after the 
probe ‘X ’ appeared preceded by the cue ‘A’, or a non-target response (left button 
press) after any other com bination o f letters. Responses were scored in a window 
betw een 100 and 2000 ms after stim ulus onset. Two distracter letters were presented 
in  red betw een cue and probe, 70% o f the tr ia ls  were target tria ls 65, 66. The tasks 
lasted  10 m inutes. To reduce learn ing effects, participan ts perform ed a practice 
session prior to the three test sessions.
Statistical analysis
Baseline differences in  GH levels, task  perform ance, and dem ographic ch arac­
teristics betw een patients and controls and the different genotypes (DRD2 and 
COMT) were com pared using analysis o f variance for continuous variables and chi 
square tests for categorical variables. D ifferences in  apom orphine response betw een 
groups (patients versus controls and genotype groups) were analyzed using repeated 
m easures analysis o f variance, w ith  accuracy (percentage com m ission  errors) on 
118 the AX-CPT and p lasm a GH levels as dependent variables, tim e as a w ith in  subject
variable, and group (patient or control) and genotypes (DRD2 and COMT) as betw een
subject variables. For the DRD2 genotype two groups were form ed (i.e. A2-carriers 
versus A1/A1), due to the low num ber o f A2-homozygotes. COMT genotype was 
analyzed in  three groups (i.e. Val/Val, Val/Met and Met/Met).
To test for a gene-dosage effect, we used special contrast analysis, testin g the 
hypothesis th at the effect o f apom orphine on cognitive perform ance was tw ice as 
strong in carriers o f two Met-allele copies than  in carriers o f one Met-allele, as 
com pared to those hom ozygous for the Val-allele.
Since patients m ore often were sm okers, had psychiatric com orbidity and used 
selective serotonin reuptake inhibitors (SSRIs), these factors were added as 
covariates in the repeated m easures analysis. To protect an overall alpha level o f 
.05, the Bonferroni-Holm correction was applied to the four independent tests, and 
only adjusted p-values are presented.
To analyze the prediction  o f alcohol dependence by genotypes and interm ediate 
phenotypes logistic  regression  was used, w ith group (patient or control) as the 
dependent variable, u sing the forced entry m ethod. In order to test a m odel o f 
m ediation , the in term ediate phenotypes (m axim um  GH response and m axim u m  
cognitive response to apom orphine) were entered in block 1, and the genetic factors 
(DRD2, COMT) were added into the m odel in  a second block.
Data were analyzed using SPSS version 16.0. Alpha (two-sided)=.05 was used as 
sign ifican ce threshold, throughout.
Results
Baseline comparison:
D em ographics o f the study population  are shown in Table 1. Patients more 
often  were sm okers, had psychiatric com orbidity and used selective serotonin 
reuptake inhibitors (SSRIs). These factors were therefore added as covariates in  the 
repeated m easures analysis.
Genotype frequencies did not deviate from  Hardy-W einberg equilibrium  (DRD2:
C2=2.1, p=.159; COMT: c2=.7, p=.4). The genotype frequencies are shown in  Table 2 and 
are sim ilar to those reported in  other European sam ples 67. There was no association  
o f DRD2 TaqlA  or COMT Val158Met genotype w ith  alcohol dependence.
At baseline, patients perform ed worse on the AX-CPT (Table 2). Neither DRD2 nor 
COMT genotype was associated w ith baselin e AX-CPT task-perform ance (error 
percentage: DRD2: F(2,95)=1.1, p=.318, COMT: F(2,95)=1.0, p=.381; reaction tim e: DRD2:
F(2,95)=1.6, p=.208, COMT: F(2,95)=.7, p=.482).
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Table 2 Genotype distribution for healthy controls and alcohol-dependent 
patients
Healthy controls 
(N=99) 
Mean (SD)
Alcohol-dependent 
patien ts (N=110) 
Mean (SD)
Test
statistic
c2
p value
DRD2 TaqlA
-Al/Al 1% 2% X2=.534 .766
-A1/A2 29% 32%
-A2/A2 70% 66%
COMT Val158Met
-Val/Val 22% 24% C2=3.6 .153
-Val/Met 54% 41%
-Met/Met 24% 35%
Effects of apomorphine administration:
There were no differences in  apom orphine levels between genotype groups or 
betw een patients and controls at any tim e po in t (Table 3).
Accuracy on the AX-CPT decreased after apom orphine adm inistra tion  (error 
percentage: F(1.9, 205)=4.2, p=.016; Figure 1). Patients were less sensitive to the 
effects of apom orphine on accuracy th an  controls (apomorphine-by-group: F(1.9, 
205)=5.3, p=.005). Carriers of one or two COMT Met-alleles were more sensitive to the 
detrim en ta l effects of apom orphine on accuracy th a n  non-carriers of a Met-allele, 
w ith  homozygous Met-allele carriers being m ost sensitive (apomorphine-by- COMT: 
F(3.8, 205)=3.1, p=.016). The special contrast analysis for a gene dosage effect ju st 
fell short of being significant (contrast value=.061(degrees of freedom: 4, 205), 
p=.060). There was no difference in  the effect of COMT genotype betw een patients 
and controls (apomorphine-by-COMT-by-group: F(4,93)=1.6, p=.166). DRD2 genotype 
did not affect sensitivity to the effect of apom orphine on accuracy on the AX-CPT 
(apomorphine-by-DRD2: F(1.6, 205)=.5, p=.583).
GH levels increased after apom orphine adm inistra tion  (F(1.6, 205)=104.6, 
p<.001; Figure 2). Patients showed lower GH responses to apom orphine com pared to 
controls (apomorphine-by-group: F(1.6, 205)=6.2, p<.001). Carriers of at least one 
DRD2 Al-allele had lower GH responses to apom orphine th a n  DRD2 A2-homozygotes 
(apomorphine-by-DRD2: F(1.6, 205)=4.3, p=.005). There was no difference in  the 
effect of DRD2 genotype between patients and controls (apomorphine-by-DRD2-by- 
group: F(1.6, 205)=.2, p=.882). There was no difference in  GH response between the 
120 th ree  COMT genotypes (apomorphine-by-COMT: F(3.1, 205)=.4, p=.900).
Table 3 Endophenotype measures for healthy controls and alcohol dependent 
patients, including plasma grow th horm one (GH) levels, cognitive 
perform ance on the AX-cpt (reaction tim e and error rate), plasma 
apom orphine (APO) levels
Healthy 
controls (N=99) 
Mean (SD)
Alcohol dependent 
patien ts (N=110) 
Mean (SD)
Test statistic  
F
p value
GH levels (N=87)
-baseline .5 (1.7) .6 (2.0) F(1,195)=.3 .595
-T1 (30 minutes) 25.7 (25.7) 14.4 (22.4) F(1,195)=10.8 .001
-T2 (50 minutes) 27.0 (21.1) 21.1 (19.4) F(1,195)=4.1 .045
-T3 (70 minutes) 20.0 (18.1) 16.5 (15.2) F(1, 195)=2.1 .149
APO levels (N=92) (N=90)
-T1 (10 minutes) 1.59 (.94) 1.48 (1.22) F(1,180)=.5 .476
-T2 (30 minutes) .80 (.64) .94 (.65) F(1, 180)=2.4 .123
-T3 (50 minutes) .50 (.51) .60 (.34) F(1, 180)=2.5 .114
Task performance
-accuracy (%)
-baseline 3.0 (.3) 7.4 (.7) F(1, 207)=29.4 <.001
-T1 (20 minutes) 5.1 (.6) 7.2 (.9) F(1, 207)=4.0 .046
-T2 (40 minutes) 4.9 (.6) 7.0 (.9) F(1, 207)=4.0 .047
-reaction time (msec)
-baseline 330 (58) 406 (130) F(1, 207)=28.4 <.001
-T1 (20 minutes) 350 (90) 412 (146) F(1, 207)=13.2 <.001
-T2 (40 minutes) 350 (84) 410 (121) F(1, 207)=17.4 <.001
Table 4 Regression analysis, predicting alcohol dependence based on
DRD2 Taq1A and COMT Val158Met genotypes and dopam ine receptor 
sensitivity
Factors included: K (SE)
Block I 
p-value OR (95% C.I.) K (SE)
Block II 
p-value OR (95% C.I.)
- Growth hormone -.02 (.01) .008 .98 (.97-.99) -.02 (.01) .009 .98 (.97-.99)
response
- Task performance .06 (.02) .012 1.06 (1.01-1.11) .06 (.02) .010 1.06 (1.02-1.11)
response
-COMT Val158Met - - - -.23 (.20) .258 .80 (.54-1.18)
-DRD2 Taq1A - - - -.01 (.31) .986 1.00 (.54-1.84)
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Prediction of alcohol dependence:
The results of the logistic regression analyses are sum m arized in Table 4. GH 
response and cognitive task perform ance after the dopam ine agonist predicted 
alcohol dependence (Block 1: model c2=17.1, p<.001; 62% of subjects correctly 
predicted). Adding DRD2 and COMT to the model did not significantly add to the 
prediction of alcohol dependence by the model (Block 2: model %2=1.3, p=.523; 63% 
of subjects correctly predicted). The to tal variance explained by the model was 11% 
(Nagelkerke R2). Interaction between genotypes and interm ediate phenotypes was 
not significant.
Figure 1 Effect of genotype (COMT Val158Met and DRD2 Taq1A) on 
endophenotype (apomorphine reactivity)
a) Plasma growth hormone levels and DRD2 Taq1A genotype
- o -  Ctrl-A1+ 
Ctrl-A2/A2 
•©■■ Pat-A1 + 
Pat-A2/A2
b) Cognitive performance and COMT Val158Met genotype
Ctrl-Val/Val 
-*-■ Ctrl-Val/Met 
- o -  Ctrl-Met/Met 
Pat-Val/Val 
Pat-Val/Met 
Pat-Met/Met
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Discussion
This is the firs t study showing added value of apom orphine sensitivity as an 
in term ediate phenotype in  alcohol dependence. As predicted by our f irs t hypothesis 
bo th  the plasm a GH response and the disruptive effect on cognitive perform ance 
after apom orphine adm inistra tion  were reduced in  alcohol-dependent patients 
com pared to controls. These findings are in  line w ith  previous reports in  (smaller 
samples of) alcohol-dependent patients 20, 21, 68. The cu rren t findings confirm  the 
presence of reduced dopam ine receptor sensitivity in  alcohol dependence, even 
after in itia l detoxification. Alcohol dependent patients perform ed worse on the 
AX-CPT at baseline, com pared to healthy  controls. Though the data show th a t 
alcohol dependent patients can still deteriorate fu rth e r  after adm inistra tion  of 
apom orphine, depending on the COMT genotype, a po tential ceiling effect could 
not be ru led  out completely.
In line w ith  the second hypothesis, dopam inergic alcohol dependence genes 
affected central dopam ine receptor sensitivity. DRD2 genotype specifically affected 
apom orphine effects on plasm a GH levels. These findings suggest th a t DRD2 
genotype is m ainly  related to subcortical dopam ine functioning. Some previous 
studies have shown th a t DRD2 genotype is associated w ith  reduced dopam ine D2 
receptor density in  the stria tum , though th is was not always replicated 33. W ith GH 
response being a neuro in fund ibu lar dopam ine function, our data suggest th a t 
dopam ine D2 receptor density may also be reduced in  the neuro in fund ibu lum  in 
carriers of the DRD2 Taq1A genotype. W hether neuro in fund ibu lar apom orphine 
reactivity  is directly  related to stria tal dopam ine D2 receptor density is unknow n.
The DRD2 Taq1A genotype is p a rt of a gene cluster neighboring the ANKK1 gene 
cluster. O ther genes w ith in  these clusters have also been shown to be po ten tia l risk 
genes for alcohol dependence. Moreover, one sm all sample study in  alcohol 
dependent patients did show an association of the ANKK1 genotype w ith  the 
apom orphine induced GH response.
COMT genotype affected reactivity  to apom orphine on AX- CPT task perform ance.
Since AX- CPT task perform ance requires PFC dopam ine functioning, th is suggests 
th a t COMT is particu larly  relevant to p refron tal dopam ine function ing  69-72. Our 
observations may be explained by the inverted-U hypothesis on prefrontal 
dopam ine function ing  and cognitive perform ance. Carriers of the COMT Val/Val 
genotype, are presum ed to have reduced PFC dopam ine functioning, due to more 
efficient clearance of synaptic dopam ine 73. Suboptimal p refron tal dopam ine levels 
at baseline may be com pensated by dopam ine stim ulation  after apom orphine 
adm inistra tion. However, in  carriers of one or two Met-alleles adm in istra tion  of 
apom orphine may lead to an overshoot of dopam ine stim ulation, and reduce task 
perform ance. Thus, the effect of a phasic sh ift in  dopam ine levels after 123
adm inistra tion  of a dopam ine agonist on cognitive perform ance, may be dependent
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on tonic variation in  dopam ine levels, based on variation  in  COMT genotype. Future 
studies are needed to fu rth e r  confirm  the inverted-U hypothesis.
Previous studies have suggested th a t the COMT genotype may also be involved 
in  im pulsivity and affective processing. Im pairm ents of executive control in  
carriers of the COMT Val/Val genotype may be associated w ith  increased im pulsivity 
or novelty seeking. However, one previous study did not find a correlation between 
apom orphine-induced GH response and personality  tra its  such as novelty seeking. 
In addition, genetic variation  in  COMT has been suggested to be related to affective 
processing. This has been form ulated in  the tentative “w arrior-w orrior” model. In 
th is model the COMT Met-allele is hypothesized to be advantageous in  m em ory and 
atten tion  tasks, whereas reactivity  to unpleasant stim uli is increased in  Met-allele 
carriers. This increased reactivity  to unpleasant stim uli m ight cause a lower 
em otional resilience against negative mood states observed in  individuals w ith  a 
h igher Met158 allele load (the w orrier strategy). Thus the Met-allele seems to be 
beneficial during the perform ance of w orking m em ory and attention-related tasks, 
whereas the Val allele may be advantageous during  the processing of aversive 
em otional stim uli (warrior strategy).
The effect of COMT genotype was sim ilar across patients and controls. However, 
in  the alcohol-dependent patients im provem ent after apom orphine was seen in 
genotypes w ith  at least one Val-allele, whereas th is was only the case in  homozygous 
Val-allele carriers in  the controls. A dm inistration  of apom orphine may thus be less 
likely to resu lt in  dopam ine overstim ulation in  alcohol-dependent patients. This 
may suggest th a t p refrontal dopam ine function ing  is fu rth e r  reduced in  alcohol- 
dependent patients, consistent w ith  a leftw ard sh ift of the inverted-U curve in  
these individuals.
Although both  genetic variants affected dopam ine receptor sensitivity, they 
were not associated w ith  alcohol dependence. The sample size may have been too 
sm all to detect an association w ith  alcohol dependence. Nonetheless, power was 
sufficient to show a relation w ith  dopam ine receptor sensitivity. This is consistent 
w ith  the idea th a t in term ediate phenotypes are genetically less complex and the ir 
use can improve the validity of genetic association studies.
The cu rren t findings may either indicate a model of pleiotropy, or a causal 
model w ith  reduced dopam ine receptor sensitivity m ediating the genetic risk for 
alcohol dependence of the genotypes 7. However, it is to be expected th a t in  a model 
of m ediation adding DRD2 and COMT in to  the regression model would not improve 
the prediction of the model based on the in term ediate phenotypes alone, as is the 
case in  the cu rren t study. In addition, the large body of clinical and preclinical 
litera tu re  on the role of dopam ine dysfunctioning in  the etiology of alcohol 
dependence, makes a model of m ediation plausible 2 14.
The cu rren t findings suggest th a t d ifferent genes confer the ir effect on disease 
vu lnerability  th rough  d ifferent biological pathways. COMT specifically affected
dopam ine sensitivity at the level of the PFC. This may resu lt in  increasing the 
vu lnerability  to develop alcohol dependence th rough  im paired response inh ib ition  
and control '. DRD2 Taq1Aaffected dopam ine dopam ine sensitivity in  the h indbrain  
(neuroinfundibulum ). H indbrain dopam ine sensitivity may be related to alterations 
in  rew ard processing, and in  th a t way increase the vulnerability  to develop alcohol 
dependence.
Our results should be considered in  the context of strengths and lim itations of 
our design. S trengths are th a t we used a functional in term ediate phenotype of 
alcohol dependence by m easuring the response to apom orphine adm inistra tion , in  
a substantially  large sample, after in itia l detoxification, including a healthy 
control group. Further, un like previous studies w ith  a challenge paradigm  w ith  a 
dopam ine agonist, we did m easure plasm a levels of the adm inistered  drug and 
found equal plasm a apom orphine levels in  patients and controls. The differences 
found in  the response to apom orphine between patients and healthy controls and 
betw een the d ifferent genotype groups are thus likely tru e  pharm acodynam ic 
differences. Our previous studies have shown th a t bo th  AX-CPT perform ance and 
plasm a GH levels are stable under placebo condition 28. Therefore, we felt it 
unnecessary to include a placebo condition in  th is larger scale study. However, 
particu larly  w ith  respect to AX-CPT perform ance, a genotype effect on habituation 
or a learning effect cannot be ru led  out, completely. It has to be recognized th a t 
th is  study included males only. Additional work is needed to exam ine if these 
results can be generalized to females.
Previously, it has been suggested th a t GH levels after apom orphine norm alize 
after 24 hours to eight days of abstinence 17. In our study, challenge tests were 
perform ed after an average of 30 days of abstinence. This suggests th a t reductions 
in  apom orphine reactivity  in  alcohol-dependent patients may be a stable 
in term ediate phenotype. If th is  were true, fu tu re  studies should confirm  reduced 
apom orphine reactivity  in  subjects at risk, who are not alcohol dependent (i.e. 
unaffected fam ily m em bers of alcohol dependent patients). A nim al studies have 
shown th a t apom orphine sensitivity is transm itted  over generations, suggesting 
heritable factors to be involved. However, up to date, evidence for heritab ility  of 
apom orphine sensitivity in  hum ans is lacking 18, 29-31, 38, 74, 75. In addition, scarring 
effects of excessive alcohol consum ption or prior detoxifications on the brain, 
producing persistent reductions in  the sensitivity of the dopam ine system rem ain  
possible. Indeed, studies in  monkeys have shown th a t reduced brain  dopam ine D2 
receptor densities are related to increased self adm in istra tion  of cocaine, but th a t 
cocaine adm inistra tion  itself fu rth e r reduces dopam ine D2 receptor densities. In 
the cu rren t study, it cannot be excluded th a t reduced apom orphine sensitivity is a 
residual m arker, ra the r th a n  an in term ediate phenotype.
In the cu rren t study no neuroim aging measures were included. Instead of 
neuroim aging techniques, two functional m easures were used, based on previous
E
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findings w ith  an APO challenge paradigm . This has the advantage of m easuring 
functional outcome m easures, w ith  a good tim ely resolution. However, any 
in terp re ta tion  on localization of the observed effects should be seen w ith in  this 
lim itation . Clearly, the GH response is predom inantly  indicative for neuroinfun- 
d ibular dopam ine sensitivity and AX-CPT perform ance is predom inantly  indicative 
for p refron tal cortex dopam ine sensitivity. However, the absence of an effect of 
COMT on the GH response does not completely ru le out th a t COMT exerts an effect 
on o ther subcortical measures of dopam ine sensitivity. Similarly, despite the 
absence of an effect of DRD2 on the task perform ance response, DRD2 may still affect 
cortical dopam ine sensitivity w hen m easured w ith  d ifferent tasks.
It is likely th a t o ther neurobiological pathways th a n  the dopam ine system, and 
other genetic polym orphism s w ith in  those, also play a role in  the susceptibility to 
alcohol dependence, e.g. w ith in  the HPA axis or the opioid, glutam ate or serotonergic 
systems. The relative contribution of such other neu ro transm itte r systems in  
addition to central dopam ine sensitivity rem ains to be studied.
In sum m ary, the present study provides evidence th a t 1) dopam ine receptor 
sensitivity is lower in  alcohol-dependent patients th a n  in  m atched healthy controls, 
2) dopam ine receptor sensitivity is associated w ith  dopam inergic, alcoholism-relat­
ed genes, and 3) alcohol dependence is more robustly associated w ith  reduced 
dopam ine receptor sensitivity th a n  w ith  dopam inergic genotypes. This study 
em phasizes the im portance of using dynam ic or functional interm ediate 
phenotypes in  genetic studies on alcohol dependence.
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Abstract
Introduction
It is well established th a t bo th  genetic factors and childhood adverse experiences 
contribute to the vu lnerability  to alcohol dependence. Yet, em pirical data on the 
interplay  between genes and such environm ental factors in  th is field are few. This 
study tested the hypothesis th a t variation  in  dopam ine-related genes (COMT and 
DRD2) in te ract w ith  childhood adverse experiences to predict alcohol dependence. 
Methods
Male abstinen t alcohol-dependent patients (N=110) and age-matched healthy  male 
controls (N=99), were genotyped for the COMT Val158Met (rs4680) and the DRD2 
Taq1A (rs1800497) polym orphism s. Childhood adverse events were m easured using 
th ree  self-report questionnaires: the Childhood Trauma Q uestionnaire (CTQ), the 
Parental Acceptance and Rejection Q uestionnaire (PARQ), and the Stressful and 
Traum atic Events Q uestionnaire (STEQ). Age of onset, duration  and severity of 
alcohol dependence were analyzed as secondary outcome measures. Statistical 
analysis involved logistic regression analysis and analysis of variance.
Results
Childhood adversity scores were h igher for patients th a n  for controls (CTQ: ft=.24, 
p=.003; PARQ: ft =.09, p<.001; STEQ: ft =.38, p=.001). Interactions of childhood 
adversity scores w ith  the COMT genotype added significantly to the prediction  of 
alcohol dependence on two of th ree  questionnaires (COMT-by-PARQ: ft =.03, p=.001; 
COMT-by-STEQ: ft =.09, p=.036). Similar interactions were also present for the 
secondary outcome m easures alcohol dependence severity (COMT-by-PARQ: 
F(2,108)=7.0, p=.001; COMT-by-CTQ: F(2,108)=3.7, p=.028), age of onset (COMT-by-PARQ: 
F(2,108)=4.1, p=.004; COMT-by-STEQ: F(2,108)=8.7, p<.001) and duration of alcohol 
dependence (COMT-by-STEQ: F(2,108)=5.7, p=.005). The DRD2Taq1A genotype was not 
related to alcohol dependence, nor did it in teract w ith  childhood adversity in  
predicting  alcohol dependence.
Conclusion
The relation  between childhood adversity and alcohol-dependence is m odulated by 
COMT genotype. The low activity COMT allele increases the hazardous effects of 
childhood adverse experiences on the risk to develop severe alcohol dependence.
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Introduction
Alcohol dependence is considered a chronic relapsing neuropsychiatric disorder, 
w ith a m ultifactorial aetiology 1 2. Heritability estimates are as high as 60%, w ith 
m ultiple genes involved, each explaining only a small fraction of the heritability  3' 4. 
Environm ental factors, such as stressful adverse experiences during childhood, also 
increase the risk of developing alcohol dependence 5 6. However, not all people 
exposed to stressful life experiences during childhood develop alcohol dependence.
D uring the past decade, the in teraction  between genetic vu lnerability  and 
adverse environm ental factors is increasingly em phasized as an im portan t 
m echanism  in  the development of neuropsychiatric disorders 7 8. It is thought th a t 
individual sensitivity to stressful events depends on the genetic background. To 
date, em pirical data on gene-environm ent interactions in  alcohol dependence are 
few (see review 9. The purpose of th is  study was to exam ine the in teraction  between 
selected genetic factors and stressful adverse experiences during  childhood in  the 
development of alcohol dependence. In a recent paper, a plea was made for a con- 
struct-validity (theory-guided) approach to gene-environm ent in teraction  studies. 
Such studies should be based on convergent evidence from  hum an  epidemiology as 
well as anim al studies, concerning the neurobiological m echanism s of the disorder. 
In addition, various m easures of bo th  the phenotype and the environm ental 
exposure should be used 8.
The b ra in ’s dopam ine pathways play a key role in  the pathophysiology of 
alcohol dependence 1 2 10, n . W ith in  the ventral s tria ta l dopam ine pathway, often 
referred to as the “rew ard” pathway, reduced dopam ine receptor densities have 
been observed in  alcohol dependent patients. Decreased stria ta l dopam ine 
responsiveness is though t to be associated w ith  reduced sensitivity of subjects w ith  
a predisposition for addiction to “n a tu ra l” reinforcers. This increases the 
vu lnerability  to alcohol dependence, since alcohol consum ption stim ulates stria tal 
dopam ine activity 1 2 10, 12-14. In alcohol dependence, deficits have also been observed 
w ith in  the dopam ine pathway located in  the  p refron tal cortex (PFC), often referred 
to as the “contro l” pathway 2 10. Reduced activity in  the PFC dopam ine pathway is 
though t to cause im paired control over compulsive drug tak ing  behavior, resulting 
in  continued drug use, despite the negative consequences 15.
Genes th a t affect dopam ine function ing  in  the s tria tum  and the PFC are 
therefore im portan t candidates in  genetic studies on alcohol dependence. The 
dopam ine D2 receptor gene (DRD2) and its genetic polym orphism  TaqlA (rs1800497) 
has probably been studied m ost extensively. DRD2 TaqlA genotype is associated 
w ith  a 30% reduction in  dopam ine D2 receptor density in  the stria tum  of healthy 
volunteers 16, 17. Meta-analysis of association studies on the relation betw een TaqlA 
genotype and alcohol dependence show an increased risk of alcohol dependence for 
carriers of the A1 allele, though  odds ratios are sm all (OR-range: 1.22-1.9) 18-20.
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A gene repeatedly im plicated in  p refrontal dopam ine function  is COMT. The 
enzym e Catechol-O-Methyl Transferase (COMT), encoded by th is  gene, metabolizes 
dopam ine, adrenalin  and noradrenalin , and is the m ain  factor controlling 
dopam ine levels in  the PFC. A com mon functional single nucleotide polym orphism  
(SNP) in  the coding region of the COMT gene, leading to a valine to m ethionine 
substitu tion (Val158Met; rs4680), is associated w ith  a 40% reduction in  enzyme 
activity 21, 22. COMT genotype has been associated w ith  (subtypes of) alcohol 
dependence, w ith  a higher frequency of the Met allele in  type I alcohol dependent 
patients 23-25. However, also negative association results have been reported 26-29.
Given the know n relation  betw een dopam ine function ing  and stress sensitivity 
(for reviews see 30-34, genes and th e ir  varian t affecting central dopam ine functioning 
may be particu larly  relevant in  the context of gene-environm ent in teraction  
studies of adversity exposure. A large body of hum an  and anim al data indicates 
th a t early adverse experiences can resu lt in  perm anen t changes in  the mesolimbic 
and PFC dopam ine pathways, and increase the risk of substance use 30, 32, 35-42. In 
addition, data suggest th a t the PFC controls the mesolimbic dopam ine response to 
stress 43. We anticipate th a t genetic variation  in  dopam ine functioning, in  bo th  the 
PFC and the stria tum , interacts w ith  childhood adversity in  increasing the risk to 
develop alcohol dependence. For the DRD2 TaqlA genotype an in teraction  w ith  
fam ily environm ent has been shown to predict adolescent and adult d rink ing  
behavior 44, 45. However, these studies did not include m easures of alcohol 
dependence. No studies have investigated the in teraction  of the COMT Val158Met 
polym orphism  w ith  childhood adverse experience in  the development of alcohol 
dependence. However, several studies do suggest th a t the Met allele increases stress 
sensitivity 46-48.
The cu rren t study was designed to investigate gene-environm ent interactions 
in  alcohol dependence, by studying d ifferent m easures of exposure to environm ental 
adversity in  childhood and the DRD2 TaqlA and COMT Val158Met genotypes. We 
tested the hypothesis th a t either genotype modifies the association between 
childhood adversity and (the severity of) alcohol dependence, w ith  subjects th a t are 
homozygous for the DRD2 A1 allele and carriers of the COMT Met allele being most 
susceptible to the effect of childhood adversity.
Methods
Subjects
In a case control design, a consecutive series of male alcohol dependent patients 
(diagnosed according to the DSM-IV criteria; n=113), adm itted to our detoxification 
134 clinic, were compared to healthy, male controls (n=104), matched for age and level of
education. Controls were recruited th rough advertisements in  regional newspapers.
Exclusion criteria consisted of cu rren t or past neuropsychiatric disorder related to 
dysfunction of the dopam ine system (like psychosis, Korsakoff’s syndrome, 
Parkinson’s disease), foreign ancestry, language disabilities interfering w ith  w ritten 
inform ed consent and any other severe medical condition. Healthy controls w ith  any 
psychiatric history or psychiatric fam ily history (including substance dependence) 
were excluded. A total of 110 eligible patients and 99 healthy controls could be 
recruited. See Table 1 for a description of both  groups and Figure 1 for a consort 
flow chart.
Figure 1
Consort flow chart of participants in  the study
To assess drug and alcohol dependence we used the Dutch version of the 
Addiction Severity Index (ASI), section 4 49 50. The ASI has been shown to be a reliable 
tool to assess alcohol and drug  dependence in  clinical samples 51-53. Lifetime 
occurrence of axis-I disorders was assessed using the Dutch version of the Mini 
In ternational Neuropsychiatric Interview  for psychiatric disorders version 2.1 and 
the Dutch version of the ADHD rating  scale 54-56.
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Table 1 Demographic characteristics, COMT and DRD2 genotypes and childhood 
adversity scores for healthy controls and alcohol dependent patients
Healthy
controls
(N=99) 
Mean (SD)
Alcohol 
dependent 
patients 
(N=110) 
Mean (SD)
Test
statistic
F/C2
p value
Age (years) 39 (9) 41 (11) F(1,208)=2.6 .107
Age start alcohol use disorder - 24 (9.4) NA NA
Education level (%)*
-None 1 (1%) 4 (4%) C2=5.1 .274
-Basic 7 (7%) 15 (14%)
-Low 41 (41%) 46 (43%)
-Intermediate 34 (34%) 28 (26%)
-High 16 (16%) 16 (15%)
Substance use (current)
-Habitual smoking 42 (42%) 73 (68%) C2=14.0 <.001
-Habitual caffeine use 95 (96%) 106 (98%) C2=.9 .337
-SSRI use 3 (3%) 11 (10%) C2=4.1 .054
Psychiatric co-morbidity
-Depression - 29 (27%) C2=28.4 <.001
-Anxiety disorder - 17 (16%) C2=16.7 <.001
-OCD - 2 (2%) C2=1.8 .178
-ADHD - 10 (9%) C2=9.5 .002
Co-morbid substance use (past)
-Stimulants - 11 (10%) NA NA
-Opioids - 9 (8%) NA NA
-Cannabis - 38 (35%) NA NA
-Hallucinogens - 6 (6%) NA NA
*H ighest d ip lo m a  o b ta in e d : n o n e  is p r im a ry  sch o o l, no  d ip lo m a ’s, basic  is s e c o n d a ry  sch o o l, low  level 
o f e d u c a tio n  is low er v o c a tio n a l e d u c a tio n , in te rm e d ia te  level o f ed u c a tio n  is h ig h e r  v o c a tio n a l 
e d u c a tio n , h ig h  level o f  e d u c a tio n  is h ig h e r  p ro fe s s io n a l ed u c a tio n / u n iv e rs ity .
The study was approved by the regional medical eth ical board ((METiGG), protocol 
271, P04.0388L. All participants gave w ritten  inform ed consent.
Genotyping of COMT Val158Met and DRD2 TaqI A C >T
Blood was taken by venapuncture and DNA was isolated using standard 
136 protocols. Molecular analyses were perform ed in  a CCKL accredited laboratory at
the D epartm ent of Hum an Genetics of the Radboud University Medical Centre in
Nijmegen, The Netherlands. The COMT Val158Met (rs4680) polym orphism  was 
genotyped using Taqman-based analysis 57. Genotyping was carried out in  a volume 
of 10 |jl contain ing 10 ng of genomic DNA, 5 |jl of ABgene M asterm ix (2x) (ABgene 
Ltd., Hamburg, Germany), 0.125 j l  of the Taqman assay (assay ID: Taqman assay:
C__25746809_50; reporter 1: VIC-A-allele; Applied Biosystems, Nieuwerkerk a/d
Ijssel, The Netherlands) and 3.875 j l  of H2O. Am plification was perform ed on an 
7500 Fast Real-Time PCR System, sta rting  w ith  15 m in at 95° C, followed by 50 
cycles of 15 s at 95°C, 1 m in  at 60° C. Genotypes were scored using the algorithm  
and software supplied by the m anufacturer (Applied Biosystems). Also the DRD2 
TaqI A C >T polym orphism  (rs1800497) was genotyped using Taqman-based analysis 
(assay ID: Taqman assay:C_7486676_10; reporter 1: VIC-A-allele, reverse assay; 
Applied Biosystems, Nieuwerkerk a/d Ijssel, the Netherlands). Genotyping was 
carried out in  a volume of 10 m l contain ing 10 ng of genomic DNA, 5 m l of Taqman 
M asterm ix (2_; Applied Biosystems), 0.125 m l of the Taqman assay and 3.875 m l of 
H2O. To investigate the random  genotyping error rate in  the two assays, the lab 
included 5% duplicate DNA samples, w hich showed 100% consistency in  genotype 
called. In addition, 4% blancs were included, w hich were all negative.
For the DRD2 genotype two groups were form ed (i.e. A2-carriers versus A1/A1), 
due to the low num ber of A2-homozygotes. COMT genotype was analyzed in  th ree 
groups (i.e. Val/Val, Val/Met and Met/Met).
Table 2 COMT (rs4680) and DRD2 (rs1800497) genotype d istribu tion  for healthy 
controls and alcohol dependent patients
Healthy 
controls (N=99) 
Mean (SD)
Alcohol dependent 
patien ts (N=110) 
Mean (SD)
C2-statistic p-value
DRD2 TaqAl
-A1/A1 1 (1%) 2 (2%) C2=.534 .766
-A1/A2 29 (29%) 35 (32%)
-A2/A2 69 (70%) 73 (66%)
COMT Val158Met
-Val/Val 22 (22%) 27 (24%) C2=3.6 .153
-Val/Met 52 (54%) 45 (41%)
-Met/Met 24 (24%) 38 (35%)
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Childhood adversity measurement
Childhood adversity was m easured by means of th ree  self report questionnaires, 
in  order to increase consistency of the findings. To assess psychological, physical 
and sexual abuse, and physical and em otional neglect before the age of 18, the 
Dutch version of the Childhood Trauma Q uestionnaire (CTQ) developed by 
Bernstein was used 58-60. We calculated the composite score, weighted for age of 
occurrence, for frequency of occurrence and for perpetrator, as described elsewhere 
61-63. Studies in  clinical and com m unity based samples have consistently supported 
the reliability  and validity of the CTQ, including replications of its five-factor 
s truc tu re  63-65, convergent and d iscrim inan t validity w ith  o ther traum a instrum ents 
such as clinical interviews or independent case records 66, 67, and criterion-validity 
w ith  independently  corroborated traum a ratings 63, 66. Good psychometric 
properties have also been described for the Dutch version of the CTQ 61, 62.
To m easure subjective experience of paren tal acceptance and rejection during 
childhood, we used the Parental Acceptance and Rejection Q uestionnaire (PARQ) 
developed by Rohner 68. It distinguishes w arm th, hostility, indifference and 
rejection for bo th  m other and father separately. We also calculated the to ta l score 
for paren tal acceptance and rejection by sum m ing up the scores for father and 
m other. This questionnaire has shown good psychom etric properties both  
adolescents and adults 69-71. Moreover, reliability  and validity of the PARQ have been 
confirm ed across worldwide clinical samples 72, 73.
To enhance reliability  of m easuring life events, we also used the Stressful and 
Traumatic Events Q uestionnaire (STEQ) developed by A rensm an and Kerhoff 74-76. In 
th is questionnaire, 96 items address traum atic  and stressful life events th a t 
occurred in  two periods during  childhood, i.e. before the age of five years, and 
betw een 5 and 15 years of age. The reported events are sum m ed up, irrespective of 
frequency, age of occurrence and perpetrator, resu lting  in  two sub scores (for the 
period 0-5 years and 5-15 years of age) and one sum  score. The STEQ has been shown 
to be a reliable in stru m en t in  diverse psychiatric populations 75.
Statistical analysis
Differences betw een patients and controls in  dem ographic characteristics and 
the genotypes (COMT and DRD2) were com pared using analysis of variance for 
continuous variables and chi square tests for categorical variables.
To analyze the in teraction  betw een exposure to adversity during  childhood 
and the dopam ine genotypes logistic regression was used, w ith  group (patient or 
control) as a dependent variable. The forced en try  m ethod was used to analyze the 
predictive value of the factors, in  two steps. In step 1, the factors childhood 
adversity sum  scores and bo th  the COMT and DRD2 genotype were entered into the 
138 model. In the second step the in teraction  betw een childhood adversity and both
genotypes was added. This analysis was performed for each questionnaire separately,
Table 3 Childhood adversity m easures for healthy controls and alcohol 
dependent patients
Healthy 
controls 
(N=99) 
Mean (SD)
Alcohol 
dependent 
patien ts (N=110) 
Mean (SD)
Test
statistic
F
p value
Trauma score (N=104)
-physical abuse 1.4 (2.2) 2.2 (2.8) F(1, 201)=5.4 .022
-physical neglect 1.0 (1.1) 1.4 (1.4) F(1, 201)=6.3 .013
-emotional abuse 1.3 (1.1) 2.1 (2.0) F(1, 201)=13.0 <.001
-emotional neglect 1.1 (1.4) 2.1 (2.0) F(1, 201)=8.6 .004
-sexul abuse .1 (.5) .6(1.3) F(1, 201)=10.7 .001
-composite score 5.0 (6.1) 10.4 (10.4) F(1, 201)=19.3 <.001
Parental acceptance and
rejection (N=91) (N=84)
-maternal score 83.8 (13.3) 76.2 (15.4) F(1, 173)=5.4 .001
-paternal score 78.3 (15.1) 70.5 (17.3) F(1, 173)=6.3 .002
-total score 162.0 (26.6 146.7 (28.7) F(1, 173)=13.2 <.001
Life events score 
-below five years of age 
-5-15 years of age 
-total score
.7 (1.3) 
1.5 (1.7) 
2.2 (2.6)
2.1 (3.2)
3.5 (3.9)
5.5 (6.4)
F(1, 207)=16.5 
F(1, 207)=21.6 
F(1, 207)=21.9
<.001
<.001
<.001
resulting in  three regression functions. To visualize the interaction betw een childhood 
adversity and the COMT Val158Met genotype in  a graph (Figure 2) we com puted the 
probability of alcohol dependence, given d ifferent levels of adversity scores.
To fu rth e r  explore the relationships described above, we analysed, w ith in  the 
patien t group, the relation betw een COMT and DRD2 genotypes, childhood adversity, 
and th ree  m easures of the severity of the alcohol dependence: age of onset of alcohol 
dependence, duration  of alcohol dependence, and the severity score for alcohol 
dependence on the ASI. We used m ultivariate analysis of variance, w ith  COMT and 
DRD2 and childhood adversity sum  scores as independent variables and severity 
scores on the ASI, age of onset or duration  of alcohol dependence as dependent 
variables.
Data were analyzed using SPSS version 16.0. Alpha (two-sided)=0.05 was used 
throughout.
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Results
Demographics:
Patients more often had psychiatric co-morbidity and more often were smokers 
or used Selective Serotonin Inhibitors as a antidepressant m edication (demographic 
characteristics are shown in Table 1). Genotype frequencies did not deviate from  
Hardy-Weinberg equilibrium  (COMT: c2=0.7 , p=.400; DRD2: f = 2 1 ,  p=.159). The 
frequency of the COMT Val158Met and DRD2 genotypes did not differ between 
patients and controls (Table 2).
Childhood adversity:
Alcohol dependent patients reported h igher adversity scores com pared to 
healthy  controls on all th ree  questionnaires, see Table 3 (childhood traum a score 
(CTQ): F(1,201)=19.3, p<.001; paren tal acceptance and rejection (PARQ): F(,173)=13.2, 
p<.001; life events score (STEQ): F(1,207)=21.9, p<.001). The th ree  questionnaires 
showed substantial correlation (CTQ/PARQ: Rho= .65, p<.001; CTQ/STEQ: Rho=.63, 
p<.001; PARQ/STEQ: Rho=.52, p<.001). There were no differences w ith  regard to any 
of the th ree  childhood adversity m easures between groups according to the COMT 
or DRD2 genotypes (See Table 5).
Interaction of genotype and childhood adversity:
The results of the logistic regression analyses are sum m arized in  Table 4. In the 
final models, childhood adversity (childhood traum a score, paren tal acceptance 
and rejection, and the life events score), and the in teraction  between childhood 
adversity and the COMT Val158Met genotype (for paren tal acceptance and rejection 
and life events score) significantly predicted alcohol dependence.
The final models (including adversity scores from  the th ree  questionnaires, the 
genotypes and the in teraction  betw een adversity scores and genotypes) showed 
m oderate predictive value, w ith  68% correctly predicted cases for the childhood 
traum a score (model c2=3.0, p=.220), 67% for paren ta l acceptance and rejection 
(model c2=11.4, p=.003) and 68% for the life events score (model c2=4.3, p=.119). The 
in teraction  betw een childhood adversity (measured w ith  the life events 
questionnaire) and the COMT Val158Met genotype in  the prediction of alcohol 
dependence is shown in  Figure 2.
Severity of alcohol dependence:
There were no differences w ith  regard to any of the th ree  severity measures 
betw een groups according to the COMT or DRD2 genotypes (See Table 5). The severity 
m easures were not significantly correlated w ith  any of the childhood adversity 
140 m easures. However, there was a significant in teraction  betw een COMT and the life
events score on alcohol dependence severity (COMT-by-CTQ: F(2,108)=3.7, p=.028); in
Table 4 Regression analysis, predicting  alcohol dependence based on th ree  m easures of childhood adversity exposure, 
COMT Vall58Met and DRD2 TaqAl genotypes and the in teraction  betw een genotypes and childhood adversity
Block I Block II
OR OR
Factors included: K(SE) p-value (95% C.I.) K(SE) p-value (95% C.I.)
-Childhood traum a score .11 (.02) <.001 1.12 (1.07-1.17) .24 (.08) .003 1.27(1.09-1.49)
-COMT Vail 58/Met -.05 (.21) .826 .96 (.63-1.44) .34 (.32) .292 1.40 (.75-2.64)
-DRD2 TaqAl -.24 (.32) .460 .79 (.42-.48) -.03 (.48) .955 .97 (.38-2.49)
-Trauma score“COMT - - - .05 (.03) .107 .95 (.90-1.01)
-Trauma score"DRD2 - - - .03 (.05) .517 .97 (.88-1.07)
-Parental acceptance .03 (.01) <.001 .97 (.96-.98) .09 (.02) <.001 .92 (.88-.96)
-COMT Vall58Met -.19 (.21) .368 .83 (.56-1.24) -4.23 (1.26) .001 .02 (.0-.17)
-DRD2 TaqAl -.39 (.32) .219 .68 (.35-1.26) -1.10 (2.09) .598 .33 (.01-19.91)
-Acceptance*COMT - - - .03 (.01) .001 1.02 (1.01-1.04)
-Acceptance"DRD2 - - - 0(.01) .772 1.0 (.98-1.03)
-Life events <16 yrs .18 (.03) <.001 1.2 (1.12-1.27) .38 (.12) .001 1.46 (1.16-1.84)
-COMT Vail 58Met -.10 (.21) .647 .91 (.60-1.38) .31 (.30) .287 1.37 (.77-2.44)
-DRD2 TaqAl -.42 (.33) 208 .66 (.34-1.26) -.36 (.44) .412 .70 (.30-1.65)
-Life events*COMT - - - .09 (.04) .036 .92 (.84-.99)
-Life event s“DRD2 - - - .03 (.08) .689 .97 (.84-1.12)
Gene environm ent interaction in alcohoI dependence rr\
the presence of childhood adversity exposure Met allele carriers displayed increased 
overall addiction severity.
In the model for the paren tal acceptance and rejection score (PARQ), there was 
a significant m ain  effect of COMT and DRD2 on the severity score for alcohol 
dependence (COMT: F(2,108)=6.5, p=.002; DRD2: F(1,109)=9.9, p=.002, respectively). In 
addition, the re  was a significant in teraction  betw een bo th  COMT and DRD2 and the 
PARQ score on the severity of alcohol dependence (COMT-by-PARQ: F(2,108)=7.0, 
p=.001; DRD2-by-PARQ: F(1,109)=8.1, p=.005, respectively). In the presence of high 
paren ta l rejection, Met allele carriers displayed an increased alcohol dependence 
severity score.
For the life events score (STEQ), there was a significant m ain  effect of COMT on 
the age of onset of alcohol dependence (COMT: F(2,108)=4.1, p=.019). There was a 
significant in teraction  between COMT and adversity score on the age of onset and 
duration  of alcohol dependence (COMT-by-STEQ: F(2,108)=8.7, p<.001; F(2,108)=5.7, 
p=.005, respectively). In the presence of adverse life events, Met allele carriers 
displayed a lower age of onset and a longer duration  of alcohol dependence.
Table 5 Alcohol ;everity and childhood adverse experience d istribu tion  by 
COMT genotype for alcohol dependent patients
COMT COMT COMT F- statistic p -
Val158Val Val158Met Met158Met value
Mean (SE) Mean (SE) Mean (SE)
Alcohol dependence
severity
- Age of onset 22 (1.8) 25 (1.4) 24 (1.5) F(2,108)=.6 .578
- Duration of alcohol 18 (1.9) 14 (1.4) 17 (1.6) F(2,108)=2.8 .064
dependence
- Severity score for 6.1 (.3) 6.2 (.2) 6.3 (.2) F(2,108)=.3 .725
alcohol dependence
- Overall addiction 3.4 (.2) 3.2 (.2) 3.4 (.2) F(2,108)=.4 .676
severity score
Childhood adversity score
- Childhood traum a 11.2 (1.8) 10.8 (1.4) 13.4 (1.5) F(2,108)=.8 .433
score (VBG)
- Parental acceptance 146 (5.5) 146 (4.2) 143 (4.6) F(2,108)=.2 .858
and rejection (PARQ)
- Life events score 9.1 (1.8) 9.8 (1.4) 9.2 (1.5) F(2,108)=.1 .937
(STEQ)
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Discussion
This study shows th a t the contribution  of childhood adversity to the vulnerability  
to alcohol dependence is m odified by genetic background in  the dopam ine pathway. 
In the persons w ith  h igh scores on childhood adversity, an increasing num ber of 
Met alleles of the COMT Val158Met polym orphism  was associated w ith  a h igher risk 
of alcohol dependence. This in teraction  was replicated w hen severity param eters of 
alcohol dependence were considered as outcome variable, and was consistent across 
d ifferent in strum ents used to m easure childhood adversity. This can be considered 
as an in te rna l replication, indicating  robustness of our findings. The DRD2Taq1A 
genotype was not related to alcohol dependence, nor did it in te ract w ith  childhood 
adversity in  predicting  alcohol dependence.
a) -
b)
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It is tem pting to speculate th a t the p refrontal cortex dopam ine system is 
involved in  the observed in teraction  between COMT and childhood adversity. The 
COMT Val158Met polym orphism  is considered to be associated w ith  differences in  
p refron tal dopam ine functioning, w ith  the low-activity Met allele resulting  in  
h igher levels of cortical dopam ine function ing  21, 22. Exposure to stressful events 
has been shown to increase PFC dopam ine levels 37-39. In addition, the PFC has been 
shown to control the  mesolimbic dopam ine response to stress 43. As dopam ine 
function ing  follows an inverted U-shaped dose response curve 77, 78, in  the presence 
of the low-activity Met allele, the increased PFC dopam ine concentrations may 
exceed optim al levels, m aking its carriers particu larly  sensitive for adverse 
environm ental stim uli 79. Indeed, increased sensitivity to stress, pain  and fear 
induction  have been reported in  healthy  carriers of the low-activity Met allele 46-48, 
80"88. Such increased sensitivity to detrim ental effects of adverse experiences in  Met 
allele carriers due to an exaggerated dopam ine response to stress has previously 
been suggested as p a rt of the w arrior-w orrier model 89 in  w hich the COMT Val allele 
may confer an advantage in  the processing of aversive stim uli (warrior strategy), 
w hile the Met allele may be advantageous in  m em ory and atten tion  tasks (worrier 
strategy). Under conditions of increased dopam ine release (eg, stress), individuals 
homozygous for COMT Val alleles may have improved dopam inergic transm ission 
and better perform ance, while individuals w ith  (one or more) Met alleles may have 
less efficient neurotransm ission and worse perform ance. 90, 91. Excessive use of 
alcohol may be a way to cope w ith  th is  increased stress sensitivity when carriers of 
a Met allele have been exposed to adverse experiences.
The DRD2Taq1A genotype did not in te ract w ith  childhood adversity in  
predicting  alcohol dependence. Our study was too small to form ally exclude a role 
of th is variant, and it may still be related to alcoholism in a subgroup of impulsive 
alcohol dependent patients w ith  a positive fam ily history  of alcohol dependence, as 
suggested in  the litera tu re  92-94. Im portantly, a previous repo rt by our group showed 
DRD2 genotype to in te ract w ith  paren tal ru le setting in  predicting adolescent 
alcohol consum ption 44. The DRD2Taq1A genotype may thus in teract w ith  
environm ental factors o ther th a n  childhood adversity in  the development of a 
subtype of alcohol dependence, or alcohol drink ing  behaviors o ther th an  
dependence.
Childhood adversity scores also predicted alcohol dependence independent of 
genotype in  our study. These findings are in  accordance w ith  previous studies th a t 
showed a strong association between adverse childhood experiences and alcohol 
abuse and dependence later in  life 95, 96. Exposure to stress, particu larly  early in  life, 
has been shown to induce perm anen t changes in  the mesolimbic dopam ine rew ard 
pathway 30, 32, 35, 36. In addition to the (more acute) effects on PFC dopam ine 
144 function ing  as explained above, th is effect may also contribute to the increased
vulnerability  to alcohol dependence.
Our results should be considered in  the context of the lim itations of our design. 
Firstly, a general lim ita tion  of studies retrospectively m easuring exposure to 
childhood adversity is the possible confounding by m em ory bias. Yet, several 
studies have shown th a t the Dutch version of the Childhood Trauma Q uestionnaire 
(CTQ) and the Stressful and Traumatic Events Q uestionnaire (STEQ), used in  this 
study, are a reliable instrum ents, w ith  good in ternal consistency, convergent 
validity (correspondence w ith  o ther inventories) and criterion  validity 
(correspondence w ith  file inform ation)61, 62, 75, 97. The concept of perceived paren tal 
acceptance and rejection is a m easure th a t is more d ifficu lt to validate, since it 
aims to m easure subjective paren ting  perceptions. Particularly  w hen perceptions 
of paren ting  are assessed retrospectively during  adulthood, th is may be subject to 
m em ory bias. A lthough several studies have shown construct, concurren t and 
d iscrim inan t validity of the PARQ used in  the cu rren t study 70-73, an effect of 
m em ory bias cannot be form ally ru led  out.
Secondly, since the COMT Val158Met varian t affects PFC dopam ine functioning 
in  hum ans, and early life experiences affect p refron tal dopam ine function ing  in  
anim als, it is likely th a t the observed in teraction  betw een COMT genotype and 
childhood adversity is m ediated by reduced PFC dopam ine functioning. Yet, since 
the cu rren t data do not include a d irect m easure of dopam ine functioning, it 
rem ains to be studied w hether th is is indeed the underlying m echanism . It also 
rem ains to be elucidated if  o ther neurobiological pathways related to o ther genetic 
polym orphism s also play a role in  th is interaction; po ten tia l candidates may be 
found in  the opioid, glutam ate or serotonergic systems.
In summ ary, the present study provides evidence th a t the effects of early 
environm ental risk factors on the risk to develop alcohol dependence are m odulated 
by COMT genotype. This study em phasizes the im portance of studying gene-envi- 
ronm ent interactions in  complex disorders.
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Abstract
Aims
Detection of errors is crucial for efficient goal-directed behavior. The ability to 
m onitor behavior is found to be dim inished in  patients w ith  substance dependence, 
as reflected in  decreased error-related b rain  activity, i.e. error related negativity 
(ERN). The ERN is also decreased in  o ther psychiatric disorders w ith  im paired 
response inhibition , like ADHD and borderline personality  disorder, bu t increased 
in  anxiety disorders. The objective of the cu rren t study was to assess error 
m onitoring in  alcohol dependent patients in  relation  to psychiatric co-morbidity. 
We expected decreased error m onitoring in  alcohol dependent patients w ith  
im pulse control disorders and increased error m onitoring in  anxious alcohol 
dependent patients.
Design
In a case control design alcohol dependent patients were com pared w ith  healthy 
controls.
Participants and setting
A consecutive series of 29 m ale alcohol dependent patients, between 18 and 55 
years of age, applying for inpa tien t detoxification were recruited  at Novadic 
Kentron, center for Addiction Treatm ent. Fifteen age-matched healthy  controls 
were recru ited  th rough  advertisem ents in  regional newspapers.
Measurements
Event-related potentials were recorded while perform ing a speeded choice-reaction 
task, from  w hich ERN am plitudes were calculated. Axis-I and -II psychiatric 
co-morbidity were assessed using the MINI neuropsychiatric interview  and the 
S tructured  Interview  for DSM-IV Personality disorders. All participants filled out 
the Tem peram ent and Character Inventory and Profile of Mood States.
Findings
ERN am plitudes were increased for alcohol dependent patients com pared to healthy 
controls, particu larly  in  patients w ith  co-morbid anxiety disorders.
Conclusions
Increased error m onitoring in  alcohol dependent patients, particu larly  those w ith  
co-morbid anxiety disorders, is in  contrast w ith  previous studies th a t suggested 
decreased error m onitoring to be a general feature in  substance use disorders. 
Psychiatric disorders co-occurring w ith  alcohol dependence, such as anxiety 
disorders, may indicate sub-populations of alcohol dependent patients, w ith  
d istinct neurobiological and genetic characteristics, possibly requiring  different 
trea tm en t strategies.
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Introduction
Fast detection of errors is crucial for efficient goal-directed behavior. There is 
ample evidence th a t posterior m edial fron ta l cortex, including the anterior 
cingulate cortex (ACC) , plays an im portan t role in  error m onitoring1. Error-related 
ACC activity is also reflected in  a response-locked event-related potential, known 
as the error-related negativity or ERN, elicited im m ediately following erroneous 
responses2-4.
D im inished error m onitoring, as reflected in  decreased ERNs or error-related 
hypoactivity of the ACC, has previously been dem onstrated in  abstinent cocaine 
and opiate dependent patients, as well as in  cu rren t alcohol and cocaine dependent 
patien ts5-8. In addition, the consum ption of m oderate am ounts of alcohol has been 
shown to reduce the ERN am plitude in  healthy subjects9. D im inished m onitoring of 
behavior has therefore been hypothesized to underlie continued excessive use of 
drugs in  face of its adverse consequences5-8.
Reduced ERN am plitudes have also been found in  psychiatric disorders 
characterized by behavioral disinhibition , like borderline personality  disorder10, 11 
or ADHD12, and in  healthy controls w ith  h igh tra it im pulsivity13. Since both  
im pulsivity and im pulse control disorders are common among patients w ith  
substance dependence, reduced ERN am plitudes in  cocaine, opiate and alcohol 
dependent patients may be explained by high levels of impulsivity, rather th an  
substance dependence per se14.
In contrast increased ERN am plitudes have been dem onstrated in  patients w ith  
anxiety disorders and healthy  controls w ith  h igh tra it anx iety15. Since alcohol 
dependence often co-occurs w ith  anxiety  disorders16, 17, error m onitoring may be 
increased in  alcohol dependent patients w ith  co-morbid anxiety.
A lthough these contrasting  effects of im pulsivity and anxiety on error 
m onitoring have repeatedly been dem onstrated, it is to th is date unknow n how 
psychiatric co-morbidity and personality  characteristics im pact on error related 
b rain  activity in  substance dependence. We assessed error processing, psychiatric 
co-morbidity, and personality  traits in  abstinen t alcohol dependent patients and 
healthy  volunteers. Our hypotheses were th a t (1) abstinent alcohol dependent 
patients would show decreased error m onitoring com pared to healthy  controls, 
and (2) co-morbid psychiatric disorders and personality  traits would m odulate 
error m onitoring in  alcohol dependent patients, w ith  patients w ith  high levels of 
anxiety (i.e. anxiety disorders or high harm  avoidant score) showing increased 
error m onitoring and patients w ith  high levels of im pulsivity (i.e. ADHD, or high 
novelty seeking scores) showing decreased error m onitoring.
155
Er
ro
r 
re
la
te
d 
ne
ga
tiv
ity
 
an
d 
al
co
ho
l 
de
pe
nd
en
ce
Materials and methods
Participants
A consecutive series of m ale alcohol dependent patients (according to DSM-IV, 
N=29), applying for detoxification between January  and December 2007. All patients 
were adm itted to a detoxification clinic, w ith  routinely  controls of alcohol use, 
w ith  bo th  daily self report as well as regular b rea th  tests as p a rt of the trea tm en t 
as usual, and tested after one m onth  of abstinence. Healthy m ale controls (N=15), 
m atched for age and level of education, w ithou t psychiatric (family) h istory 
(including substance use disorders) were recruited  th rough  advertisem ents in  
regional newspapers. See Table 1 for a full description of the two groups.
Procedure
Participants were screened on m edical illness and psychiatric disorders by a 
tra ined  MD (AS). Patients w ith  psychotic symptoms or Korsakov’s syndrome were 
excluded. Participants using m edication know n to affect ERN (benzodiazepines, 
antipsychotics, m ethylphenidate), or w ith  a change in  any m edication during  th ree  
m onths prior to the study were excluded. Participants were not allowed to smoke 
or use caffeine contain ing drinks w ith in  3 hours prior to m easurem ents. The study 
protocol was approved by the regional m edical eth ical board (METiGG, protocol n r 
271). All participants gave w ritten  inform ed consent.
Measurements
A detailed description of the instrum ents used, the task, EEG recording and 
data m anagem ent is given in  the supplem entary text. Psychiatric disorders and 
history  on alcohol and drug use were assessed using structu red  interviews. ADHD 
was assessed using a self report questionnaire. Personality traits and mood states at 
the tim e of neurophysiological testing  were assessed using self report questionnaires. 
EEG was recorded w hile participants perform ed a m odified Eriksen flanker task, 
as described before10.
Analysis
Differences between alcohol dependent patients and healthy controls on ERN 
amplitude, task performance (reaction times; accuracy) and personality characteristics 
were tested using univariate ANOVAs. We used Chi-square tests to assess differences in 
prevalence of psychiatric disorders between both groups. W ithin the alcohol dependent 
sample an association between ERN amplitude, and axis I and II psychopathology, was 
analyzed using univariate ANOVA. Use of SSRI’s and anti-craving medication was 
entered as a covariate, to control for medication effects. Pearson’s correlations were 
156 used to analyze the correlation between duration of alcohol dependence, personality
traits, mood profile during measurements and ERN amplitudes.
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Supplementary figure 1 Consort flow chart of participants in  the study
Alcohol dependent patients Healthy controls
Error related negativity and alcohol dependence
Sample size
Based on previous studies the sample size for each group was estim ated to be 
15. To be able to analyze the po ten tia l influence of psychiatric co-morbidity and 
personality  characteristics on the ERN in  the patien t sample, the num ber of 
patients included was doubled.
Psychiatric assessment
The MINI in ternational neuropsychiatric interview  was used to assess axis I 
psychiatric disorders, according to DSM-IV criteria18. To assess ADHD, a self report 
questionnaire, w ith  good validity  and reliability, was used19. Personality disorders 
were assessed using the sem i-Structured Interview  for DSM-IV Personality disorders 
(SIDP-IV)20. Socio-demographic characteristics and history  on drug and alcohol use 
were assessed using the Dutch version of the Addiction Severity Index (EuropASI), 
sections 2 and 321.
Assessment of trait and state variables
Personality traits were assessed using the Dutch version of Cloninger’s 
Tem peram ent and Character Inventory22. It consists of four tem peram ent scales: 
novelty seeking, rew ard dependence, h arm  avoidance and persistence. Before 
com m encing neurophysiological assessment participants filled out the profile of 
mood states (POMS), to assess the state of mood at tim e of neurophysiological 
testing23.
Neurophysiological assessment
A tria l started  w ith  the presentation  of a fixation po in t (300 ms) on a screen, 
after w hich a string  of five letters was presented for 100 ms. Participants were 
in struc ted  to press a righ t bu tton  if  the central le tter of th is string  was an H, and 
left if  the central le tter was an S. Letter strings were 50% congruent (SSSSS or 
HHHHH) and 50% incongruent (SSHSS or HHSHH). After an in terval of 900 ms, 
visual feedback was presented for 1000 ms. The in te r-tria l in terval was 100ms. 
Participants were instruc ted  to perform  as fast and accurate as possible. An 
individual reaction-tim e deadline was introduced by adding 0.5 SD to the m ean 
reaction tim e, during  a practice block of 50 trials. The experim ent consisted of 10 
blocks of 50 trials.
EEG recordings were perform ed using th ree  Silver Chloride electrodes, 
m ounted in  an elastic cap, placed over the scalp m idline (Fz, FCz, Cz) in  accordance 
w ith  the in ternational 10-20 system, w ith  a linked ears reference. The vertical and 
horizontal electro-oculogram  were bipolarly recorded, for correction of eye 
movements. Electrode im pedances were kept below 5 kQ. EEG and EOG signals 
158 were am plified using a tim e-constant of 8 seconds (high-pass .02 Hz), filtered
off-line (low-pass: 15 Hz), and digitized w ith  a sam pling rate of 500 Hz.
Table 1 Demographic characteristics of alcohol dependent patients and healthy 
controls, based on EuropASI, sections 1 and 4, MINI in ternational 
neuropsychiatric interview, semi structu red  interview  for DSM-IV 
personality  disorders (SIDP-IV) and ADHD self report questionnaire
Demography Controls 
Mean (SD) 
(N=15)
Patients
w ithout
anxiety
disorder
(N=21)
Patients 
w ith  anxiety 
d isorderf 
(N=8)
P-
value
Age (years) 44 (8.7) 47 (8.5) 43 (4.9) n.s.
Age start alcohol use disorder NA 28 (10.3) 22 (6.2) n.s.
(years) NA 16 (1.7) 17 (2.7) n.s.
Duration of alcohol use disorder NA 20 days 21 days n.s.
(years) NA 29% 25% n.s.
Days of excessive alcohol use NA 24% 13% n.s.
past m onth
History of alcohol detoxification
History of alcohol delirium
Dexterity 80% 90% 86% n.s.
Education level (%)
-Low 13% 24% 25% n.s.
-Intermediate 53% 57% 62%
-High 33% 19% 13%
Use of psychoactive substances
(%) 40% 43% 50% n.s.
-Nicotine 93% 100% 100% n.s.
-Caffeine 0% 40% 13% n.s.
-SSRI 0% 5% 25% n.s.
-Anticraving medication
Axis I psychopathology (%)
-major depressive disorder 0% 0% 38%* p=.001
-bipolar disorder 0% 10% 0% n.s.
-past psychosis due to substance 0% 10% 0% n.s.
use 0% 5% 0% n.s.
-ADHD
Axis II psychopathology (%)
-Cluster A
• Paranoid 0% 0% 13% n.s.
-Cluster B
• Antisocial 0% 38% 25% n.s.
• Narcistic 0% 14% 0% n.s.
• Histrionic 7% 5% 0% n.s.
-cluster C
• Avoidant 0% 14% 50%* p=.007
• Dependent 0% 5% 13% n.s.
• Obsessive Compulsive 0% 14% 13% n.s.
r7
n.s.: p>.08; *=deviant group; |:a n x ie ty  d isorders consist of: panic disorder, social phobia, agoraphobia,
generalized  anxiety. 159
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ERN am plitudes were determ ined at electrode FCz, defined as the difference 
betw een the m ost negative peak in  a 0-150 ms tim e-window following response 
onset, and its preceding positive peak.
Results
Anxiety disorders and avoidant personality  disorder were more prevalent 
among alcohol dependent patients com pared to healthy controls (c2=5.1, p=.024, 
C2=4.5, p=.034 respectively). Alcohol dependent patients scored h igher on harm  
avoidance (F(1,43)=11.2, p=.002), rew ard dependence (F(1,43)=4.3, p=.044) and 
persistence (F(1,43)=4.8, p=.034). See table 1.
Alcohol dependent patients had longer reaction tim es on the Eriksen Flanker 
task (F(1,43)=22.6, p<.001), w ith  the same accuracy (F(1,43)=.3, p=.567, Table 2). ERN
Table 2 Perform ance on Eriksen flanker task and ERN during  task
perform ance, for alcohol dependent patients and healthy controls
Results Controls 
Mean (SD) 
(N=15)
Patients
w ithout
anxiety
d isorder
(N=21)
Patients 
w ith  
anxiety 
d iso rderf (N=8)
Test
statistic
P-
value
Accuracy (%)
-errors on congruent 10% (3.3)* 15% (7.3) 16% (5.8) F=3.8 .030
trials 34% (9.8) 34% (6.3) 32% (7.0) F=0.3 .774
-errors on incongruent 23% (5.8) 25% (6.1) 24% (5.8) F=0.8 .460
trials
-errors overall
Reaction tim e (ms)
-correct responses 364 (26.0)* 416 (36.8) 405 (32.4) F=11.5 <.001
-incorrect responses 331 (30.7)* 388 (49.1) 375 (56.7) F=7.1 .002
-difference between 33 (18.6) 28 (22.0) 30 (29.6) F=0.2 .827
correct and incorrect
responses 352 (22.5)* 400 (32.9) 393 (29.0) F=12.5 <.001
-correct responses on
congruent trials 380 (33.1)* 437 (43.4) 420 (37.2) F=9.2 .001
-correct responses on
incongruent trials
N(e) peak to peak (|jVolt) -6.38 (3.9)* -8.54 (3.5)* -11.55 (2.9)* F=5.5 .007
FCz
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n.s.: p>.40;*=deviant group; |:a n x ie ty  d isorders consist of: panic disorder, social phobia, agoraphobia,
generalized  anxiety.
F igure 1 Event related potentials (ERP) in  alcohol dependent patients, 
compared w ith  healthy controls
a)
FCz
Control group
response
onset
c)
FCz
Incorrect responses
= Alcohol dependent group 
-  Control group
b)
FCz
Alcohol dependent group
-  -  -  = Correct responses 
------ = Incorrect response
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am plitudes were increased in  alcohol dependent patients com pared to healthy 
controls, as can be seen in  Figure 1 and 2 (F(1,43)=6.5, p=.015, Table 2). Alcohol 
dependent patients w ith  co-morbid anxiety disorders showed increased ERN 
am plitudes, com pared to those w ithout anxiety disorders (F(1,28)=4.6, p=.041). 
Adding the use of SSRI’s or anti-craving m edication as a factor did not alter the 
results substantially  (F(1,28)=4.3, p=.048). ERN am plitudes did not differ between 
alcohol dependent patients w ith  and w ithou t major depressive disorder (F(1,28)=1.5, 
p=.229), bipolar disorder (F(1,28)=0.3, p=.629), personality  disorder cluster B 
(F(1,28)<.01, p=.884) and personality  disorder cluster C (F(1,28)=1.1, p=.296). 
Personality traits did not correlate w ith  ERN am plitudes (table 3). Self reported 
tension and duration  of alcohol dependence did correlate w ith  ERN am plitudes 
(R=.39, p=.039; R=.46, p=.002 respectively).
Event related potentials (ERP’s) at FzC to both correct and incorrect responses on the 
Erikson flanker task are shown in figure 1. a) and b) for healthy controls and alcohol 
dependent patients respectively. The error related negativity (ERN) for both groups is 
shown in  figure 1. c), showing a larger ERN am plitude in  alcohol dependent patients.
Table 3 Trait (Temperament and Character Inventory) and state characteristics 
(Profile Of Mood State) in  alcohol dependent patients and healthy 
controls
Results Controls
Mean(SD)
(N=15)
Patients 
w ithou t anxiety 
d isorder 
(N=21)
Patients w ith  
anxiety 
d iso rderf 
(N=8)
P-
value
Temperament 
(TCI scores) 
-novelty seeking 19 (6) 21 (6) 19 (5) n.s.
-harm avoidance 11 (6)* 19 (8) 20 (8) .006
-reward dependence 16 (3) 14 (4) 14 (5) n.s.
-persistence 3 (2) 4 (2) 5 (2) n.s.
Mood state 
(POMS scores) 
-Depression 1 (2) 3 (4) 8 (8)* .002
-Anger 1 (1) 2 (4) 2 (2) n.s.
-Fatigue 2 (3) 3 (4) 4 (4) n.s.
-Vigor 12 (4) 11 (4) 10 (3) n.s.
-Tension 1 (1)* 3 (6) 3 (6) .001
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n.s.: p>.09; *=deviant group; |:a n x ie ty  d isorders consist of: panic d isorder, social phobia, agoraphobia,
generalized  anxiety.
Behavioral data
The groups differed w ith  regard to reaction tim es on correct responses, w ith 
the alcohol dependent group overall responding more slowly (416 ms) than  the 
control group (364 ms; F (1,43)=22.6, p<.001). Usually, responses to congruent 
stim uli are given faster th an  responses to incongruent stim uli. This congruency 
effect was also present in the cu rren t data, as the reaction tim es for correct 
responses were shorter following congruent (383 ms) th an  following incongruent 
stim uli (415 ms; F(1,43)=149.2, p<.001). The in teraction  between congruency and 
group was not significant (F(1,43)=1.3, p=.257). As in sim ilar studies, incorrect 
responses were faster (366 ms) than  correct responses (396 ms; F(1,43)=77.1, p<.001). 
The in teraction  between correctness and group was not significant (F(1,43)=0.3, 
p=.571).
Often reaction tim e increases after com m itting  an error, a behavioural 
adjustm ent known as post-error slowing. Post-error reaction times were longer (402 
ms) com pared to post-correct reaction tim es (396 ms; F(1,43)=4.6, p=.037). There was 
no in teraction  betw een post error reaction tim e and group (F(1,43)=0.1, p=.755). 
Overall, error rate did not differ between the two groups (F(1,43)=1.3, p=.257). More 
errors were made to incongruent trials (33.9%) th an  to congruent ones (14.1%; 
F(1,43)=347.1, p<.001). A significant in teraction  between group and congruency 
revealed th a t th is effect differed between the two groups: the alcohol dependent 
group made more errors in response to congruent trials (16.9%) than  the control 
group (10.7%; F(1,43)=7.2, p=.010).
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Figure 2 Error related negativity (ERN) in alcohol dependent patients w ith and 
w ithout co-morbid anxiety disorders and healthy controls
Discussion
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Alcohol dependent patients showed increased error m onitoring compared to 
healthy controls, as reflected in  larger ERN amplitudes. Error processing deficits 
have previously been argued to contribute to m aintenance of addiction, based on 
observations of reduced ERN am plitudes or error-related hypoactivity in  the ACC in 
cocaine7, 8, opiate6 and alcohol5 dependent patients and the presum ed relation w ith 
reinforcem ent learning4. The finding of increased error m onitoring in  alcohol 
dependent patients crucially dem onstrates th a t reduced action m onitoring is not a 
general feature of substance dependence. Prolonged excessive intake of a drug despite 
adverse consequences in  substance dependence is thus not merely a consequence of 
dim inished ability to m onitor behavior as suggested by previous studies.
Increased ERN am plitudes in  alcohol dependent patients w ith  anxiety disorders 
and high state anxiety is in  line w ith  a recent model on the association between 
ERN and psychopathology, th a t dissociates betw een in ternaliz ing  versus 
externalizing  psychopathology15. The firs t is hypothesized to be characterized by 
hyperactive, the la tte r by hypoactive error m onitoring, as indexed by the ERN15. 
Indeed, patients w ith  anxiety disorders and healthy  subjects w ith  high tra it 
anxiety  are know n to have increased ERN am plitudes15.
Anxiety may be associated w ith exaggerated unconscious appraisal of a perceived 
failure and increased error processing, resulting in increased ERN amplitudes. In 
anxious alcohol dependent patients, continued alcohol use may be a deficient way to 
cope w ith anxiety. Importantly, in  the previous reports on reduced action m onitoring 
in  cocaine and heroin dependent patients, psychiatric co-morbidity was not reported. 
The current findings m erit fu rther research into the relation between error m onitoring 
and psychiatric co-morbidity in other substance disorders6, 7.
Alcohol dependent patients w ith  anxiety disorders also showed high levels of 
tension, depression and harm  avoidance. Though these characteristics were not 
directly  related to ERN am plitudes, they may contribute to the observed increase in  
ERN am plitudes in  alcohol dependent patients w ith  anxiety  disorders.
We did not find a relation  between ERN am plitudes and other psychiatric 
disorders, nor personality  traits. The alcohol dependent group scored low on tra it 
im pulsivity and im pulse control disorders, and high on anxiety disorders and 
avoidant personality  disorder com pared to healthy controls and patien t samples in  
previous studies 14. The low levels of im pulsivity and im pulse control disorders in  
th is sample may explain the absence of an association w ith  error m onitoring, as 
found in  previous studies.
The dom inant view on the neurochem ical m echanism s underlying the ERN 
assigns a major role to the dopam ine system4, 24. There is however, increasing 
evidence for the role of the serotonergic system in  processing errors and negative 
feedback25. The short form  (s allele) of a polym orphism  in  the prom oter region of
the gene coding for the serotonin transpo rte r (5-HTTLPR), results in  a decreased 
num ber of serotonin transporters, w ith  subsequently increased serotonin levels.
This allele has been associated w ith  increased ERN am plitudes in  healthy controls, 
and also w ith  anxiety disorders and alcohol dependence26-28. It is tem pting to 
speculate th a t the group of alcohol dependent patients w ith  h igh anxiety, may 
have abnorm alities in  the serotonergic pathway, of genetic origin.
Moreover, anxious and depressed alcohol dependent patients have been shown to 
benefit from  serotonin reuptake inhibitors (SSRI’s), whereas impulsive alcohol 
dependent patients benefit from  the selective serotonin (5HT3) receptor antagonist 
ondansetron29. The present findings support the idea of subgroups of alcohol |
dependent patients, w ith  possible d istinct underlying neurobiological abnormalities. -S
Therefore, studies focusing on the clinical relevance of the ERN to identify subgroups ^
<V
of alcohol dependent patients are needed. ^
Since all patients were m easured after at least one m onth of controlled abstinence, -g
acute effects of alcohol or alcohol w ithdraw al are unlikely. Yet, long-lasting effects of ^
detoxification on ERN amplitudes cannot be ruled out. Moreover, long term  excessive « 
substance use itself may influence ERN amplitudes. Indeed, duration of excessive
alcohol use correlated w ith  ERN amplitudes. However, duration of alcohol dependence -5
did not differ between alcohol dependent patients w ith  and w ithout anxiety. The “
difference in  ERN am plitude can therefore not be explained by a difference in  ^
<V
duration of alcohol use. Future studies should also explore the long term  effects of «
prolonged excessive use of other drugs on the ERN. £
A lim itation of the cu rren t study is th a t only males were included. Since gender 2
differences in  error m onitoring have been reported30, fu tu re studies should inform  
us whether the cu rren t results in  male alcohol dependent patients also hold for 
females. A m inority  of patients were using psychotropic medication. Though we 
controlled for the use of medication statistically, an effect of medication on ERN 
am plitudes could not be completely ruled out.
Conclusions
Increased error m onitoring in  alcohol dependent patients, particu larly  those 
w ith  co-morbid anxiety disorders, is in  contrast w ith  previous studies suggesting 
decreased error m onitoring to be a general feature in  substance use disorders. The 
cu rren t findings em phasize the im portance of investigating sub-populations 
w ith in  the heterogeneous group of alcohol dependent patients. Psychiatric 
disorders co-occurring w ith  alcohol dependence, such as anxiety disorders, may be 
associated w ith  d istinct neurobiological and genetic characteristics, e.g in  the 
serotonergic system. Future studies are needed to confirm  these findings, and 
explore neurobiological underp inn ing  and clinical relevance of error-processing 
abnorm alities in  sub-populations of alcohol dependent patients.
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Abstract
Introduction
Alcohol dependence and anxiety disorders often co-occur. Yet, the effect of 
co-morbid anxiety disorders on the risk to relapse after trea tm en t of alcohol 
dependence is under debate. Recent studies em phasized on the d istinction  between 
relapse during  the firs t m onths of trea tm en t and relapse after th is period. The aim  
of th is  study was to investigate the effect of co-morbid anxiety disorders on relapse 
rates, tak ing  th is d istinction  into account. We hypothesized th a t co-morbid anxiety 
disorders would be particu larly  predictive for early relapse.
Methods
In a prospective design, m ale alcohol dependent patients (N=155) were recruited  
from  an inpatien t detoxification clinic. Psychiatric diagnoses and personality  
tra its  were assessed using the Mini In ternational Neuropsychiatric Interview  for 
psychiatric disorders and the Tem peram ent and Character Inventory. The Addiction 
Severity Index was used to asses addiction severity, at base-line and follow-up. All 
patients were interview ed by telephone, one year after trea tm en t in itiation .
Results
One year after detoxification 81 patients (53%) relapsed and n ine patients (7%) were 
deceased, due to alcohol related causes. Co-morbid anxiety disorder, the addiction 
severity score, in  particu la r severity of legal problems, and low harm  avoidance 
predicted relapse. Anxiety disorders were specifically related to early relapse. 
Conclusion
Alcohol dependence is a severe m ental disorder, w ith  high relapse rates and high 
m ortality. Alcohol dependent patients w ith  co-morbid anxiety disorders are 
particu larly  prone to relapse during  the firs t th ree  m onths of trea tm en t and may 
require additional medical and psychological treatm ent.
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Prior research has consistently shown a strong association between alcohol 
dependence and anxiety  disorders. Alcohol dependent patients w ith  co-morbid 
anxiety disorders have been shown to exhibit increased levels of w ithdraw al 
symptoms during alcohol w ithdraw al '. Moreover, anxiety  levels have been shown 
to be increased in  patients w ith  co-morbid anxiety  disorders during  and after 
detoxification 2-4.
This suggests th a t co-morbid anxiety disorders may complicate trea tm en t of 
alcohol dependence. However, there still is ongoing debate on the effect of co-morbid 
anxiety disorders on outcome of alcohol dependence trea tm en t 5-7. The purpose of 
th is  study was to exam ine w hether alcohol dependent patients w ith  an anxiety 
disorder differ from  those w ithout an anxiety disorder in  term s of relapse rates 
during  a one year follow-up, tak ing  into account o ther factors know n to be related 
to risk of relapse.
N aturalistic studies on predictors of prognosis in  alcohol dependence have 
focused m ainly  on identification of factors associated w ith  relapse, one year after 
treatm ent. Addiction severity, as indicated by num ber of previous treatm ents, 
duration  of alcohol use disorder and age of onset, has repeatedly been shown to be 
predictive of poor prognosis 8-10. In addition, the personality  tra its  low persistence, 
high novelty seeking and low or h igh harm  avoidance have been associated w ith  
relapse 11-15.
There is evidence th a t psychiatric co-morbidity also increases the risk for 
relapse in  alcohol dependence 5-7, 9 16, 17. For depression it appears th a t depressive 
symptoms, ra the r th a n  a diagnosis of major depression is predictive for relapse 5. A 
relation  between relapse and anxiety disorders has m ainly been shown for post 
traum atic  stress disorder (PTSD), and there are some indications th a t also other 
anxiety disorders may predispose to relapse after detoxification, however, evidence 
is lim ited (see Bradizza, Stasiewicz & Paas 2006 for review). Inform ation from  
trea tm en t studies is also lim ited, since pharm acological and psychological 
trea tm en t studies on alcohol dependence often exclude cases w ith  psychiatric 
co-morbidity, 18-21, address groups w ith  specific psychiatric co-morbidity only (e.g. 
patients w ith  m ajor depression) 22-24, or do not thoroughly  assess co-morbid 
psychiatric disorders at all 22, 25, 26.
Recently, is has been shown th a t in itia l recovery, i.e. abstinence during  the 
firs t m onths after in itia l detoxification, is an im portan t predictor for long term  
rem ission rates 27. Yet, only two studies exam ined variation in  predictor profiles 
during  early versus late phases of treatm ent. One study showed th a t predictors of 
relapse during the firs t th ree  m onths after detoxification, i.e. dom iciliary stay and 
level of education, differ from  predictors of relapse after the firs t th ree  m onths, i.e. 
level of education, addiction severity scores and depression 9. The o ther study has
Introduction
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shown th a t high levels of impulsivity, cluster B personality  disorder and poly 
substance abuse were associated w ith  relapse during the firs t four weeks of 
trea tm en t after in itia l detoxification 28. The la tte r study exam ined alcohol 
dependent patients in  an ou tpatien t trea tm en t setting and excluded those using 
psychiatric m edication, thereby excluding a large group of patients, particu larly  
those w ith  psychiatric co-morbidity. Thus, th e  shifting  in  the salience of predictors 
of abstinence across tim e after detoxification, appears to be a h ighly understudied  
area in  litera tu re  9.
W ith respect to co-morbid anxiety  disorders, no studies to date exam ined the 
relation  w ith  tim ing  of relapse in  alcohol use. Interestingly, studies th a t failed to 
show a relation  betw een co-morbid anxiety disorders and relapse in  alcohol use, 
m easured follow-up only after a successful in itia l detoxification of four to six 
weeks was attained  6 7. Yet, since co-morbid anxiety disorders have been shown to 
increase the severity of alcohol w ithdraw al symptoms and anxiety levels will 
increase during  detoxification 1-3, it is likely th a t an effect of anxiety disorders on 
the relapse risk w ill m anifest particu larly  during  the firs t m onths th a t patients 
come into treatm ent.
The cu rren t study prospectively investigated w hether alcohol dependent 
patients w ith  an anxiety disorder differ from  those w ithout an anxiety disorder in  
term s of relapse rates during  a one year follow-up, tak ing  the d istinction  between 
early versus late relapse into account. We hypothesized th a t co-morbid anxiety 
disorders would predict early relapse (i.e. during  the firs t th ree  m onths of 
treatm ent) and not late relapse (after in itia l recovery).
Method
Participants
A naturalistic , prospective, one year follow-up study of 189 m ale alcohol 
dependent patients (according to DSM-IV), m ean age 46 years (SD 9.9) was perform ed. 
Patients consecutively applying for detoxification were recruited, from  an inpatien t 
clinic. Patients w ith  severe axis I psychiatric co-morbidity, in terfering  w ith  w ritten  
inform ed consent, such as cu rren t psychosis, were excluded. Tem peram ent traits 
and axis I psychiatric co-morbidity were assessed after one m oth  of abstinence, to 
avoid state dependent confounding effects 29. If a patien t relapsed w ith in  the first 
m onth  of en tering  the study, assessment was perform ed after the firs t 1 m onth 
period of abstinence, w ith in  the firs t th ree  m onths of admission. In 5 cases, relapse 
in terfered  w ith  psychiatric assessment. These patients were excluded from  the 
analysis. A nother 30 patients were lost to follow-up (see Fig. 1). The study was 
172 approved by the regional m edical ethical board (METiGG; protocol 271, P04.0388L).
All partic ipants gave w ritten  inform ed consent.
Figure 1 Consort flow chart of participants in the study
Instruments
To assess sociodem ographic characteristics and severity of alcohol dependence 
we used the D utch version of the Addiction Severity Index (EuropASI), adm inistered  
by tra ined  research nurses 30. This in stru m en t contains seven addiction related 
dom ains of po ten tia l problems covered in a s tructu red  interview, i.e. physical 
health , em ploym ent and finance, history on drug and alcohol use, including 
trea tm en t history, legal issues, social relations, including fam ily relations, 
psychological symptoms, and gam bling.
Patients were screened on cu rren t and life tim e axis I psychiatric disorders 
using the Mini In ternational Neuropsychiatric Interview  (MINI) for psychiatric 
disorders, version 2.1, adm inistered  by a tra ined  medical doctor / researcher 31 and 
the Dutch version of the ADHD rating  scale 32.
173
Pr
ed
ic
to
rs
 
of 
re
la
ps
e 
in 
al
co
ho
l 
de
pe
nd
en
ce
To asses personality  traits we used the Tem peram ent and Character Inventory, 
developed by Cloninger 33. The TCI is a 240-item self-report questionnaire, w hich 
m easures four tem peram ent dim ensions, i.e. novelty seeking, h arm  avoidance, 
rew ard dependence and persistence.
To asses follow-up data, we used the follow-up version of the EuropASI. Relapse 
was defined as a day of heavy d rink ing  (i.e. consum ption of at least 5 alcoholic 
beverages on one day) according to in te rnational consensus 34, 35. A relapse was 
considered early relapse if it occurred during the first three months after admission 9. 
A relapse occurring  betw een th ree  m onths and one year after adm ission was 
considered a late relapse.
Statistical analysis
Data were analyzed using SPSS version 16. M ultivariate Cox-regression analysis 
was perform ed to test know n predictors of relapse, i.e. sociodem ographic charac­
teristics (including age, m arita l status and level of education), ASI severity indices, 
co-morbid axis I diagnosis and personality  tra its  (novelty seeking, h arm  avoidance, 
rew ard dependence and persistence) over tim e. In addition, a second Cox-regression 
analysis was perform ed on the tim e w indow after the firs t twelve weeks, in  order 
to identify  specific predictors of late relapse. Kaplan-Meier analyses was used to 
visualize the results graphically.
To test the differences betw een early and late relapsers and abstainers, we used 
Chi square for dichotom ous variables (i.e. psychiatric co-morbidity and m arital 
status) and m ultivariate Analysis of Variance (ANOVA) for continuous variables (i.e. 
personality  traits, ASI severity scores, age and level of education).
Results
Follow-up data were available for 154 patients (81%), of whom 81 relapsed (53%). 
Demographic variables for all patients are depicted in  Table 1. One year after 
detoxification 53% of the patients had relapsed. The m ean post-withdrawal 
abstinence period was 33 weeks (SD 18.8). The m ean duration  of adm ission of 19 
weeks (SD 15.9). In addition, 9 patients (7%) were deceased, during  the one-year 
follow-up. Six cases had died due to m edical com plications of excessive alcohol use 
(i.e. cirrhotic liver disease, hypotherm ia). One case died in  a un ila te ra l car crash, 
while intoxicated. In the o ther two cases the cause of death  is unknow n, however 
patients had relapsed in  the m onths prior to death  occurred.
In the un ivariate cox regression analysis low harm  avoidance, anxiety disorders, 
174 ASI severity of legal problems and single m arita l status were all significant
predictors of relapse (ft=-.04, p=.042; ft=.88, p<.001; ft=.34, p=.002; ft=.28, p<.001
Table 1 Description of the study population, including dem ographic variables, illness characteristics and ASI severity scores
A bstainers 
Mean (SD) 
(N=73)
Early relapsers 
Mean (SD) 
(N=41)
Late relapsers 
(Mean (SD) 
(N=40)
Test statistic p-value
Demographic factors
-Age (years) 42 (10.6) 41 (9.6) 44 (10.2) F(127,2)=.6 .540
- Marital status (single)
- Level of education
72%| 89% 90% t= 7 A .025
No diploma 
Secondary school 
Low vocational 
High vocational 
University
4%
10%
45%
25%
16%
0%
27%
37%
27%
10%
3%
25%
38%
25%
10%
X2=9.3 .315
Illness characteristics
-Age of onset (years) 24 (11.4) 20 (5.2) 24 (9.4) F(127,2)=1.5 .221
-Duration (years) 18 (11.0) 19 (10.2) 17(10.2) F(127,2)=.8 .925
-Number of previous détoxifications 0 (-8) 1 (-9) 1 (2.1) F(127,2)=2.5 .087
-Family history 54% 71% 75% X2=3.1 .216
ASI severity index
-Alcohol use problems 6 (1.0) 6 (1.1) 6 (1.8) F(127,2)=.0 .981
-Drug use problems 2 (2.6) 2 (2.7) 2 (2.6) F(127,2)=.8 .475
-Medical problems 2 (2.2) 3 (2.2) 3(2.1) F(127,2)=1.2 .293
-Employment problems 3 (2.0) 4 (2.4) 4(2.2) F(127,2)=2.2 .115
-Legal problems 1 (1.3)1 2(1.9) 2 (2.3) F(127,2)=9.1 <.001
-Social problems 4(2.0) 5(1.8) 4(2.3) F(127,2)=.6 .547
-Psychological problems 5 (2.0) 5(1.7) 5(1.9) F(127,2)=.0 .986
-Gambling problems 0(1.3) 1 (1.4) 1 (2.1) F(127,2)=1.4 .247
-Total score 23 (7.1)1 28 (7.8) 28 (11.1) F(127,2)=3.1 .048
|=  Group th a t was significantly different in post-hoc test
Predictors of relapse in  alcohol dependence
respectively). M ultivariate cox-regression analysis resulted in  a significant 
prediction model (c2=27.7, p=.002) w ith  harm  avoidance, co-morbid anxiety 
disorders and ASI severity index as independent predictors of relapse (ft=-.04, 
p=.042; ft=.87, p=.003; ft=.29, p=.001 respectively). In the analysis of predictors 
relapse after the detoxification phase, tak ing  twelve weeks as baseline sta rting  
point, Cox regression analysis showed th a t only addiction severity score (ft=.50, 
p=.001) and harm  avoidance (ft=-.05, p=.034) were significant predictors of relapse 
after the detoxification phase (see Fig. 2).
In the com parison of early versus late relapsers, early relapsers more often had 
co-morbid anxiety disorders (c2=27.9, p<.001), com pared to bo th  late relapsers and 
abstainers (see Table 2). Specifically agoraphobia and social phobia were more 
prevalent among early relapsers com pared to abstainers and late relapsers (c2=15.0, 
p=.001; c2=9.7, p=.008, respectively). Abstainers more often had a stable relationship 
(C2=7.4, p=.025) and lower severity of legal problems (F(128,2)=9.1, p<.001) th a n  both  
early and late relapsers (see Table 1). There were no differences w ith  respect to 
personality  characteristics among the groups (see supplem entary Table 1).
Supplementary Table 1
Personality characteristics for alcohol dependent patients th a t rem ained 
abstinent, or relapsed (both early and late relapsers)
A bstainers Early Late Test statistic  P-
Mean (SD) 
(N=73)
relapsers 
Mean (SD) 
(N=41)
relapsers 
(Mean (SD) 
(n =40)
value
Personality traits
-Novelty seeking 22 (7.0) 21 (6.0) 21 (6.5) F(127,2)=.2 .843
-Harm Avoidance 19 (8.1) 19 (6.6) 19 (7.7) F(127,2)=.0 .983
-Reward Dependence 14 (3.2) 13 (4.8) 14 (4.4) F(127,2)=1.0 .367
-Persistence 5 (1.8) 5 (1.2) 4 (2.2) F(127,2)=.7 .500
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Table 2 Psychiatric co-morbidity and co-morbid substance abuse among alcohol dependent patients th a t rem ained abstinent, or 
relapsed (both early and late relapsers)
A bstainers 
Mean (SD) 
(N=73)
Early relapsers 
Mean (SD) 
(N=41)
Late relapsers 
(Mean (SD) 
(N=40)
Test statistic p-value
Co-morbid substrance abuse
-Co-morbid cannabis abuse 9.1% 24.3% 12.5% X2=5.0 .083
-Co-morbid stim ulant abuse 7.8% 5.4% 10% x2=-6 .754
-Co-morbid opioid abuse 5.2% 10.8% 7.5% X2=1.2 .549
Co-morbid psychiatric disorders
-Mood disorder 28.6% 35.1% 35.0% x2=-7 .688
-ADHD 13.0% 8.1% 10.0% x2=-7 .717
-Life tim e psychosis 4% 7% 10% X2=1.5 .463
-Anxiety disorder 11.7% 56.8%! 20.0% X2=27.9 <.001
-panic disorder 5.2% 13.5% 2.5% X2=4.3 .118
-agoraophobia 3.9% 29.7%! 15.0% X2=15.0 .001
-social phobia 3.9% 21.6%! 7.5% X2=9.7 .008
-specific phobia 5.2% 10.8% 2.5% X2=2.5 .282
-generalized anxiety 2.6% 5.4% 2.5% X2=-7 .697
-hypochondriasis 0 0 0 NA NA
-obsessive compulsive disorder 0 2.7% 5.0% X2=3.6 .166
Use of substances 
-regular smoker 
-SSRI use
75.3%
9.1%
86.5%
5.4%
72.5%
2.5%
X2=2.5
X2=2.0
.290
.372
|=  Group th a t was significantly different in post-hoc test
Predictors o f relapse in  alcohol dependence
Figure 2 Kaplan-Meier survival curve for tim e un til relapse, w ith addiction
severity (median split) and co-morbid anxiety disorders as predictors
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a) Early relapse (i.e. w ithin 1-3 months after detoxification)
b) Late relapse (i.e. w ithin 3-12 months after detoxification)
Discussion
W ith a relapse rate of 53% w ith in  one year after trea tm en t and m orta lity  of 7%, 
th is  study confirm s the severe and chronic character of alcohol dependence. These 
findings are in  line w ith  literature , showing relapse rates of 20-80% w ith in  one to 
th ree  years after trea tm en t 9 36. Previous studies have reported m orta lity  rates 
betw een two and tw enty percent over one, up to sixteen years of follow-up, 
respectively 8 37, 38. These results em phasize the severity of alcohol dependence 
and indicate the relevance of identification  of predictors of the course after 
detoxification.
In line w ith  our hypothesis, co-morbid anxiety disorders were predictive of 
relapse during the detoxification phase (i.e. w ith in  the firs t th ree  m onths of 
admission) ra the r th a n  relapse after detoxification. Previous studies m easuring the 
effect of anxiety  disorders on the relapse risk have focused m ainly on relapse after 
in itia l successful recovery (i.e. 4-8 weeks of abstinence), showing mixed results. It 
may be particu larly  the early phase of detoxification, th a t is the most vulnerable 
w indow for relapse in  patients w ith  co-morbid anxiety disorders. Specifically 
agoraphobia and social phobia were more prevalent among the early relapsers. 
However, given the lim ited num ber of cases, the effect of anxiety disorders could 
not be separated in  the regression analysis.
Since early relapse is associated w ith  decreased long te rm  rem ission rates 27, 
alcohol dependent patients w ith  co-occurring anxiety disorders may need 
additional medical and psychological atten tion  when applying for detoxification, 
in  order to improve long-term outcome. An increase in  anxiety levels, particu larly  
during  the firs t th ree  weeks of alcohol detoxification has been well docum ented 
39-42. Alcohol dependent patients suffering from  anxiety  disorders may be 
particu larly  vulnerable for th is hyper-anxious state, and subsequently more prone 
to relapse during the detoxification phase 2-4, 16, 29. It has been suggested th a t the 
GABA system is involved in  th is hyper-anxiety during  alcohol w ithdraw al, and 
trea tm en t w ith  GABA-ergic m edication is recom m ended 39, 43, 44. On the o ther hand, 
trea tm en t of co-morbid anxiety disorders w ith  cognitive behavioral therapy 
reduced anxiety  symptoms, bu t did not improve outcome of alcohol trea tm en t 43. 
Pharm acological trea tm en t of anxiety symptoms during  detoxification of alcohol 
dependence may thus be particu larly  im portan t.
Addiction severity was associated w ith the risk of relapse w ith in  one year after 
treatm ent initiation. Several studies have shown different aspects of addiction severity 
to be predictive of relapse, like num ber of previous treatm ents, duration of excessive 
alcohol use and age at onset 8 45-47. We did not find a difference in  specific parameters 
of alcohol dependence between relapsers and abstainers. Clinical assessment of the 
severity of alcohol dependence, combining various aspects of the disorder into one 
composite score of addiction severity may be more useful in  this respect.
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Of the eight severity dom ains of alcohol dependence, only the score on legal 
problems differed betw een patients w ith  and w ithout relapse. Legal problems may 
specifically be associated w ith  a high relapse risk in  alcohol dependence, 
irrespective of the tim ing  of relapse. High levels of legal problems are often 
indicative of co-morbid antisocial personality  and disorders of im pulse control. An 
increased relapse risk in  patients w ith  legal problems, may be related to this 
co-morbidity ra ther th a n  to addiction severity.
In contrast w ith  our hypothesis, and w ith  previous studies in  ou tpatien t 
samples, novelty seeking was not related to relapse and h arm  avoidance was 
protective ra the r th a n  a risk factor for relapse 11 13, 48. In the litera tu re  negative 
findings on the relation  betw een the personality  tra it novelty seeking and relapse 
risk are often reported 11 12, 14, 15. Several explanations for absence of an association 
betw een novelty seeking and relapse have previously been suggested. An association 
betw een novelty seeking and relapse may be apparent only in  outpatients, in  
patients th a t rely on self help groups, or have less severe alcohol dependence, only 
in  m ale patients or patients at a younger age. Since we included inpatients, w ith  
severe alcohol dependence scores, w ith  an average age of 43 years, th is may explain 
the absence of an association between novelty seeking and relapse in  our sample.
In th is  study harm  avoidance appeared to be protective for relapse. Previous 
reports on the role of harm  avoidance in  relapse have shown either no relation  or 
identified harm  avoidance as a risk factor for relapse 11-15. In line w ith  the findings 
in  novelty seeking the trea tm en t setting  may m odulate the effect of the personality  
on the vu lnerability  to relapse after treatm ent. The only study th a t reported harm  
avoidance to be a risk factor studied an ou tpa tien t sample th a t relied on self help 
groups 11. Harm  avoidant individuals were shown to abandon such groups or not to 
attend at all 11. In an inpa tien t population avoidance of high risk environm ents 
outside the  clinic may be protective ra the r th a n  increasing the risk of relapse.
Some lim itations of the cu rren t study have to be taken into account. In the 
cu rren t study only males participants were included. This reduces generalizability  
of the findings, particu larly  since differences between males and females w ith  
respect to predictors of relapse have previously been suggested 49. It rem ains to be 
investigated if  the cu rren t findings can be generalized to females.
Second, we used a ra the r stric t defin ition  of relapse, of daily use of either at 
least 5 alcohol contain ing beverages. In the litera tu re  d ifferent definitions of 
relapse have been used 50. It has been shown th a t a stric t defin ition  of relapse, th a t 
includes heavy drinking, is more predictive of functional outcome th a n  a loose 
defin ition  th a t includes relapse into any drink . It is unlikely  th a t our results have 
been flawed by using th is stric t defin ition  of relapse, since relapse rates are 
com parable to literature . However, the defin ition  of relapse may influence the 
180 predictive value of individual predictor factors. The cu rren t findings therefore
need replication in  other independent samples, using o ther definitions of relapse.
Third, w ith in  the natu ra listic  design of th is study the participants received 
d ifferent treatm ents after in itia l detoxification. Type and duration  of trea tm en t 
may have influenced the course of alcohol dependence and therefore may confound 
our findings. Yet, since trea tm en t m odalities were individually m atched, it was 
impossible to correct for trea tm en t in  the analysis. Future studies applying 
standardized trea tm en t m odalities may overcome th is issue 51.
Finally, the assessment of anxiety disorders in  the cu rren t study was made 
using a structu red  screening interview  for psychiatric disorders (MINI) after 1 
m onth  of controlled abstinence. It can be argued th a t using more com prehensive 
diagnostic tools would improve diagnostic reliability. However, several studies 
have shown th a t the MINI, when adm inistered  a trained  interview er, can be used 
to reliably assess DSM-IV axis 1 disorders 31, 52"54. Though assessment of axis 1 
disorders, including anxiety disorders, in  alcohol dependent patients has been 
recom m ended to be perform ed after at least one m onth  of abstinence, and the 
prevalence of co-morbid anxiety  disorders is com parable to the literature , any 
effect of prolonged w ithdraw al or intoxication on the assessment of axis 1 disorders 
cannot be ru led  out completely 3-5, 29, 29, 55"58. However, even if  p a rt of the co-morbid 
anxiety disorders rem it after prolonged abstinence, the im portance of h igh levels 
of anxiety in  p redicting  early relapse rem ains an im portan t finding for clinical 
practice.
Conclusions
Alcohol dependence is a severe m ental disorder, w ith  high relapse rates and 
high m ortality. Prediction of the course of alcohol dependence after trea tm en t is 
therefore of major clinical im portance. Anxiety disorders were indicative of early 
relapse after detoxification. It is im portan t to identify  th is group of patients when 
applying for detoxification and provide them  w ith  appropriate m edical and 
psychological treatm ent. Addiction severity, particu larly  severity of legal problems 
and low h arm  avoidance are o ther predictors of relapse during  in itia l recovery (i.e. 
after the firs t th ree  m onths of abstinence), th a t may be taken into account in  
trea tm en t planning.
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Abstract
Background
Hyper-reactivity and im paired sensory gating of the acoustic startle  response 
in  alcohol dependence has been suggested to reflect a residual effect of previous 
detoxifications, increasing the severity of subsequent w ithdraw al episodes. 
Previous studies on the acoustic startle  only included early-onset alcohol dependent 
patients. The observed abnorm alities may therefore also be specific for this 
sub-type of alcohol dependence.
We investigated the acoustic startle  response in  alcohol dependent patients 
and healthy controls and hypothesized th a t 1) early-onset alcohol dependent 
patients show increased acoustic startle  responses com pared to late-onset alcohol 
dependent patients and healthy  controls, and 2) the duration  of alcohol dependence 
or the num ber of prior detoxifications would not explain the differences in  the 
acoustic startle  between early and late-onset alcohol dependence.
Methods
The acoustic s ta rtle  reflex was assessed in  detoxified, m ale alcohol dependent 
patients (N=83) and age m atched healthy m ale controls (N=86). Reflex eye blink 
responses to an auditory startle  stim ulus were m easured by means of EMG 
recordings over the righ t orbicularis oculi muscle. Reflex am plitudes and levels of 
prepulse inh ib ition  (PPI) were analyzed.
Results
There was no association betw een num ber of previous w ithdraw als and the 
s ta rtle  response or PPI. Early-onset alcohol dependent patients showed higher 
acoustic startle  am plitudes com pared to late-onset alcohol dependent patients and 
healthy  controls (75/105 dB: F(2,166)=9.2, p<.001; 85/105 dB: F(2,166)=12.1, p<.001; 95 
dB: F(2,166)=8.2, p<.001; 105 dB: F(2,166)=9.7, p<.001), there were no differences in 
PPI.
Conclusions
Increased acoustic startle  response in  detoxified early-onset alcohol dependent 
patients may reflect a tra it m arker specifically involved in  early-onset alcohol 
dependence. The findings of the cu rren t study do not support the hypothesis th a t 
the increased startle  response is a residual state marker.
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Introduction
A num ber of clinical and experim ental studies suggest th a t previous experience 
of w ithdraw al from  alcohol increases the severity of subsequent w ithdraw al 
episodes. For example, patients who undergo alcohol detoxification are more likely 
to experience seizures and subsequently delirium  trem ens, if  they have undergone 
previous episodes of detoxification 1-4. The proposed underlying m echanism  is th a t 
repeated w ithdraw al from  alcohol results in  a sensitization of the brain, sim ilar to 
th a t occurring  during  epileptic k ind ling  5 6.
The possibility of a k indling  effect of alcohol detoxifications, was fu rth e r 
corroborated by the findings of Krystal e t al who found the num ber of episodes of 
ethanol w ithdraw al to be an im portan t factor increasing neuronal excitability, as 
indexed by an increased acoustic startle  response. However, the  study by Krystal 
et al. could not d istinguish  w hether increased startle  am plitudes reflected a 
predisposition to alcohol dependence (trait marker), an indicator of sub-acute 
ethanol w ithdraw al (state marker), or the cum ulative neurotoxicity  associated 
w ith  excessive alcohol use or prior detoxifications (residual marker). Yet, it has 
been suggested th a t the increased startle  response reflects a hyper-excitatory state, 
related to neurotoxic effects of prior detoxifications, since increased startle amplitudes 
were particu larly  observed in  those w ith  two or more prior detoxifications 7.
The acoustic startle  response refers to a sta rtling  reflex in  reaction to a sudden 
acoustic stim ulus, e.g a noise burst, and can be observed in  bo th  anim als and 
hum ans 8. In hum ans it is com monly assessed quantitatively  by means of e lectro­
myographic recording of the eye b link  response to a sudden noise. The startle 
response may also be used to m easure “sensorim otor gating”. Sensorimotor gating 
refers to the ability to filter out irrelevant stim uli and is typically studied 
m easuring prepulse inh ib ition  (PPI) of the acoustic startle  reflex. PPI refers to the 
decrease in  response to a s ta rtling  stim ulus w hen preceded by a stim ulus of lower 
in tensity  (the “prepulse”)9. Deficits in  sensorim otor gating are though t to contribute 
to disturbances of thought and perception 10. A previous p relim inary  study strongly 
suggested th a t there is a deficit in  sensory gating in  alcohol-dependent patients 
undergoing alcohol w ithdraw al. This was most apparent in  those w ith  a h istory  of 
delirium  trem ens (Keedwell et al 2001).
The assessment of the acoustic startle  response has been used to study 
sensorim otor gating and hyper-arousal in  various neuropsychiatric disorders. 
Sensorimotor gating deficits have been observed in  several neuropsychiatric 
disorders, including schizophrenia, bipolar disorder, Tourette syndrome and 
H unting ton’s disease (see Braff 2001 for review8). All of these disorders are known 
to be related to increased mesolimbic DA function ing  11-13. In addition, infusion of 
DA-agonists, particu larly  in  the nucleus accum bens (NAc), has been shown to 
d isrup t PPI in  anim als and hum ans 14-19. Yet, also other neuro transm itte rs are
c
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though t to play a role in  sensorim otor gating, since adm inistra tion  of psilocybin, 
MDMA (ecstasy), and ketam ine have all been shown to affect sensorim otor gating 
and sensorim otor gating deficits have been observed in  patients w ith  posttraum atic 
stress disorder or obsessive compulsive disorder (see Braff 2001 for review8).
Hyper-arousal, reflected in  an increased acoustic startle  response, has 
predom inantly  been shown in  patients w ith  posttraum atic stress disorder and to a 
lesser ex ten t in  o ther anxiety disorders 8 20"22. Both noradrenergic and serotonergic 
m echanism s have been though t to be involved in  hyper-arousal in  anxiety 
disorders. Indeed, adm in istra tion  of noradrenergic agents increases the acoustic 
s ta rtle  response in  bo th  anim als and hum ans 7 23 25. In addition, adm inistra tion  of 
serotonin (5-HT) also affects the acoustic sta rtle  response in  anim als, w ith  either 
an increases or decrease, depending on the site of injection 26"31. In hum ans no 
consistent effects of serotonergic agents on the acoustic startle have been observed 7.
As stated above, it has been suggested th a t in  alcohol dependence increased 
s ta rtle  responses reflect a hyper-excitatory state, related to neurotoxic effects of 
prior detoxifications (residual m arker)7. Increased acoustic startle  responses have 
indeed been shown in  alcohol dependent patients during  acute w ithdraw al and in  
early onset alcohol dependent patients after protracted w ithdraw al 32 7. Several 
issues regarding these previous studies on the acoustic startle  in  alcohol dependence 
have to be taken into account.
First, bo th  studies had a small sample size7, 32. The findings of Krystal et al. 
(N=22) and Keedwell et al. (N=8) therefore need confirm ation in  substantially  large 
samples. Second, alcohol dependent patients included in  the study of Krystal et al. 
were exclusively early-onset patients (i.e. onset of alcohol dependence before 25 
years) 33. Early onset alcohol dependence is associated w ith  a h igher heritab ility  of 
alcohol dependence, impulsive personality  traits and increased severity of alcohol 
dependence 34 35 36 37-39.
It is unknow n if  increased acoustic startle  responses are also present in  late 
onset alcohol dependent patients. If increased startle  reflexes would be a residual 
m arker (related to prior detoxifications or excessive alcohol intake) a difference 
betw een early and late onset alcohol dependence is likely, since by defin ition  early 
onset patients have increased duration  of alcohol dependence, when m atched for 
age, and probably also have an increased num ber of prior detoxifications. Any 
difference betw een early and late onset patients would th en  be explained by the 
either the num ber of prior detoxifications, or param eters of excessive alcohol 
intake, e.g. the duration  of alcohol dependence.
Yet, two alternative options should be considered. First, if  the observed 
increased acoustic sta rtle  reflex in  early onset alcohol dependent patients is a 
general feature of protracted w ithdraw al (state marker), increased startle  responses 
190 should be equally observed in  bo th  early and late onset alcohol dependent patients.
Second, there is reason to assume th a t early and late onset alcohol dependent
patients differ on the acoustic startle  reflex, as a tra it difference. Early onset 
alcohol dependent patients have been shown to have reduced serotonin (5HT) and 
dopam ine (DA) function ing  com pared to late onset alcohol dependent patients, 
irrespective of w ithdraw al or the num ber of prior detoxifications40-49. Since 
heritab ility  is higher in  early onset alcohol dependent patients, alterations in  DA or 
5HT function ing  in  early onset alcohol dependent patients, may be related to tra it 
differences, of genetic orig in  34, 36, 38, 39. Increased startle  am plitudes specifically in 
the sub-group of early onset alcohol dependent patients, may thus also represent a 
stable tra it m arker.
The cu rren t study investigated the acoustic startle  response and PPI in  early- 
and late-onset alcohol dependent patients com pared to healthy  controls. In line 
w ith  the prem ise th a t increased acoustic sta rtle  responsivity could be a tra it 
m arker for early onset alcohol dependence we hypothesized th a t after in itia l 
detoxification 1) the acoustic startle  response would be increased in  early-onset 
alcohol dependent patients, bu t not in  late onset alcohol dependent patients, when 
com pared to healthy  controls (suggesting a tra it or residual marker); and 2) the 
duration  of alcohol dependence and the num ber of prior detoxifications would not 
explain the difference in  the acoustic startle  m agnitude betw een early and late 
onset alcohol dependence (suggesting a tra it, ra ther th an  a residual marker).
Materials and methods
Population
Male alcohol dependent patients (according to DSM-IV) applying for inpatien t 
detoxification were recruited  at Novadic-Kentron Centre for Addiction Care (N=83). 
To exclude a confounding effect of psychiatric co-morbidity patients w ith  a history 
of psychosis or bipolar disorder were excluded, as well as patients w ith  severe 
depression or Korsakoff’s syndrome. Participants were also excluded in  case of any 
m edical condition th a t required  acute treatm ent. Healthy m ale controls w ith  no 
h istory  of substance abuse were found by advertisem ents in  regional newspapers 
(N=86). The study was approved by the regional m edical eth ical board (METiGG, 
protocol 271, P04.0388L).
M edication was allowed, except for sedatives, agents w ith  dopam inergic 
activity, e.g. m ethylphenidate, or antipsychotics, or any other m edication when 
changed during  th ree  m onths prior to the study (see Table 1). Tests were perform ed 
after one m onth  of controlled abstinence and after at least one week w ithout ben­
zodiazepines. In order to avoid acute effects of n icotine and caffeine, participants 
were not allowed to smoke or use caffeine contain ing drinks on study days.
After w ritten  inform ed consent, subjects were screened for axis I psychiatric 
disorders using the Dutch version of the Mini in te rnational Neuropsychiatric
c
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Interview  for psychiatric disorders version 2.1 and the Dutch version of the ADHD 
rating  scale (see Table 1)50-52. To assess socio-demographic characteristics and 
inform ation on drug and alcohol use (including addiction history, severity 
param eters, and the fam ily history  on alcohol and drug abuse) we used the Dutch 
version of the Addiction Severity Index (EuropASI) 53, 54. Early onset alcohol 
dependence was defined as the beginning of alcohol dependence before the age of 
25 years 37, 55. The num ber of prior detoxifications was defined as the to ta l num ber 
of prior detoxifications, bo th  inpa tien t and ou tpatient, or any other unguided 
attem pt to qu it d rink ing  for more th a n  one week, as obtained from  the EuropASI.
Methods
Reflex eye blink  responses were m easured as electrom yographic activity over 
the righ t orbicularis oculi muscle, w ith  a sam pling frequency of 1,000 Hz56. 
Background sound consisted of 70dB noise, w ith  w hite noise pulse-alone tria ls of 
95dB and 105dB and prepulse tria ls of either 75 or 85dB bursts preceding 105dB 
pulses. Noise bursts had an in stan t rise tim e. Pulse duration  was 20 ms for prepulses 
and 40 ms for startle  pulses. Interstim ulus in terval was 100 ms, in te rtria l intervals 
ranged between 8-12 s randomly. Each PPI m easurem ent started w ith  15 habituation 
tria ls (105 dB PA trials), followed by 12 tria ls of each type (95dB, 105 dB, 85/105 dB, 
75/105 dB) in  a pseudo-random  order.
Data cleaning was perform ed off-line w ith  MIDAC software (test organizer-MI- 
DAC polygraphy module, Instrum entation  Service, UMC St Radboud, Nijmegen, The 
Netherlands), w ith  a response w indow from  20-150 ms after stim ulus onset. Startle 
responses w ith  an inconstan t baseline 20 ms before the stim ulus, w ith  a response 
to the prepulse, or tria ls in  w hich no startle  response was detected were excluded 
from  fu rth e r  calculations.
The average am plitude of startle  responses was calculated for each tr ia l type 
(95 dB, 105 dB, 75/105 dB and 85/105 dB). Percentage PPI was calculated for 75/105 
dB and 85/105 dB trials, per startle  session, as follows: (amplitude 105dB - am plitude 
prepulse trial) / (amplitude 105dB) * 100%. Absolute PPI was calculated for 75/105 dB 
and 85/105 dB tria ls as (amplitude 105dB - am plitude prepulse trial).
Data analysis
Data analysis was perform ed using Statistical Package for the Social Sciences 
(SPSS) for Windows, 16th edition. Demographic differences betw een groups were 
tested using analysis of variance for continuous variables and chi-square tests for 
dichotom ous variables.
To analyze differences in  param eters of the acoustic startle  response (startle 
am plitude and PPI; for startle  latency, see supplem entary table 2) between groups 
192 we used m ultivariate analysis of variance (ANOVA), w ith  s ta rtle  am plitude and PPI
for each tr ia l type as dependent variables and group (early or late onset alcohol
dependence, or healthy  control) as independent variables. For the PPI difference 
score we corrected for the sta rtle  response am plitude on the 105dB stand alone 
trials, by adding am plitude to 105dB tria ls as a covariate. Since the Levene’s test 
showed a significant violation of the assum ption of hom ogeneity of variance, the 
Brown-Forsythe F-ratio is presented. The firs t fifteen  hab ituation  tria ls were 
analyzed separately in  a repeated m easures ANOVA, w ith  tim e as a w ith in  subject 
factor, and group as a between subject factor.
In order to analyze the effect of the num ber of prior detoxifications and the 
duration  of alcohol dependence on the param eters of the startle  reflex (amplitude 
and PPI level), these variables were added as a covariates in  the m ultivariate 
analysis. In addition we perform ed correlation analysis to explore any relation 
between the num ber of prior detoxifications and the duration of alcohol dependence 
on the param eters of the startle  reflex.
Results
Demography and sample characteristics
Demographic variables are displayed in  Table 1. Alcohol dependent patients 
were more often hab itual smokers and had a lower level of education com pared to 
healthy controls (%2(2)=9.3, p=.010, %2(8)=31.3, p<.001). Alcohol dependence parameters 
are displayed in  Table 2. Early onset alcohol dependent patients had a lower age of 
onset, longer duration  of the alcohol dependence, more d rink ing  days per m onth, 
and more often had a history  of stim ulan t m isuse w ith  a h igher severity score on 
the drug use dom ain, com pared to late-onset alcohol dependent patients 
(F(1,80)=232.9, p<.001; F(1,80)=28.4, p<.001; F(1,80)=9.9, p<.002; c2(1)=4.3, p=.045; 
F(1,80)=7.6, p=.007, respectively). Early onset alcohol dependent patients had a 
h igher density of fam ily history  on substance abuse, as com pared to late onset 
alcohol dependent patients (c2(1)=14.3, p=.001).
Acoustic Startle
Results are displayed in  table 3 and graph 1. S tartle am plitudes were increased 
in  early-onset AD patients (75/105 dB: F(2,90.6)=11.2, p<.001; 85/105 dB: F(2,83,3)=13.4, 
p<.001; 95 dB: F(2,72.8)=9.2, p<.001; 105 dB: F(2,96.5)=11.8, p<.001). There were no 
differences in  latency tim es between groups (F(4,160)=1.8, p=.075, see supplem entary 
Table 1).
Specific contrast analysis showed a significant difference in  startle  am plitudes 
betw een the early-onset and the control group (75/105 dB: p<.001; 85/105 dB: p<.001; 
95 dB: p<.001; 105 dB: p<.001), and early onset and late onset (75/105 dB: p=.008; 
85/105 dB: p=.014; 95 dB: p=.026; 105 dB: p=.006), b u t no difference betw een controls 
and late-onset AD patients.
c
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Table 1 Description of demographic variables and regular use of other drugs
Control
(N=86) 
Mean (SD)
Early- 
onset 
(N=61) 
Mean (SD)
Late- 
onset 
(N=22) 
Mean (SD)
Statistic
(df)
P-
value
Age (years) 40 (11.4) 40 (10.1) 42 (7.1) F(2,163)=0.5 .604
Education level (%)
-no certificate 
-primary/secondary 
school
0%
4%
3%
16%
5%
14%
C2(8)=31.3 <.001
-low vocational education 37% 62% 41%
-high vocational 
education 
-university level
39%
20%
14%
5%
35%
5%
Medication use (%) 
-use of SSRI NA 12% 14% C2(1)=.1 .720
Habitual substance use (%) 
-habitual smoking 
-habitual caffeine use
48%
88%
67%
93%
77%
91%
C2(2)=9.3
C2(2)=5.9
.010
.584
There were no difference in  prepulse inh ib ition  levels betw een groups 
(F(8,328)=1.9, p=.059). However, absolute PPI levels on 75/105dB tria ls were increased 
in  early onset alcohol dependent patients (F(2,166)=4.2, p=.017). This difference 
disappeared when we corrected for sta rtle  am plitude on the 105dB stand alone 
tria ls (F(2,165)=.0, p=.993).
Analysis of the habituation trials shows decreasing startle amplitudes over the 
first 15 trials (105dB pulse alone) in  the th ree groups (effect of time: F(13, 153)=5.3, 
p<.001). In addition the re  is a m ain  effect of group on the startle  am plitude during 
the firs t 15 hab ituation  trials (F(2, 165)=8.1, p<.001), w ithout an in teraction  effect 
betw een tim e and group F(26, 153)=.6, p=.964), indicating  increased startle 
am plitudes in  early onset alcohol dependent patients during  the habituation 
period.
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Table 2 Description of characteristics of alcohol dependence and co-morbid 
psychiatric disorders
CU(A=0Inrtw V(An0irt-J Statistic P-
(N=61) (N=22) (df) value
Mean (SD) Mean (SD)
Alcohol use disorder
-age of onset 18 (3.3) 36 (6.5) F(1,80)=232.9 <.001
-duration in  years 20 (9.6) 8 (5.6) F(1,80)=28.4 <.001
-number of prior detoxifications .8 (1.7) 0.6 (1.0) F(1,80)=.5 .498
-number of prior alcohol deliriums .4(1.1) 1.5 (4.4) F(1,80)=2.8 .097
-number of using days per m onth 23.5 (9.3) 17.7 (11.5) F(1,80)=9.9 .002
Co-morbid disorders (%)
-anxiety disorder 12% 18% C2(1)=.6 .471
-major depression 31% 27% C2(1)=.1 .793
-obsessive compulsive disorder 2% 5% c2(1)=.6 .462
-ADHD 10% 5% C2(1)=.6 .669
History of substance misuse
-hallucinogens 15% 9% C2(1)=. 5 .719
-cannabis 57% 36% C2(1)=2.7 .136
-heroin 12% 0% C2(1)=2.9 .181
-stimulants 48% 23% C2(1)=4.3 .045
Family history of substance use
disorder
-none 32% 32% C2(1)=14.3 .001
-1 family member 13% 50%
->1 family members 54% 18%
Severity of addiction related
problems: 2.6 (2.0) 2.5 (2.3) F(1,80)=.1 .790
-Physical domain 4.1 (1.8) 3.2 (2.0) F(1,80)=3.9 .052
-Work and income domain 6.4 (.09) 6.1 (1.0) F(1,80)=1.2 .273
-Alcohol use domain 2.1 (2.6) .6 (1.1) F(1,80)=7.6 .007
-Drug use domain 1.8 (1.8) 1.1 (1.7) F(1,80)=2.6 .108
-Legal domain 4.4 (1.7) 4.1 (1.7) F(1,80)=.2 .644
-Social domain 5.2 (1.7) 4.9 (1.8) F(1,80)=.4 .522
-Emotional domain .3 (1.1) .8 (1.5) F(1,80)=2.8 .096
-Gambling domain
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Table 3 Acoustic startle  response for alcohol dependent patients (early and 
late onset) and healthy controls
Control
Mean (SD) 
(N=86)
Early- 
Onset 
Mean (SD) 
(N=61)
Late- 
Onset 
Mean (SD) 
(N=22)
F statistic  
(df)
P-
value
Startle amplitude (|jVolt) 
-75/105 dB trials 328.3
(182.2)
488.8
(359.2)
354.8
(1357)
7.2 (2, 166) 0.001
-85/105 dB trials 286.5
(115.4)
447.9
(322.1)
331.0 (92.8) 6)6.30. <0.001
-95 dB trials 257.9 (73.6) 364.8
(259.4)
296.9
(109.2)
7.1 (2, 166) 0.001
-105 dB trials 374.9
(241.9)
610.3
(467.9)
409.0
(200.8)
9.0 (2, 166) <0.001
Prepulse inhibition 
-percentage 75/105 dB 6.7 (17.1) 11.6 (26.6) 7.9 (24.4) .9 (2, 166) 0.397
-percentage 85/105 dB 13.6 (22.4) 12.4 (44.7) 12.8 (34.5) .0 (2, 166) 0.976
-difference 75/105 dB 46.6 (129.6) 121.5
(202.3)
54.2 (116.3) 4.2 (2, 166) 0.017
-difference 85/105 dB 88.4 (170.4) 162.4
(335.9)
78.0 (210.9) 1.9 (2, 166) 0.159
Effects o f detoxifications, and the use o f alcohol and drugs on 
sensorim otor gating
The num ber of prior detoxifications and the duration  of alcohol dependence 
were not related to any of the param eters of the acoustic startle  response (prior de­
toxifications: 75/105 dB: F(2,166)=2.0, p=.156; 85/105 dB: F(2,166)=1.1, p=.296; 95 dB: 
F(2,166)=.3, p=.572; 105 dB: F(2,166)=1.2, p=.280; duration  of dependence: 75/105 dB: 
F(2,166)=1.4, p=.245; 85/105 dB: F(2,166)=.0, p=.998; 95 dB: F(2,166)=.3, p=.578; 105 
dB: F(2,166)=2.7, p=.102). W hen these variables were added in  the analysis as 
covariates, the m ain  effect of group did not alter substantially  (75/105 dB: 
F(2,166)=6.7, p=.012; 85/105 dB: F(2,166)=2.9, p=.095; 95 dB: F(2,166)=1.3, p=.253; 105 
dB: F(2,166)=8.6, p=.005). Since early-onset alcohol dependent patients more often 
had a history  of stim ulan t abuse, w ith  a h igher severity score on the drug use 
dom ain and had a h igher num ber of d rink ing  days per m onth  these variables were 
added as a co-variates. None of these variables was related the acoustic startle  
196 am plitude (history of stim ulan t abuse: F(4,152)=.2, p=.937; severity on drug use
dom ain: F(4,152)=.9 p=.454; num ber of d rink ing  days per m onth: F(4,152)=.1, p=.980).
Supplem entary Table 1
Latency of the acoustic sta rtle  per tr ia l type by group (early and late onset 
alcohol dependent patients and healthy controls)
Control 
(N=86) 
Mean (SD)
Early-onset 
(N=61) 
Mean (SD)
Late-onset 
(N=22) 
Mean (SD)
Statistic
(df)
P-
value
Latency tim e (msec) 
-75/105dB trials 50.3 (12.9) 44.2 (14.8) 49.8 (21.6) F(2,166)=3.4 .027
-85/105dB trials 54.5 (15.0) 45.5 (15.4) 52.6 (17.1) F(2,166)=6.1 .003
-95dB trials 56.8 (16.0) 54.7 (27.5) 52.2 (19.8) F(2,166)=0.5 .619
-105dB trials 53.4 (23.9) 49.6 (19.8) 53.4 (23.9) F(2,166)=0.7 .503
■[i
Supplem entary Table 2
Correlation betw een the num ber of prior detoxifications and the duration  
of alcohol dependence w ith  acoustic startle  response param eters in  alcohol 
dependent patients (early and late onset)
Num ber of p rio r 
detoxifications 
C orrelation 
coefficient
P-
value
D uration of alcohol 
dependence 
C orrelation 
coefficient
P-
value
Startle amplitude 
-75/105 dB trials -.13 .247 .01 .927
-85/105 dB trials -.10 .395 .10 .351
-95 dB trials -.05 .684 .14 .197
-105 dB trials -.09 .422 -.03 .810
Prepulse inhibition 
-percentage 75/105 dB .11 .329 .02 .847
-percentage 85/105 dB .03 .771 -.15 .167
-difference 75/105 dB -.02 .851 .00 .994
-difference 85/105 dB -.02 .558 -.13 .253
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Only the severity score on the drug use dom ain showed a non significant trend  
of association w ith  PPI (history of stim ulan t abuse: F(4,152)=.1, p=.987; severity on 
drug use domain: F(4,152)=3.1, p=.053; num ber of d rink ing  days per month: 
F(4,152)=.3, p=.777, respectively).
Correlation analysis showed th a t the num ber of prior detoxifications, neither 
the duration  of alcohol dependence correlated w ith  any of the acoustic startle 
measures (with R<.15, see supplem entary Table 2).
Figure 1 Startle am plitude by group (early onset, late onset alcohol dependent 
patients and healthy controls) and by startle m odality (prepulse trials: 
75/105dB and 85/105dB; stand alone trials: 95dB and 105dB)
**= p<.001
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Discussion
To the best of our knowledge, th is  is the firs t report to show a difference in 
sta rtle  response betw een early and late onset alcohol dependent patients, during 
protracted  w ithdraw al. In line w ith  our f irs t hypothesis early-onset alcohol-de­
pendent patients showed an increased acoustic sta rtle  reflex when com pared to 
late-onset alcohol-dependent patients and healthy controls. These findings are in  
line w ith  a previous repo rt on an increased startle  response in  early onset alcohol 
dependent patients com pared to healthy  controls 7 and w ith  findings of increased 
sta rtle  reactivity  in  alcohol preferring ra ts57. The observed difference between 
early and late onset alcohol dependent patients however, suggests th a t is in  not a 
general feature of alcohol dependence or detoxification (state marker), bu t possibly 
reflects a difference betw een subgroups of patients.
In line w ith  the second hypothesis, the difference betw een early and late onset 
alcohol dependent patients could not be explained by a difference in  the duration  
of the disorder, or the num ber of previous detoxifications (residual marker). F urther 
analysis showed no relation betw een the num ber of prior detoxifications or 
duration  of alcohol dependence and the acoustic sta rtle  response. The observed 
difference in  startle  response between early and late onset alcohol dependence may 
thus indicate a stable neurobiological difference betw een these two subgroups of 
patients (trait marker). This is in  line w ith  previous indications of a genetic 
relationship betw een greater baseline acoustic startle  responses and high alcohol 
preference in  mice, based on observations of increased startle  am plitudes in  mouse 
lines specifically bred for high alcohol preference, prior to exposure to alcohol.
There was no difference between groups in  levels of prepulse inhibition . The 
observed increase in  absolute PPI in  early-onset AD patients was completely 
abolished, w hen we corrected for the am plitude on 105dB stand alone trials. This 
indicates th a t the s ta rtle  am plitude was equally increased for all tr ia l types, w ith  
or w ithout a prepulse. The increased acoustic startle  response in  early onset alcohol 
dependent patients is likely to reflect hyper-arousal, ra ther th a n  a sensorim otor 
deficit, possibly reflecting  a difference at the neurobiological level. Since both  
adm inistra tion  of noradrenergic and serotonergic agents have been shown to affect 
the acoustic startle  response in  anim als and hum ans, these neuro transm itters may 
be involved in  the observed differences between early and late onset alcohol 
dependent patients. Indeed, early-onset alcohol dependent patients have been 
shown to have reduced 5HT functioning, com pared to late-onset alcohol dependent 
patients.
Hyper-arousal, indexed by increased startle  reactivity, could represent hyper­
excitability of the nervous system as a stable tra it m arker or an indicator of 
prolonged detoxification in  early onset alcohol dependence. As alcohol consum ption 
leads to a decrease in  acoustic startle  reflex in  bo th  hum an and anim al models, one
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could theorize th a t the early onset alcohol dependent patients d rink  to dam pen 
th is hyper-excitability of the nervous system 58, 59. Hyper-excitability of the nervous 
system may thus be either a pre-morbid vulnerability  factor, or a contributing 
factor in  the high propensity to relapse in  early alcohol dependent patients.
In line w ith  the literature , early onset alcohol dependent patients showed a 
h igher density of fam ily history  on substance abuse, com pared to late onset alcohol 
dependent patients. This finding is particu larly  im portan t, since several studies 
have shown th a t bo th  a positive fam ily history  as well as an early of onset of alcohol 
dependence increase the role of genetic factors. The findings of increased fam ily 
history  in  early onset alcohol dependent patients, th a t also have increased startle 
reactivity, provides fu rth e r support for our hypothesis th a t in  early onset alcohol 
dependent patients increased s ta rtle  response may be an indicator of a neurobio- 
logical, heritable tra it. Moreover, there is ample evidence th a t abnorm alities in  
electrophysiological measures are specifically observed in  alcohol dependent 
patients w ith  either a positive fam ily history  of alcohol dependence, or an early 
onset of alcohol dependence. Some studies show th a t non-alcoholic fam ily members 
of alcohol dependent patients also show such electrophysiological abnorm alities, 
providing fu rth e r evidence for the heritab ility  of neurophsyiological biomarkers.
A nother possible explanation is th a t in itia tion  of alcohol abuse in  an early 
stage of life, when the b rain  is not yet fully developed, could lead to dam age in  the 
structures involved in  the acoustic startle  reflex. Until the age of tw enty five the 
developm ent of the p refron tal and tem poral cortex and sub-cortical structures 
(such as the NAc) is still ongoing 60, 61. Since early onset alcohol dependence is 
defined as an age of onset before 25 years, it may well be th a t excessive alcohol use 
during  th is critical developm ental period leads to irreversible changes in  these 
b rain  structures. Since the PFC and sub-cortical structures are crucial for cognitive 
processing (e.g. inhibition) and sensorim otor gating, th is may contribute to the risk 
to become alcohol dependent and develop o ther im pulse control disorders 
com monly associated w ith  early onset alcohol dependence, such as antisocial 
personality  disorder62.
Several lim itations have to be taken  into account. Since only males were 
included, fu tu re  studies should investigate w hether these findings also hold for 
females. The same issue applies for patients w ith  a history  of psychosis. Since 
sensorim otor gating deficits have been observed in  patients w ith  schizophrenia, it 
may be possible th a t alcohol dependent patien t w ith  co-morbid psychotic disorders 
represent yet another sub-group of patients w ith  a d istinct acoustic startle  response.
In addition, anxiety disorders have been reported to increase the fear potentiated 
startle, but effects on startle responsivity w ithout affective probing is less consistent. 
Moreover, in  our sample there was no difference between early and late onset alcohol 
200 dependent patients, w ith respect to the prevalence of anxiety disorders. A confounding
effect of anxiety disorders on the curren t findings is therefore unlikely.
Despite bo th  groups were m easured after at least th ir ty  days of abstinence, w ith  at 
least five days w ithout benzodiazepines, and there were no differences in  disease 
characteristics betw een early and late onset patients (other th a n  duration  of illness 
and num ber of prior detoxifications), an effect of o ther differences in  the course of 
the disorder or detoxification cannot be completely ru led  out.
Another issue is th a t in  the cu rren t study no data on the duration  and severity 
of the detoxification were available and th a t the acoustic startle  response was 
m easured only after 1 m onth  of controlled abstinence. In order to ru le out an effect 
of detoxification, fu tu re  studies on the acoustic sta rtle  response in  alcohol 
dependence should include m easurem ents of the duration  and severity of 
detoxification and re-assess the acoustic startle  response after fu ll rem ission (i.e. 
>6 m onths of abstinence). Moreover, w hen analyzing the effect of previous detoxifi­
cations on startle  am plitude, short episodes of any cessation of alcohol use, resulting 
in  w ithdraw al symptoms (that can be very frequent) were not included. An effect of 
such short periods of w ithdraw al on m easures of b ra in  responsivity, as m easured 
by the acoustic startle, can therefore not be ru led  out completely.
Finally, in  the cu rren t paper no distinction  was made betw een heavy and light 
nicotine users. Though bo th  acute and w ithdraw al effects of nicotine use were 
m inim ized, by asking the participants not to smoke w ith in  two hours prior to the 
study, any confounding effect of an unequal d istribu tion  of the am ount of cigarettes 
consum ed over the populations under study, cannot be completely ru led  out.
In conclusion, th is is the firs t report on increased acoustic startle  response in  
early-onset alcohol dependent patients, com pared to late onset alcohol dependent 
patients and healthy controls. These findings indicate hyper-arousal in  this 
subgroup of alcohol dependent patients after protracted  w ithdraw al, possibly 
related to differences in  serotonergic or noradrenergic systems. Future studies 
should address w hether differences in  hyper-arousal reflect state or tra it dependent 
differences betw een early and late onset alcohol dependent patients.
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Summary and discussion
The overall aim  of th is  thesis is to explore neurobiological aspects of alcohol 
dependence by investigating gene environm ent in teraction  and various 
in term ediate phenotypes in  alcohol dependent patients. W ith in  the scope of this 
thesis I focused on 1) the lack of translational research th a t applies results from  
anim al studies into hum an situation, 2) the problems linked to the broad phenotype 
of substance dependence and 3) the relative neglect to study the influence of 
environm ental factors in  neurobiological studies. This resulted in  the following 
specific aims:
1. To test the translational in term ediate phenotype of apom orphine sensitivity for 
use in  hum ans (chapter 2).
2. To study in term ediate phenotypes th a t improve genetic association findings in 
alcohol dependence (chapter 3,4,5).
3. To study interaction between identified relevant alcohol genes and environm ental 
factors in  alcohol dependence (chapter 6).
4. To study alternative in term ediate phenotypes th a t help to delineate the broad 
phenotype of alcohol dependence (chapter 7, 8, 9).
Chapter 2:
One of the anim al models of addiction described in  the litera tu re  is the 
sensitivity to the dopam ine agonist apom orphine (APO). The pharm acological 
challenge w ith  APO induces m easurable changes on several outcome measures, 
such as increased stereotypes gnaw ing and alterations in  the acoustic startle 
response. Animals w ith  low sensitivity to the effects of APO self adm inister more 
alcohol com pared to APO sensitive anim als. In order to translate  th is  anim al model 
for addiction vu lnerability  to hum ans the firs t step was to find a way to apply 
analogous m ethodology in  hum ans. We were able to show th a t adm inistra tion  of 
APO to healthy  volunteers induces m easurable changes on the acoustic startle 
reflex, plasm a grow th horm one levels and cognitive perform ance. Moreover, in te r­
individual differences in  the sensitivity for the effects of APO were observed.
We conclude th a t the APO challenge can be used as a translational interm ediate 
phenotype. The m ethdodology of the larger scale research in  alcohol dependent 
patients was based on the results of the pilot study. It appeared th a t sub cutaneous 
adm inistra tion  of 0.005mg/kg was the optim al dosing schedule. Outcome m easures 
could best be assessed from  as early as 10 m inutes after adm inistra tion , un til 
approxim ately 60 m inutes after adm inistration .
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Chapter 3:
The next step was to test for differences in  the interm ediate phenotype of 
apom orphine sensitivity between alcohol dependent patients and healthy  controls. 
Chapter 3 is the firs t report on reduced sensitivity to the effects of apom orphine on 
cognitive perform ance in  alcohol dependent patients, com pared to a group of 
healthy  controls. The results show th a t APO sensitivity is lower in  alcohol dependent 
patients. This is in  line w ith  observations in  anim als, w here rats w ith  low sensitivity 
for the effects of APO self adm inister more alcohol. Moreover the results confirm  
previous research in  hum ans showing a reduced grow th horm one responses to 
APO in alcohol dependent patients in  com parison w ith  controls. Yet, it rem ained 
unclear w hat factors were related to apom orphine sensitivity in  bo th  the alcohol 
dependent sample as well as in  the healthy control group.
Chapter 4&5:
Sensitivity to APO in anim als is transm itted  over generations. This suggests a 
possible genetic m echanism . I continued w ith  testing  the role of genetic factors in 
APO sensitivity in  hum ans, f irs t in  healthy controls (chapter 4), next in  alcohol 
dependence (chapter 5). Several genetic variants involved in  dopam ine functioning 
have been described in  hum ans. In the cu rren t study th ree  genes w ith  com mon 
variants (polymorphisms) were selected based on previous studies, showing a 
relation  w ith  either substance dependence or dopam ine functioning. The following 
genotypes were tested: the gene encoding the enzym e Catechol-O-Methyltransfer- 
ase (COMT), the dopam ine D2 receptor (DRD2) and the dopam ine transpo rte r (DAT1). 
COMT is know n te affect dopam ine function ing  in  the p refron tal cortex, whereas 
DRD2 and DAT1 are more relevant for subcortical dopam ine functioning.
Chapter 4 shows the  effect of a polym orphism  of the gene encoding the COMT 
enzym e in  APO sensitivity in  healthy controls, using a task th a t requires prefrontal 
cortex function ing  (the AX-CPT). Since prefron tal dopam ine functioning is affected 
by the COMT genotytpe and AX-CPT task perform ance requires p refrontal dopam ine 
functioning, we hypothesized th a t the COMT genotype would affect sensitivity to 
the effects of APO on cognitive perform ance. Indeed, carriers of the low activity 
Met varian t (with a high dopam inergic tone in  the p refron tal cortex) showed 
increased sensitivity to the deleterious effect of APO on cognitive perform ance in  
healthy  controls. These results fit in  the proposed inverted-U relation  between 
p refron tal dopam ine functioning and cognitive perform ance. Performance may 
decrease in  carriers of the low activity Met varian t (with a h igh dopam inergic tone 
in  the prefrontal cortex), due to an overshoot in  p refron tal dopam ine stim ulation 
after APO adm inistra tion , whereas in  carriers of the h igh activity Val varian t (with 
low dopam inergic tone in  the p refron tal cortex) perform ance may improve due to 
210 im provem ent of sub-optim al dopam ine activity after adm in istra tion  of APO.
APO sensitivity can be m easured using d ifferent outcome m easures, as is shown in
chapter 2. The effects of APO on these d ifferent outcome m easures are hypothesized 
to reflect dopam ine sensitivity in  d ifferent b ra in  pathways. Genes involved at 
d ifferent levels in  the dopam ine pathway may be involved in  d ifferent m easures of 
APO sensitivity. We hypothesized th a t the COMT genotype would affect the effect of 
APO on task perform ance, i.e. p refron tal dopam ine sensitivity, and th a t the DRD2 
genotype would affect the grow th horm one response, i.e. subcorical dopam ine 
sensitiv ity.
In Chapter 5 we confirm  the observations on the COMT genotype described in  
chapter 4 in  alcohol dependent patients. Moreover, we also show th a t the DRD2 
genotype affects the grow th horm one response to APO. Thus, the COMT Val 
polym orphism  is related to a reduced cognitive response to APO and the  DRD2 
TaqlA polym orphism  is related to a reduced grow th horm one response. Though 
reductions in  APO sensitivity were observed in  alcohol dependent patients, the two 
genetic variants were not d irectly  associated w ith  alcohol dependence. This 
suggests th a t o ther factors may in teract w ith  genetically determ inde dopam ine 
sensitivity in  the risk to become alcohol dependent.
Chapter 6:
Finally we tested the previously identified genotypes (DRD2 and COMT) in  a gene 
environm ent in teraction  model. From the litera tu re  it is know n th a t dopam ine 
function ing  affects stress sensitivity. For example, carriers of the COMT Met 
genotype have an increased sensitivity to pain  and other aversive stim uli. In 
addition it is well know n th a t alcohol dependent patients repo rt high levels of 
exposure to adverse experiences during childhood. We hypothesized th a t variation 
in  dopam ine genes m odulates the relation betw een exposure to adversity 
experiences during  childhood and alcohol dependence.
Chapter 6 shows an in teraction  betw een exposure to adverse experiences during 
childhood and the DRD2 and COMT genotypes. Particularly, the COMT genotype 
m odulates the sensitivity for adverse experiences during childhood. Exposure to 
adversity experiences during  childhood increased the risk to become (more 
severely) alcohol dependent, particu larly  in  carriers of a Met genotype. These data 
confirm  the previously proposed w orrior-w arrior model in  w hich Met genotype 
carriers have a cognitive advantage, bu t are more vulnerable to stress (worriors) 
and Val genotype carriers are more impulsive and less sensitive to stress (warriors).
Chapter 7:
After the study of the translational in term ediate phenotype apom orphine 
sensitivity we studied several other po ten tia l in term ediate phenotypes th a t may 
help to delineate the broad phenotype of alcohol dependence. An im portan t issue 
to take into consideration is th a t alcohol dependence is often associated w ith  
psychiatric co-morbidity. Taking psychiatric co-morbidity into account, the group
211
G
en
er
al
 d
is
cu
ss
io
n
212
of alcohol dependent patients appears to be a very heterogeneous group of patients. 
Both in te rnaliz ing  m ental disorders, like anxiety and depression, and ex ternalizing 
disorders, such as ADHD and antisocial personality  disorder are com mon among 
alcohol dependent patients. Psychiatric co-morbidity may be related to the patho­
physiology underlying the alcohol use disorder.
An example is the processing of errors by the brain. Patients w ith impulse control 
disorders, such as ADHD, show reduced error related brain activity, whereas error 
related brain activity is increased in  patients w ith anxiety disorders. Previously it has 
been shown tha t in  substance dependence error related brain activity is reduced. 
However, these studies did not take psychiatric co-morbidity into account.
In Chapter 7 we tested the error related brain  activity in  alcohol dependent 
patients, in  relation  to psychiatric co-morbnidity. We hypothesized th a t alcohol 
dependent patients w ith  co-morbid im pulse control disorders would show reduced 
error related b rain  activity, and th a t in  patients w ith  co-morbid anxiety  disorders 
error related brain  activity would be increased. It is shown th a t error related brain  
activity is increased in  alcohol dependent patients w ith  co-morbid anxiety 
disorders. Excessive alcohol use in  th is sub-group of alcohol dependent patients 
may be a way to dam pen these exaggerated brain  responses to m istakes.
Chapter 8:
In chapter 8 we studied the effect of co-morbid anxiety  disorders on the course 
of alcohol dependence after detoxification. We show th a t alcohol dependent 
patients w ith  co-morbid anxiety disorders have an increased risk for relapse during 
the firs t th ree  m onths after detoxification. Anxiety disorders in  alcohol dependent 
patients thus indicate a group w ith  increased error related b rain  activity and worse 
prognosis, th a t may have a d istinct genetic profile, and may require specific 
trea tm en t strategies.
Chapter 9:
The acoustic startle  response is a m easure of excitability of the brain. Previous 
studies have shown an increased startle  response in  alcohol dependent patients 
after detoxification, com pared to healthy  controls. However, th is study included 
only early onset alcohol dependent patients. Though the authors suggest th a t an 
increased startle  response is a com mon feature in  alcohol dependence after 
detoxification, the increased sta rtle  response may also be related to a specific 
subtype of alcohol dependence, i.e. early onset alcohol dependence.
We show th a t the acoustic startle  response is increased in  the subgroup of early 
onset (before the age of 25) alcohol dependent patients com pared to bo th  healthy 
controls and alcohol dependent patients w ith  a late onset (after the age of 25). There 
was no difference in  acoustic sta rtle  response between late onset alcohol dependent 
patients and healthy controls. Since early onset alcohol dependence is related to a
higher heritab ility  th a n  late onset alcohol dependence, th is subgroup may represent 
yet another subgroup of patients w ith  a specific genetic profile and neurobiologi- 
cal abnorm alities. The clinical relevance of increased acoustic startle  response is 
yet to be studied.
In summ ary, th is thesis shows th a t in term ediate phenotypes can be used to 
study neurobiological abnorm alities in  alcohol dependence. These neurobiological 
abnorm alities affect the sensitivity for childhood adverse experiences and the risk 
for alcohol dependence. By using these interm ediate phenotypes subgroups of 
alcohol dependent patients were identified w ith  d ifferent neurobiological, genetic 
and clinical features, possibly requiring  d ifferent trea tm en t strategies.
Alcohol dependence a complex disorder
Though m any attem pts have been undertaken  to identify  genes related to 
alcohol dependence, genetic studies are often ham pered by non-replication. In this 
thesis I show th a t the re  are at least th ree  issues to be taken into account in  genetic 
studies on alcohol dependence, as show in  figure 1.
First is the issue of gene environm ent interaction. From a clinical point of view 
it has long been recognized th a t bo th  environm ental and heritable factors may be 
related to the development of neuropsychiatric disorders such as alcohol 
dependence. This study is one of the firs t to consistently show the role of an 
in teraction  betw een the COMT Val158Met and alcohol dependence (severity). We 
show th a t the COMT Met genotype is a risk genotype, only in  presence of adverse 
experiences during  childhood.
The second issue is the im portance to use an objectively m easurable phenotype. 
It has been recognized th a t psychiatric classification systems (DSM-IV and ICD-10) 
do not necessarily point to nosological disease entities. W hen applying genetic 
research it is very im portan t to attem pt to define a group of patients as narrowly as 
possible. We show th a t the use of in term ediate phenotypes may be a way to define 
groups of patients in  biological term s. We show th a t the use of the interm ediate 
phenotype APO sensitivity uncovers a relation  betw een dopam ine genes and 
alcohol dependence. It is likely th a t the use of in term ediate phenotyeps yields more 
replicable results, since the in term ediate phenotype can be m easured more 
objectively and precisely th a n  the broad phenotype alcohol dependence.
Finally we show the relevance of subgroups w ith in  the patien t sample. We 
identified subgroups w ith  d ifferent neurobiological features. W hen conducting 
genetic studies it is im portan t to reduce clinical heterogeneity in  the group under 
survey. In term ediate phenotypes may be a way to objectively identify  subgroups 
w ith  d istinct genetic risk profiles, in  order to improve outcome and replicablity of 
genetic studies. Morerover the  identification of subgroups may also have clinical 
relevance, for example in  term s of predicting  the course of alcohol dependence 
after detoxification, or guiding individualized treatm ent.
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Subgroups of alcohol dependent patients
Using the APO challenge test alcohol dependent patients show reduced APO 
sensitivity on d ifferent outcome measures (growth horm one response and cognitive 
response). This probably reflects reduced dopam ine sensitivity in  d ifferent brain  
areas, being the p refron tal cortex for the cognitive response and the neuroinfun- 
d ibulum  for the grow th horm one response. Reduced dopam ine sensitivity seems to 
be a general feature in  alcohol dependence in  d ifferent b ra in  regions.
However, d ifferent genes are involved in  dopam ine sensitivity in  these different 
b ra in  regions. This may indicate th a t reduced dopam ine sensitivity com monly 
observed in  alcohol dependence results from  d ifferent genetic backgrounds, 
th rough  d ifferent neurobiological pathways (see figure 1). Based on the results it 
can be hypothesized th a t there may be a executive/cognitive pathway, related to 
p refron tal dopam ine sensitivity and variation  in  the COMT gene. In addition there 
may be an endocrine pathway, related to neuro in fund ibu lar dopam ine sensitivity 
and variation  in  the DRD2 gene. W hether these d ifferent pathways end up in  a 
com mon final pathway of reduced mesolimbic dopam ine functioning, or w hether 
reduced mesolimbic dopam ine functioning is another pathway on its own rem ains 
to be studied.
Some genes come to expression in  very specific brain  regions, others are 
expressed at d ifferent regions in  the brain . It is therefore likely th a t more th a n  one 
gene contribute to one pathway and th a t one gene may influence more th a n  one 
pathway as well. This makes research into the genetic background of disorders as 
alcohol dependence very complex. Moreover, the excessive use of a drug itself also 
affects b rain  (dopamine) functioning, as indicated by the dotted arrow  in figure 1. 
In addition o ther environm ental factors, such as exposure to adversity experiences 
during  childhood, are also related to the vu lnerability  for alcohol dependence, in  
in teraction  w ith  genetic factors (as indicated by the yellow flashes in  figure 1).
Besides the dopam ine system, o ther n eu ro transm itte r systems may also be 
relevant to identify  subgroups of patients. As shown in  chapter 4, alcohol dependent 
patients w ith  co-morbid anxiety disorders, show increased error processing related 
b rain  activity. This may indicate a subgroup of alcohol dependent patients w ith  
im pairm ents p redom inantly  w ith in  the serotonergic pathway. This may be related 
to variation  in  the serotonin transpo rte r or receptor gene. How variation  in  the 
serotonergic circu itry  relates to alterations in  the dopam inergic circu itry  is 
unknow n, bu t may be relevant in  the development of alcohol dependence.
General issues and directions for future research
The cu rren t study focused on the role of dopam ine sensitivity in  gene 
environem ent in teraction  in  alcohol dependence. From the  cu rren t litera tu re  (see 
214 chapter 2) it becomes clear th a t not only dopam ine is involved in  alcohol
dependence. O ther n eu ro transm itte r systems th a t appear to play an im portan t role
Figure 1 Summary of findings, w ith  a model of different pathways from gene 
to disease
PFC: P re f ro n ta l  C o rtex ; HPA: H y p o th a lam u s-P itu ita ry -A x is ; NAcc: N uc leus  A ccu m b en s; ACC: 
A n te r io r  C in g u la te  C o rtex ; Exec: ex e cu tiv e  fu n c t io n ; E ndocr: e n d o c rin e  fu n c t io n in g ;  E rro r: e r ro r  
p ro cess in g . G lu ta m a te  (inc l NMDA) a n d  s e ro to n in  ( in c lu d in g  5HTT en  5HTR) w ere  n o t s tu d ie d  w ith in  
th e  scope o f  th i s  th e s is .
in  the  developm ent of alcohol dependence at d ifferent stages of the  addiction cycle 
are the GABA, opioid and glutam ate system. To date, it is not sufficiently known 
how these d ifferent n eu ro transm itte r systems in teract w ith  one another. It is likely 
th a t changes in  one transm itte r system in  a specific brain  area influence other 
neuro transm itte r systems in  o ther brain  areas. There have become more and more 
data th a t support such network view on brain  functioning. Future studies may try  
to fu rth e r unravel th is challenging puzzle on how d ifferent b ra in  systems in teract 
in  healthy b rain  functioning and neuropsychiatric disorders.
Another issue is th a t the cu rren t research project only partly  studied the 
clinical relevance of these findings. Im portan t questions th a t u n til now rem ain  
unansw ered are for example: Are endophenotypes im portan t in  individualizing 
treatm ent? Do endophenotypes have relevance for predicting the course of alcohol 
dependence? Can genetic or endophenotype studies help to identify  individuals at 
risk for developing alcohol dependence? And is it possible to use these m easures to
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ta rge t and evaluate prevention program s? Future studies should try  to answer 
these questions, in  order to m ake the cu rren t fundam ental research findings 
valuable for clinical practice.
The field of (behavioral)genetics is evolving rapidly. New techniques are com ing 
out w ith  seemingly endless possibilities to target the en tire  genome (genome wide 
association studies, copy num ber variation analysis, haplotype analysis, et cetera). 
Such studies w ith  very large data sets, still yield poor explained phenotypical 
variance by genetic variants in  complex disorders as alcohol dependence. It is 
tem pting to apply such new technologies in  ever larger samples. However, it is also 
im portan t to th in k  of research designs, driven by clear hypotheses, based on results 
from  anim al studies and hum an epidemiology and neuroscience. Combining 
d ifferent techniques and tak ing  environm ental factors into account when studying 
genetics in  complex neuropsychiatric disorders is crucial to really fu rth e r  our 
understanding  of brain  function  in  health  and disease.
Finally it has to be considered th a t most data in  th is thesis are cross-sectional 
m easures. In cross-sectional observational research, any relation  betw een “risk” 
factors and a disorder should be in terpreted  w ith  caution. Such an association 
could indeed po in t at an independent causal pathway, but may also indicate other 
types of association. An identified “risk” factor may also be a proxy for another risk 
factor, overlap w ith  o ther risk factors, or be a m ediator or m oderator of another 
risk factor. These options should be taken into account w hen th ink ing  of the 
clinical relevance of the cu rren t findings. Designing an in tervention to be tested in  
a random ized clinical tr ia l th a t m anipulates correlates th a t are not risk factors or 
risk factors th a t are not causal either because they cannot be changed (e.g. genetic 
variation) or because, when changed, they do not change the risk of the outcome is 
of no use. W hen there are chains of causal risk factors (all mediators), addressing 
only one link  of th a t chain  may resu lt in  trea tm en t effects of m inor clinical 
significance. At the same time, ignoring strong moderators of treatm ent response may 
m ean inclusion of m any subjects for whom the in terventions are not appropriate.
Clinical implications
Though the cu rren t study did not study the clinical relevance of interm ediate 
phenotypes extensively, the results do indicate th a t it is very im portan t to take into 
account th a t alcohol dependence is a heterogeneous disorder. This is an im portan t 
message to clinicians, since often substance dependent patients often receive 
standardized treatm ents. From a neurobiological po in t of view th is is really a m is­
understanding  of the pathophysiology of the disease.
For example patients w ith  co-morbid anxiety disorders represent a subgroup of 
216 alcohol dependent patients, w ith  d istinct neurobiological characteristics and
increased vulnerability  for relapse during  the early phases of treatm ent. This group
may benefit from  more intensive m edical and psychological trea tm en t when a 
clinical detoxification is planned. W hether the neurobiological profile can guide 
trea tm en t adjustm ents in  the individual patient, in  term s of personalized m edicine 
rem ains to be studied.
Another clinical im plication is th a t the stigm a of substance dependence does 
not comply w ith  research findings. Often alcohol dependence is in terpreted  as a 
sign of weakness of individuals. Strange enough according to Dutch law, substance 
dependence is not considered a neuropsychiatric disorder. Our results clearly 
dem onstrate th a t alcohol dependent patients suffer from  a severe neurobiological 
condition, th a t is characterized by alterations in  b ra in  functions involved in  
hedonic experience, behavioral control and cognitive functioning (including 
insight), and is associated w ith  a high m ortality. We also show th a t genetic and 
childhood experiences are particu larly  involved in  the development of a neurobio­
logical vu lnerability  to develop alcohol dependence, as is the case in  other neuro ­
psychiatric disorders, such as depression, anxiety, schizophrenia and ADHD.
Alcohol dependence should thus be regarded as a severe neuropsychiatric 
condition and treated  as such. Patients w ith  alcohol dependence have need of 
m edical and psychological treatm ents. Doctors and psychologists who trea t these 
patients require knowledge on the neurobiological background of th is devastating 
disoder. Training program s for psychologists and m edical specialists, psychiatric 
tra in in g  in  particu lar, should include courses on the neurobiology of alcohol 
dependence. It is im portan t th a t clinicians educate patients, the ir relatives and the 
public on recent scientific insights in  the neurobiology of th is  severe condition. 
This w ill contribute to destigm atization and im provem ents of trea tm en t of alcohol 
dependent patients in  the future.
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Samenvatting en discussie
Dit prom otietraject heeft als onderw erp de neurobiologie van alcoholversla­
ving, m et als specifieke doelen: het onderzoeken van gen-omgeving interacties en 
interm ediërende neurobiologische fenotypes. Binnen d it p roefschrift lig t de focus 
op 1) translationeel onderzoek, w aarin  resu ltaten  van d ierexeprim enteel onderzoek 
worden vertaald naar de hum ane situatie, 2) neurobiologische heterogeniteit van 
alcoholverslaving en 3) het gebrek aan kennis over de in teractie tussen omgevings­
invloeden en biologische factoren bij alcoholverslaving. De specifieke doelen van 
d it onderzoek zijn:
1. Het testen van het translationeel onderzoeksm odel apom orfine gevoeligheid in 
een hum ane populatie (hoofdstuk 2).
2. Het onderzoeken van d it interm ediërende fenotype voor alcohol afhankelijk­
heid in  relatie to t dopam ine genen (hoofdstuk 3,4,5).
3. Het onderzoeken van gen-omgeving interactie voor de geïdentificeerde dopamine 
genen bij alcohol afhankelijkheid (hoofdstuk 6).
4. Het testen van andere intermediërende fenotypes bij alcoholverslaving (hoofdstuk 
7, 8, 9).
Hoofdstuk 2:
Het mesolim bisch dopam ine systeem in de hersenen w ordt ook wel het 
natuurlijke beloningssysteem  genoemd. Bij prettige activiteiten kom t er dopam ine 
vrij in  d it m esolim bische systeem (met als hoofd stru c tu u r de Nucleus Accumbens). 
Verslavende stoffen zorgen ook voor dopam ine uitstoo t in  d it hersengebied. De 
hoeveelheid dopam ine die vrijkom t na het gebruik van verslavende stoffen is echter 
veel groter dan de hoeveelheid die vrijkom t na “norm ale” prettige activiteiten 
zoals sporten, eten of vrijen. Uit beeldvorm end hersenonderzoek weten we dat het 
aan ta l dopam ine receptoren in  de hersenen van verslaafde patiënten lager is dan 
bij gezonde controlepersonen.
Dopamine gevoeligheid is ook in  dierexperim enteel onderzoek beschreven als 
model voor verslavingsgedrag. Apomorfine is een dopam ine stim ulerende stof en 
dieren  die m inder gevoelig zijn voor deze stof dienen zichzelf bijvoorbeeld m eer 
alcohol of cocaïne toe. De eerste stap van m ijn onderzoek was te testen in  hoeverre 
apom orfine gevoeligheid (het dierm odel voor verslavingsgedrag) ook bij m ensen 
goed te m eten is. In hoofdstuk twee beschrijf ik de resu ltaten  van deze eerste pilot 
studie. Ik vond dat apom orfine bij m ensen m eetbare veranderingen veroorzaakt in 
de groeihormoon concentratie in  het bloed, prestatie op een cognitieve com putertaak 
en de schrikreflex op klikgeluiden. Het effect van apom orfine was het best 
m eetbaar w anneer er een subcutane dosering werd gebruikt van 0.005mg per 
kilogram  lichaam sgew icht en w anneer werd gem eten tussen tien  to t zestig
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m inuten  na toediening. Met deze m ethodologie zou het dus mogelijk m oeten zijn 
om verschillen in  dopam ine gevoeligheid te m eten tussen alcohol verslaafde 
patiën ten  en gezonde controles, analoog aan het dierm odel.
Hoofdstuk 3:
De volgende stap was het testen  van de dopam inegevoeligheid in  alcohol 
verslaafde patiënten  in  vergelijking m et een gezonde controlegroep. Mijn hypothese 
was dat alcohol verslaafde patiën ten  een lagere gevoeligheid zouden hebben voor 
apom orfine, conform  het dierm odel. In hoofdstuk drie beschrijf ik de resultaten  
van d it onderzoek. De groep alcohol verslaafde patiën ten  had inderdaad een lagere 
groeihorm oon reactie op apom orfine en had ook m inder last van de negatieve 
effecten op de com putertaak. Deze bevindingen sluiten goed aan bij de reeds 
bestaande lite ra tu u r over verm inderde dopam ine functie bij verslaafde patiënten. 
Echter, m et dit onderzoek blijft het onduidelijk w at de oorzaak van deze 
verm inderde dopam ine gevoeligheid is. Het zou im m ers een factor kunnen  zijn die 
p redisponeert voor excessief m iddelengebruik m aar ook het gevolg daarvan. In de 
volgende hoofdstukken staat deze vraag centraal.
Hoofdstuk 4&5:
Vanuit dierexperim enteel onderzoek weten we dat apom orfine gevoeligheid 
kan worden doorgegeven van generatie op generatie door selectief te fokken. Dit 
suggereert dat hierbij erfelijke factoren een rol zouden kunnen  spelen. In hoofdstuk 
vier en vijf beschrijf ik de effecten van een aantal dopam ine genen op apom orfine 
gevoeligheid bij m ensen. In deze hoofdstukken worden de effecten van drie 
genotypen beschreven: het COMT gen, het dopam ine receptor gen (DRD2) en het 
dopam ine transpo rte r gen (DAT2). Het COMT gen heeft vooral invloed op dopam ine 
functie in  de prefrontale cortex. De beide andere genotypen hebben vooral effecten 
op subcorticale dopam ine functie.
Hoofdstuk vier gaat over het effect van het COMT gen op dopam ine gevoeligheid. 
Dit gen codeert voor een enzym  dat dopam ine afbreekt. Dit enzym  is vooral actief 
in  de prefrontale cortex (hersenschors in  het voorste deel van het brein). De 
genetische varian t leidt to t een sterke verandering van de activiteit van d it enzym. 
Omdat dopam ine functie in  de prefrontale cortex cruciaal is voor cognitieve 
prestaties was de hypothese dat variatie in  het COMT genotype de effecten van 
apom orfine op cognitieve prestaties beïnvloedt.
In d it hoofdstuk is te lezen dat dragers van de trage enzym  varian t (Met 
genotype) inderdaad gevoeliger zijn voor de effecten van apom orfine op de 
com putertaak dan dragers van de snelle enzym  varian t (Val genotype). Dit past 
b innen  de veronderstelling van een omgekeerde U-vorm relatie tussen prefrontale 
222 dopam ine functie en cognitieve prestaties. Dragers van de trage enzym  varian t
(Met genotype) hebben veel dopam ine activiteit in  de prefrontale cortex. Bij hen
leidt apom orfine toediening mogelijk to t een dopam inerge overstim ulatie, m et 
afnam e van de prestaties to t gevolg. Terwijl bij dragers van de snelle enzym  varian t 
(Val genotype), m et een lage dopam ine activiteit in  de prefrontale cortex, 
apom orfine toediening ju is t zou kunnen  leiden to t verbetering van de prestaties 
door een optim alisering  van de dopam ine activiteit.
In hoofdstuk twee laat ik zien dat dopam ine gevoeligheid kan w orden gem eten 
aan de hand van verschillende uitkom stm aten. Onze hypothese is dat de effecten 
op deze verschillende u itkom stm aten te herleiden zijn to t dopam ine gevoeligheid 
in  verschillende hersengebieden. Voor de com putertaak denken we daarbij aan 
dopam ine gevoeligheid in  de prefrontale cortex en voor de groeihorm oon reactie 
denken we aan dopam ine gevoeligheid in  de hypofyse. In het volgende hoofdstuk 
testten  we of de effecten van de dopam ine genen mogelijk ook specifiek zijn voor 
bepaalde hersengebieden. Hierbij was de hypothese dat het COMT genotype, dat 
vooral to t expressie kom t in  de prefrontale cortex, de dopam ine effecten op 
cognitieve prestaties beïnvloedt en dat het DRD2 genotype, dat vooral subcorticaal 
to t expressie komt, de groeihorm oon reactie beïnvloedt.
In hoofdstuk v ijf zien we dat de effecten van het COMT genotype specifiek van 
invloed zijn op de effecten van apom orfine op de com putertaak en n ie t op de 
groeihorm oon reactie. Voor het DRD2 genotype is d it net andersom. De genetische 
eigenschappen hangen w aarschijnlijk samen m et de gem eten dopam ine 
gevoeligheid in  verschillende hersengebieden. Bovendien hang t een lagere 
dopam ine gevoeligheid samen m et alcoholverslaving. We vonden echter geen 
d irect verband tussen de dopam ine genen en alcoholverslaving. Dit suggereert dat 
er mogelijk andere factoren zijn die in  in teractie m et deze dopam ine genen 
sam enhangen m et alcoholverslaving.
Hoofdstuk 6:
In d it hoofdstuk beschrijf ik de in teractie tussen de eerder geteste dopam ine 
genen en vroegkinderlijke traum atisering . Het is bekend dat aan alcohol verslaafde 
patiën ten  een hogere m ate van vroegkinderlijke traum atisering  rapporteren. 
D aarnaast zijn er aanw ijzingen u it zowel dierexperim enteel als hum aan  onderzoek, 
dat variatie in  het dopam ine systeem de gevoeligheid voor stress beïnvloedt. Onze 
hypothese was dan ook dat variatie in  dopam ine genen de relatie tussen 
blootstelling aan vroegkinderlijke traum atisering  en alcoholverslaving beïnvloedt. 
In hoofdstuk zes beschrijf ik dat de beide dopam ine genen (DRD2 en COMT) inderdaad 
van invloed zijn op de relatie tussen vroegkinderlijke traum atisering  en het risico 
op alcoholverslaving. Vooral voor het COMT genotype vonden we dit duidelijk terug. 
Dit sluit aan bij eerdere gegevens u it de literatuur. Het “w orrior-w arrior m odel” 
(denkers en vechters) is een voorbeeld hoe d it voor het COMT genotype zou kunnen  
werken. Dragers van de trage enzym  varian t (Met genotype) hebben m eer dopam ine 
in  de prefrontale cortex, w aardoor ze beter presteren  op cognitieve taken. Echter
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bij blootstelling aan stress zou d it kunnen  leiden to t een te veel aan dopam ine 
activiteit, w aardoor ze mogelijk kw etsbaarder zijn voor de effecten van traum atische 
gebeurtenissen in  de jeugd. Hierdoor zouden ze bij vroegkinderlijke traum atisering  
m eer risico kunnen  lopen om alcoholverslaving te ontw ikkelen (het w orrior of 
denker type). Voor dragers van de snelle enzym  varian t geldt dat zij m inder 
dopam ine in  de prefrontale cortex hebben. H ierdoor zouden zij m inder goed 
presteren op cognitieve taken. Echter bij b lootstelling aan stress stijgt de dopam ine 
activiteit to t m eer optim ale w aarden, w aardoor deze personen onder stress beter 
presteren. Hierdoor zouden ze mogelijk m inder kw etsbaar zijn voor de effecten van 
vroegkinderlijke traum atisering  op het risico een alcoholverslaving te ontw ikkelen 
(warrior of vechter type).
Hoofdstuk 7, 8 & 9:
Op basis van de vorige hoofdstukken kunnen  we concluderen dat b innen  de 
groep alcohol verslaafde patiën ten  mogelijk verschillende subtypes m et 
uiteenlopende (neurobiologische) eigenschappen bestaan. Het testen van 
apom orfine gevoeligheid middels verschillende u itkom stm aten test slechts op 
enkele eigenschappen gerelateerd aan dopam ine gevoeligheid. Echter u it de 
inleid ing w ordt duidelijk dat ook andere neuro transm ittersystem en betrokken zijn 
bij alcoholverslaving. Daarom heb ik na het onderzoek van dopam ine gevoeligheid 
nog diverse andere mogelijke interm ediërende fenotypen onderzocht.
Alcoholverslaving gaat vaak gepaard m et andere psychiatrische aandoeningen. 
Zowel in ternaliserende problem atiek (bijvoorbeeld depressieve stoornissen, angst­
stoornissen) als externaliserende problem atiek (antisociale persoonlijkheids­
stoornis) komen vaak voor in  com binatie m et alcoholverslaving. Mogelijk hang t 
deze psychiatrische com orbiditeit sam en m et een verschil in  neurobiologische 
eigenschappen b innen  de groep alcohol verslaafde patiënten.
Een voorbeeld daarvan is de reactie op het m aken van fouten. Bij patiënten  m et 
een im pulscontrole stoornis is de reactie van de hersenen op fouten verlaagd 
(bijvoorbeeld bij ADHD). Maar bij patiën ten  m et een angststoornis is deze reactie 
ju is t verhoogd. Bij verslaafde patiënten  is to t op heden steeds een verlaagde reactie 
op het m aken van fouten gevonden. In deze onderzoeken is echter geen rekening 
gehouden m et de psychiatrische com orbiditeit.
In hoofdstuk zeven laat ik zien dat alcohol verslaafde patiënten die ook een 
angststoornis hebben, m eer hersenactiv iteit hebben tijdens het m aken van fouten 
op een com putertaak. De hypothese is dat deze groep patiënten  een verhoogde 
alertheid  heeft op het m aken van fouten. Onderzoeken hebben aangetoond dat dit 
mogelijk te m aken heeft m et veranderingen in  het serotonine systeem. Het gebruik 
van alcohol zou in  deze groep een m anier kunnen  zijn op deze hyperalertheid  te
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Patiënten m et een comorbide angststoornis zouden hierdoor w ellicht meer 
kw etsbaar zijn voor het risico op een terugval na ontgifting. In hoofdstuk acht heb 
ik gekeken naar het effect van comorbide angststoornissen op het beloop van de 
alcoholverslaving na ontgifting. Ik vond dat alcohol verslaafde patiën ten  m et een 
angststoornis inderdaad een verhoogd risico hebben om vooral in  de eerste drie 
m aanden na on tgifting  terug  te vallen in  alcoholgebruik. Na de eerste drie m aanden 
is vooral de e rn st van de alcoholverslaving voor opnam e voorspellend voor een 
terugval. Comorbide angststoornissen bij alcohol verslaafde patiën ten  gaan dus 
gepaard m et verhoogde reactie van de hersenen op het m aken van fouten en leiden 
to t een slechtere prognose na behandeling. In d it onderzoek is echter niet 
onderzocht of de hersenreactie op fouten de prognose beter voorspelt dat de 
aanwezigheid van een angststoornis.
In hoofdstuk negen w ordt de schrikreflex onderzocht als interm ediërend 
fenotype voor alcoholverslaving. Eerder onderzoek liet zien dat deze schrikreflex 
verhoogd is d irect na de ontgiftingsfase. In dit onderzoek was echter een specifieke 
subgroep van patiën ten  onderzocht, bij wie de alcoholverslaving reeds op jonge 
leeftijd was ontstaan. De verhoogde schrikreactie zou dus ook specifiek kunnen  
zijn voor deze subgroep van patiënten.
Dit onderzoek laat zien dat de groep alcohol verslaafde patiënten  die de 
verslaving ontw ikkelde voor het 25ste levensjaar (jong verslaafden) een verhoogde 
schrikreactie heeft op klikgeluiden in  vergelijking m et zowel gezonde controles als 
patiën ten  die hun  verslaving ontw ikkelden na hun  25ste. Er was geen verschil 
tussen de patiën ten  m et een verslaving op oudere leeftijd en de controle groep. Er 
zijn aanw ijzingen dat bij de groep jongverslaafden genetische factoren een grotere 
rol spelen dan bij patiën ten  die de verslaving op latere leeftijd ontw ikkelen en dat 
deze groep een hogere m ate van prikkelzoekendheid heeft. Dit is opnieuw een 
voorbeeld van een subgroep van patiën ten  m et specifieke neurobiologische 
eigenschappen en mogelijk een specifiek genetisch profiel. Welke genetische 
factoren mogelijk een rol spelen bij deze groep zal nog nader onderzocht m oeten 
worden. Hierbij valt bijvoorbeeld te denken aan het DRD4 gen, dat geassocieerd is 
m et prikkelzoekend gedrag.
Samenvattend, kan worden gesteld dat d it p roefschrift laat zien dat alcohol­
verslaving gepaard gaat m et uiteenlopende neurobiologische veranderingen, die 
deels genetisch verklaard kunnen  worden. Dergelijke biologische eigenschappen 
beïnvloeden de kwetsbaarheid van een individu voor de effecten van vroegkinderlijke 
traum atisering  en daarm ee het risico op het ontw ikkelen van alcoholverslaving. 
De onderzochte neurobiologische eigenschappen, ofwel interm ediërende feno­
types, kunnen  helpen om de heterogene groep alcohol verslaafde patiënten  onder 
te verdelen in  subgroepen m et specifieke neurobiologische en gedragskenm erken, 
die mogelijk ook verschillende behandeling behoeven.
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Alcoholverslaving: een complexe aandoening
Ondanks dat erfelijke factoren ongeveer vijftig procent van het risico op 
alcoholverslaving zouden m oeten verklaren, heeft genetisch onderzoek naar 
alcoholverslaving nie t geleid to t het vinden van hét gen voor alcoholverslaving. 
Integendeel, er zijn veel tegenstrijdige resu ltaten  m et betrekking  to t de effecten 
van bepaalde genen op het risico voor alcoholverslaving. In dit p roefschrift laat ik 
zien dat er verschillende redenen zijn die h ieraan  ten grondslag kunnen  liggen 
(zie figuur 1, pagina 162).
Ten eerste is het van belang van om in  genetisch onderzoek ook rekening te 
houden m et de invloed van omgevingsfactoren. Hulpverleners horen vaak de 
ernstige verhalen van hun  patiën ten  over traum atische gebeurtenissen in  hun  
leven. D aarnaast zien we in  de hulpverlening ook vaak terug dat bepaalde 
psychiatrische stoornissen b innen  fam ilies vaker voorkomen dan in  de algemene 
bevolking. Dit geldt in  het bijzonder ook voor alcoholverslaving. Dit proefschrift 
laat zien dat bijvoorbeeld het COMT Met genotype n ie t rechtstreeks geassocieerd is 
m et alcoholverslaving, m aar wel een risico gen is voor alcoholverslaving bij 
b lootstelling aan vroegkinderlijke traum atisering . Bij genetisch onderzoek naar 
alcoholverslaving is het dan ook van groot belang om gevingsfactoren zorgvuldig in  
k aart te brengen en te analyseren.
Ten tweede is het van belang dat de aandoening alcoholverslaving nie t een 
eenduidig begrip representeert. De classificatiesystem en die in  de psychiatrie 
w orden gehanteerd (DSM-IV en ICD-10) defin iëren  n ie t zo zeer specifieke ziekte 
entiteiten , m aar classificeren verzam elingen symptomen to t heterogene 
syndrom en. Bij het doen van genetisch onderzoek is het van belang deze heterogene 
syndrom en zo specifiek mogelijk te defin iëren  in  term en van bepaalde (neurobio­
logische) kenm erken. Dit p roefschrift laat zien dat het m eten van neurobiologische 
kenm erken een m anier kan zijn om de relatie tussen genetische eigenschappen en 
alcoholverslaving te onderzoeken. Dergelijke neurobiologische eigenschappen 
staan mogelijk dichterbij de genetische eigenschappen. Door deze te m eten zal 
genetisch onderzoek mogelijk m eer eenduidige resu ltaten  kunnen  opleveren in  de 
toekomst.
Tenslotte is het de vraag w at het k linische belang is van deze neurobiologische 
eigenschappen. Op basis van de huidige bevindingen kan w orden verondersteld dat 
b innen  de groep alcohol verslaafde patiën ten  subgroepen bestaan m et verschillende 
onderliggende pathofysiologie. Niet alleen is het bij genetisch onderzoek van 
belang om dergelijke subgroepen helder te defin iëren  en te onderzoeken. Ook voor 
de klinische diagnostiek en behandeling  zou het identificeren van subgroepen van 
alcohol verslaafde patiënten mogelijk relevant kunnen zijn. Door de pathofysiologie 
van de verslaving van patiënten  te begrijpen kunnen  in  de toekom st mogelijk 
behandelingen worden ontw ikkeld, toegesneden op de eigenschappen van de
individuele patiënt. Het gebruik van interm ediërende fenotypes kan hierbij 
mogelijk een rol spelen.
Subgroepen alcohol verslaafde patiënten
De apom orfine gevoeligheidstest toont aan dat de dopam ine gevoeligheid, 
gem eten middels groeihorm oon concentratie in  het bloed en de prestaties op een 
com putertaak, lager is bij alcohol verslaafde patiën ten  dan bij gezonde controles. 
De lagere gevoeligheid voor de effecten van dopam ine toediening op de prestaties 
op de com putertaak houden w aarschijnlijk  verband m et dopam ine gevoeligheid in  
de prefrontale cortex, terw ijl de lagere groeihorm oon reactie w aarschijnlijk  te 
m aken heeft m et dopam ine gevoeligheid in  de hypothalam us.
Ondanks dat de dopam ine gevoeligheid lager is bij alcohol verslaafde patiën ten  
op beide uitkom stm aten, zagen we dat h ier mogelijk verschillende genetische 
eigenschappen aan ten  grondslag liggen. Dit is schem atisch weergegeven in  figuur 
1 (pagina 162). D aarnaast zagen we dat de groep m et comorbide angststoornissen 
mogelijk weer andere neurobiologische eigenschappen heeft in  de vorm  van 
hyperalertheid  voor het m aken van fouten. En ook de groep m et verhoogde 
schrikreactie op geluiden zou een andere subgroep van patiën ten  kunnen  
aanduiden, m et een ander m echanism e dat ten grondslag lig t aan het ontw ikkelen 
van de alcoholverslaving.
Zo komen we op tenm inste vier neurobiologisch te identificeren pathways die 
mogelijk ten grondslag liggen aan de het ontw ikkelen van alcoholverslaving, te 
weten: het neurocognitieve pathway (verminderde dopam ine gevoeligheid in  de 
prefrontale cortex, gerelateerd aan het COMT genotype), het angst pathway 
(verhoogde fouten alertheid), het filter pathway (verhoogde schrikreactie op 
geluiden) en het horm onale pathway (verm inderde dopam ine gevoeligheid in  de 
hypofyse, gerelateerd aan het DRD2 genotype). Waarbij dit laatste pathway mogelijk 
m eer een aanwijzing is voor verm inderde dopam ine gevoeligheid in  het 
mesolim bische dopam ine (belonings)systeem.
W aarschijnlijk spelen bij individuele patiënten verschillende pathways in  
m eer of m indere m ate een rol. Dit kom t n ie t in  de laatste plaats doordat één gen 
invloed kan hebben op m eerdere verschillende pathways en doordat één pathway 
beïnvloed w ordt door de effecten van m eerdere verschillende genen. D aarnaast 
heeft het excessieve gebruik van m iddelen zelf u iteraard  ook weer effecten op het 
brein, onder andere op het dopam ine systeem (weergegeven door de gestippelde 
pijl in  figuur1). Ook andere omgevingsfactoren, zoals blootstelling aan vroegkin­
derlijke traum atisering , dragen bij aan de kw etsbaarheid voor alcoholverslaving 
(weergegeven door de bliksem schichten in  figuur 1). Zo on tstaat een voor elke 
patiën t unieke com binatie van neurobiologische eigenschappen die in  in teractie 
m et om gevingsfactoren van invloed zijn op de aandoening. Dit m aakt alcoholver­
slaving to t een zeer complexe aandoening, m et vele gezichten.
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Algemene opmerkingen en aanbevelingen voor toekomstig onderzoek
Dit proefschrift richt zich op dopamine gevoeligheid in  relatie to t gen-omgeving 
interacties bij alcohol verslaafde patiënten. Uit de lite ra tu u r blijkt dat naast 
dopam ine ook andere neuro transm itters van belang zijn bij alcoholverslaving. 
Hierbij zijn de meeste aanw ijzingen voor een rol voor g lutam aat, GABA en het 
opioid systeem. Tot op heden is het onduidelijk in  hoeverre al deze neuro transm it­
ter systemen m et elkaar sam enhangen en elkaar over en weer beïnvloeden. 
Toekomstig onderzoek zal mogelijk duidelijk m aken hoe het netwerk van 
hersencellen middels verschillende n eu ro transm itte r systemen norm aal gesproken 
functioneert en hoe d it mogelijk afw ijkt bij patiën ten  m et een alcoholverslaving.
Binnen d it p roefschrift is zeer beperkt gekeken naar de k linische relevantie 
van de onderzochte neurobiologische eigenschappen. Belangrijke k linische vragen 
zijn: Zijn neurobiologische eigenschappen van belang voor de behandeling van 
alcoholverslaving? Zijn neurobiologische factoren van belang voor de prognose van 
alcoholverslaving? Kan genetisch onderzoek m ensen identificeren  die een verhoogd 
risico hebben op het ontw ikkelen van alcoholverslaving? En w at kunnen  we hier 
vervolgens mee? De klinische toepasbaarheid van de m eer fundam entele 
bevindingen van dit onderzoek zal nog nader onderzocht m oeten worden.
De technische ontw ikkelingen b innen  genetisch onderzoek gaan ondertussen 
razendsnel. Het gehele genoom kan inm iddels w orden onderzocht, b innen  steeds 
grotere onderzoekspopulaties. Dergelijk hypothesevrij onderzoek vindt dan ook 
steeds m eer plaats en op steeds grotere schaal. Het is echter de vraag of dit type 
onderzoek ons leidt naar k lin isch  relevante resultaten . W anneer grotere groepen 
w orden geïncludeerd betekent dit veelal dat m en m inder precieze inform atie heeft 
over deze patiënten, laat staan  de om gevingsfactoren w aaraan deze patiënten  zijn 
blootgesteld. Dit onderzoek laat zien dat m et zeer gerichte hypothesen, gebaseerd 
op d ierexperim enteel onderzoek en gebruikm akend van verschillende neurobiolo­
gische m eetm ethoden, het mogelijk is om m eer inzich t te verwerven in  een 
complexe aandoening als alcoholverslaving, ook in  rela tief kleine onderzoeks­
groepen. Hiervoor is het van belang de onderzoekspopulatie uitvoerig te bestuderen, 
gebaseerd op reeds bestaande kennis u it de w etenschappelijke lite ra tu u r en 
rekening houdend m et mogelijke beïnvloeding door omgevingsfactoren.
Een beperking van dit onderzoek is dat de meeste data cross-sectioneel 
verzam eld zijn, dat w il zeggen middels m etingen op één p u n t in  de tijd. De 
aangetoonde relaties in  d it onderzoek kunnen  mogelijk wijzen op oorzakelijke 
verbanden. Echter om oorzakelijke verbanden aan te tonen is bevestiging in  
prospectief onderzoek nodig. De risicofactoren geïdentificeerd in  d it proefschrift 
kunnen  im m ers ook wijzen op andere vorm en van sam enhang. Zo kan een 
genetische eigenschap sam enhangen m et andere risico factoren voor alcoholversla­
ving, zonder dat er sprake is van een oorzakelijk verband. Omgekeerd kunnen  
gem eten neurobiologische eigenschappen ook het gevolg zijn van langdurig
excessief gebruik van verslavende m iddelen. Ondanks dat in  de statistische analyses 
hiervoor zoveel mogelijk is gecorrigeerd, is d it een belangrijke beperking van dit 
onderzoek.
Tenslotte zijn veel van de onderzochte factoren n ie t beïnvloedbaar door 
behandeling (bijvoorbeeld genetische eigenschappen, vroegkinderlijke traumatisering, 
etc.). Ook is het de vraag of beïnvloeding door behandeling (bijvoorbeeld 
psychotherapie of medicatie) daadwerkelijk effect heeft op het beloop van alcohol­
verslaving, gezien de vele andere factoren die van belang zijn bij de behandeling 
van deze ernstige aandoening (bijvoorbeeld psychosociale problem en, licham elijke 
ziektes, etc.). Het is dan ook van belang dat de relevantie van de huidige onder­
zoeksbevindingen voor de behandeling van patiënten  w ordt getest.
Klinische implicaties
Ondanks dat d it onderzoek geen toegepast onderzoek is, m aar eerder 
fundam enteel van aard, zijn de bevindingen van belang voor de klinische praktijk. 
Ten eerste onderstrepen deze bevindingen de grote verscheidenheid van de 
aandoening. Het lijk t dus n ie t rationeel om alle patiën ten  een identieke behandeling 
aan te bieden.
Uit d it onderzoek blijkt bijvoorbeeld dat de groep alcohol verslaafde patiënten  
m et comorbide angststoornissen w ordt gekenm erkt door specifieke neurobiologi- 
sche en dat deze groep kw etsbaar is voor terugval in  de vroege fasen van de 
behandeling. W anneer een klinische detoxificatie w ordt gepland bij patiënten  m et 
een comorbide angststoornis d ient hierop geanticipeerd te worden. Het valt te 
overwegen deze m ensen intensiever te begeleiden en mogelijk geleidelijker de 
m edicatie af te bouwen. In hoeverre neurobiologisch onderzoek kan bijdragen aan 
het afstem m en van de behandeling  op individueel niveau zal nader m oeten worden 
onderzocht.
De bevindingen van d it onderzoek kunnen  daarnaast mogelijk bijdragen aan 
destigm atisering van deze groep patiënten. Alcoholverslaving w ordt vaak gezien 
als een teken van zwakte. Vreemd genoeg w ordt alcoholverslaving voor de wet 
(bijzondere opnem ing psychiatrische ziekenhuizen, BOPZ) n ie t beschouwd als een 
psychiatrische aandoening en gaan er stem m en op om de behandeling van alcohol­
verslaving in  de toekom st n ie t langer vanuit de zorgverzekering te vergoeden.
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Dit onderzoek laat duidelijk zien dat op neurobiologisch niveau dezelfde 
hersensystem en en processen aangedaan zijn als bij de “erkende” psychiatrische 
stoornissen. Bij alcoholverslaving treed t een verstoring op in  de hersengebieden die 
betrokken zijn bij het beleven van plezier, cognitief functioneren (inclusief ziekte- 
inzicht) en im pulscontrole. Dit onderzoek toont verder aan dat een sam enspel 
tussen genetische factoren en opvoedingsomstandigheden bijdraagt aan een neuro- 
biologische kw etsbaarheid om alcoholverslaving te ontw ikkelen, zoals d it ook het 
geval is bij andere psychiatrische stoornissen zoals depressies en schizofrenie. 
Bovendien gaat alcoholverslaving gepaard m et ernstige invalidering en een hoge 
m ortalite it.
Alcoholverslaving zou dan ook m oeten worden gerekend to t de ernstige neuro- 
psychiatrische aandoeningen. Patiënten m et een alcoholverslaving behoeven 
gedegen diagnostiek en medische en psychologische behandeling. Hiervoor is een 
gedegen kennis van de huidige neurobiologische onderzoeksinzichten in  alcohol­
verslaving noodzakelijk. Binnen de onderwijs curricula van psychologen, artsen  en 
m edisch specialisten, en de psychiatrie opleiding in  het bijzonder, zou hiervoor 
dan ook aandacht m oeten zijn. Hulpverleners dienen patiënten  en hun  naasten  
u itleg te (kunnen) geven over de neurobiologische achtergronden van deze 
aandoening. D aarnaast is het van belang dat ook het brede publiek en beleidsmakers 
kennis nem en van de recente ontw ikkelingen op w etenschappelijk gebied, zodat 
de patiënten  die lijden onder deze ernstige en invaliderende aandoening de 
noodzakelijke diagnostiek en behandelingen kunnen  (blijven) krijgen.
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Het m eest kritisch  gelezen deel van het proefschrift. Hier geen peer review, m aar 
revue des amis. Het schrijven van een proefschrift lijk t soms een w at solitaire 
activiteit, m aar is geenszins het werk geweest van mij als individuele promovendus. 
Ook hier dus een in teractie tussen genen en omgeving, m et zowel vroege als late 
omgevingsfactoren. Het p roefschrift zou het endofenotype kunnen  zijn.
Ten eerste m ijn grote dank aan de vrijw illigers van het onderzoek. Alle 
patien ten  en gezonde controles ondergingen m eerdere bloed afnam en, subcutane 
toediening van een m edicam ent en  tenm inste een hele ochtend testen, aangesloten 
op electrodes. Dank voor alle m otivatie om deel te nemen! W at betre ft het m eten 
van patienten  ben ik ook dank verschuldigd aan NOVADIC-Kentron, de instelling 
w aar ik de steun kreeg om patienten  te benaderen voor d it onderzoek.
Overige late om gevingsfactoren zijn de m eest nauw  betrokken begeleiders. 
Robbert-Jan, Bart, Jan en Cor ju llie  zijn het team  van (co)promotoren die me steeds 
hebben geholpen. Ons team  nog versterkt door Barbara en Lex, voor respectievelijk 
de genetica en d ierexperim entele finesses. Ik heb altijd prettig  kunnen  sam en­
werken m et ju llie en kijk terug op een p rettig  prom otietraject. Daar hadden jullie 
zeker een belangrijk  aandeel in.
Ons team  werd daarnaast periodiek versterkt door verschillende stagiaires. 
Hopelijk was het een wederzijds genoegen om samen te werken. Ik ben blij dat ik 
heb mogen oefenen in  de begeleiding van getalenteerde jonge academici en  heb 
daar zeker veel van geleerd. Dank aan Florianne, Christa, Peter (x2), Anne, Erik, 
Annette, Wendy, Stijn, Jiska, Sharon. Verder was er de onontbeerlijke hulp van 
Jan en Arm and om de m oeizaam  te werven groep gezonde controle personen 
te verzam elen en te m eten. Zonder ju llie  hulp had ik het nooit gered om dit 
p roefschrift nu, zo, af te kunnen  ronden.
Mijn naaste collega onderzoekers m et wie het goed sparren  en borrelen was 
mogen natuurlijk  ook nie t ontbreken. Frank, Elke, Koen, Gerard, Maaike, 
Anne-Marie, Karin, Fiona, Hein, Marieke, M artine (x3), Cathelijne. En buiten  dit 
rijtje moet ik natuurlijk Pieter apart noemen, mijn tweelingbroertje van de afdeling, 
m et de gedeelde Brabantse roots. Ik vond het erg jam m er dat je je opleiding tijdelijk 
onderbrak en elders verder ging. Ik had het graag samen m et je afgem aakt in  het 
Radboud. Het was fijn een m aatje te hebben in  zowel onderzoek als opleiding. Vele 
andere m edeopleidelingen hebben zo nu en  dan ingesprongen voor een dienst, of 
k lin iek  vanwege ex tra  onderzoeksactiviteiten. Dank ju llie  wel en  in  het bijzonder 
natuurlijk  ons veelzijdige jaar clubje m et ezel, paard, schaap, hond en toekan.
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Naast deze bevriende collega’s u iteraard  ook de vrienden bu iten  het werk, die 
onm isbaar zijn voor het prettig  doorlopen van d it acht jaar durende com binatie 
traject. In het bijzonder de vrienden u it het eerste jaar geneeskunde: Marloes en 
David. Met ju llie ontdekte ik het Nijmeegse studentenleven. Ik ben erg blij dat jullie 
nu  naast me staan bij deze afronding.
Onze familie. De basis van alles, zowel vroege omgeving als genetische 
ondergrond. Ik ben blij m et m ijn Brabantse roots en het goede gezin w aarin  ik 
opgroeide sam en m et m ijn grote broer. Toen Maro geboren werd had ik het geluk 
een m oeder en schoonm oeder te hebben die w ilden inspringen om me schrijftijd 
te bieden. Maro, dank voor je inspiratie w anneer we samen achter de laptop zaten 
en Indra bedank t voor je  keiharde deadline! En Annelies... Annelies, Annelies...
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